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Abstract	
	
Human	noroviruses	(HuNoVs)	are	distributed	globally,	affect	all	age	groups	and	
place	a	significant	burden	upon	health	services.	The	diversity	of	this	RNA	virus	is	
thought	to	play	a	significant	role	in	the	persistence	of	HuNoVs	as	the	main	cause	of	
non-bacterial	gastroenteritis	globally.	Molecular	diagnostics	have	been	critical	for	
understanding	the	epidemiology	of	outbreaks	and	sporadic	cases,	and	to	design	and	
implement	effective	intervention	strategies	and	disease	control	measures.	
Immunocompromised	individuals	are	widely	considered	to	be	a	reservoir	for	
epidemic	variants	of	HuNoV	and	whilst	there	are	studies	investigating	the	
emergence	of	novel	strains	in	an	immunocompetent	general	population,	reports	at	
the	the	individual	level	are	scarce.	
Three	separate	methodologies	were	developed	to	characterise	HuNoV	persistence	
in	acute	convalescent	and	chronic	infection.	First,	a	standardised	quantification	
method	to	accurately	quantify	the	most	prevalent	HuNoV	genogroup.	Second,	a	
PGM-MB	capture	method	to	select	HuNoV	prior	to	massively	parallel	sequencing	
(MPS).	Third,	an	assay	to	measure	host	specific	coproantibody	responses	to	three	
epidemic	variants	from	different	epochs.	
Quantification	of	longitudinal	samples	from	individuals	with	acute	or	chronic	
HuNoV	infection	showed	the	virus	distribution	was	homogenous	in	stool	and	an	
RNA	external	standard,	in	contrast	to	DNA,	did	not	underestimate	virus	titre.	
HuNoV	PGM-MB	capture	meant	near	complete	viral	genomes	could	be	recovered	
at	variable	mean	coverage.	A	bioinformatics	pipeline	demonstrated	over	the	course	
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of	chronic	infection	allele	frequencies	were	much	more	variable.	In	acute	infection,	
minor	alleles	were	present	at	a	much	lower	frequency,	but	potential	immune	
escape	mutants	were	present.	Immune	escape	mutants	existed	as	minority	variants	
or	conserved	mutations	in	the	consensus	sequence,	and	were	in	the	presence	of	
HuNoV	specific-coproantibody,	which	were	mapped	to	the	protein	surface.	
In	HuNoV	chronic	infection,	immune	pressure	is	variable	or	non-existent,	and	
therefore	epidemic	variants	could	emerge	over	long	periods	of	infection	by	random	
chance.	However,	under	immune	pressure	exerted	by	coproantibodies,	escape	
variants	may	be	seen.	In	three	individuals,	acute	HuNoV	symptomatic	infection	
occurred	despite	the	presence	of	specific	secretory	Ab	responses	to	the	VLP	classed	
as	the	closest	phylogenetic	relative.	The	closest	relative	(Sydney	2012),	differed	at	
two	amino	acids,	one	of	which	has	been	previously	described	(A340T)	as	belonging	
to	an	epitope,	and	another	which	can	be	classed	as	having	a	potential	role	in	
immune	escape	(A323T).	A	single	individual	with	acute	HuNoV	infection	established	
a	more	prominent	response	to	an	earlier	strain	of	HuNoV,	rather	than	two	
contemporary	strains,	which	proposes	a	role	for	Original	Antigenic	Sin	(OAS)	or	
Antigenic	Seniority	in	the	secretory	Ab	immunity.		
Finally,	the	use	of	MPS	in	outbreak	tracking	was	assessed	and	compared	to	the	
currently	used	amplicon	and	Sanger	based	method.	Overall	both	methods	showed	
significant	correlation.	However,	MPS	provided	greater	depth	and	the	ability	to	
identify	variants	among	samples	within	an	outbreak	that	represented	consensus	
changes	in	one	or	more	samples	from	the	same	outbreak.	This	meant	that	the	MPS	
data	would	have	been	able	to	link	all	the	samples	into	a	single	outbreak	or	
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transmission	network,	where	the	current	Sanger	sequencing	may	not	have	been	
able	to	link	them	all.	
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1 Introduction	
	
1.1 Historical	background	
Zahorsky	was	the	first	to	describe	“winter	vomiting	disease”;	an	enteric	illness	that	
was	predominantly	observed	between	September	and	March	(Zahorsky	1929).	
Thereafter,	a	significant	proportion	of	sporadic	and	epidemic	gastroenteritis	(GE)	
was	referred	to	as	non-bacterial	with	no	discernible	cause	(Adler,	J.	L.	1969;	
Gordon,	I.,	H.	S.	Ingraham	1947;	Hodges	et	al.	1956).	In	subsequent	studies	the	
stool	filtrate	from	symptomatic	individuals	was	used	as	an	inoculum	to	infect	
asymptomatic	volunteers,	and	from	this	the	transmission	route	of	non-bacterial	GE	
was	found	to	be	faecal-oral	(Gordon,	I.,	H.	S.	Ingraham	1947;	W.S.	et	al.	1953).	
Serial	propagation	of	the	inoculum	between	volunteers	induced	a	similar	incubation	
period,	clinical	course	and	symptom	duration	to	that	experienced	during	outbreaks,	
implying	a	viral	agent	or	agents	to	be	responsible	(Adler,	J.	L.	1969;	Clarke	et	al.	
1972;	Dolin	et	al.	1971;	Gordon,	I.,	H.	S.	Ingraham	1947).	
In	1972,	Kapikian	was	the	first	to	observe	a	causative	agent	of	non-bacterial	GE	by	
using	serum	from	convalescent	individuals	to	capture	the	virus	in	stool,	from	the	
acute	phase	of	infection,	prior	to	electron	microscopy	(EM),	also	known	as	
immunnoelectron	microscopy	(IEM)	(Kapikian	et	al.	1972).		The	virus	identified	in	
the	study	ranged	in	diameter	from	27	to	32	nm	and	was	aggregated	by	the	serum	of	
naturally	infected	individuals	or	volunteers,	to	show	a	causal	link	between	the	
agent	and	clinical	disease	(Kapikian	et	al.	1972).	Moreover,	these	experiments	
determined	antigenic	relatedness	between	the	agent	from	an	elementary	school	
outbreak	(Norwalk,	OH,	USA),	and	the	virus	found	during	the	reproduced	illness	in	
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volunteers	(Kapikian	et	al.	1972).	The	virus	present	in	these	investigations	was	
termed	the	Norwalk	virus	(NV)	agent	(Kapikian	2000).			
	
Figure	1.1.	IEM	image	of	aggregated	NV	(Kapikian	et	al.	1972).	
In	the	years	following,	a	methodology	using	convalescent	host	sera	was	developed	
to	elucidate	virus	characteristics	and	disease	epidemiology	(Greenberg	and	Kapikian	
1978).	Seroprevalence	studies	were	undertaken	which	demonstrated	NV	to	be	
prevalent,	in	all	age	groups,	across	multiple	continents	with	an	exposure	rate	of	
70%	by	adulthood	(Blacklow	et	al.	1979;	Greenberg	et	al.	1979).		
Over	a	decade	later	Jiang	and	colleagues	cloned	and	sequenced	the	NV	genome,	
which	was	critical	for	the	development	of	contemporary	diagnostic	tools	(Jiang	et	
al.	1990).	Consequently,	the	complete	NV	nucleic	acid	sequence	led	to	the	design	of	
an	assay	to	detect	the	virus	nucleic	acid	by	reverse	transcription	polymerase	chain	
reaction	(RT-PCR)	and	numerous	recombinant	expression	systems	for	the	viral	
proteins	(Baric	et	al.	2002;	Jiang	et	al.	1992a;	Jiang	et	al.	1992b).	Recombinant	
expression	of	the	virus	capsid	protein	has	provided	a	limitless	amount	of	antigen	for	
serological	assays,	and	together	with	molecular	techniques	have	been	pivotal	in	the	
assessment	of	virus	burden,	diversity	and	spread.		
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Despite	advances	in	the	laboratory	and	a	better	understanding	of	disease	
epidemiology,	much	about	the	nature	of	the	virus	remains	unknown.	The	lack	of	a	
reproducible	virus	culture	system	or	a	suitable	small	animal	model	has	been	a	
major	barrier	in	understanding	the	virus	stability,	host	cell-virus	interactions	and	
disease	development	(Duizer	2004;	Tan	and	Jiang	2010).	However,	the	recent	
developments	of	two	different	in	vitro	culture	models	will	provide	new	avenues	to	
research	the	virus,	that	were	not	possible	previously	(Ettayebi	et	al.	2016;	Jones	et	
al.	2014).	
1.2 Taxonomy	
There	are	two	main	virus	grouping	systems	that	have	been	developed,	the	
hierarchical	system	in	1962	and	the	Baltimore	classification	in	1971	(Baltimore	
1971;	LWOFF	et	al.	1962).	The	hierarchical	system	arranges	a	virus	by	the	
composition	of	its	genetic	material,	capsid	structure	or	the	presence	of	an	
envelope.	On	the	other	hand,	the	Baltimore	classification	differentiates	a	virus	by	
genomic	material	composition	only,	due	to	its	influence	on	the	mechanism	of	
mRNA	synthesis	and	facilitation	of	protein	expression.	In	1966,	the	international	
committee	on	taxonomy	of	viruses	(ICTV),	then	the	international	committee	on	
nomenclature	of	viruses	(ICNV),	was	formed	and	accepted	the	hierarchical	system	
to	standardise	virus	classification.	The	committee	assigns	newly	discovered	viruses	
to	taxons	and	maintains	current	groupings,	under	the	definition	‘A	virus	species	is	a	
polythetic	class	of	viruses	constituting	a	replicating	lineage	and	occupying	a	
particular	ecological	niche’	(Vanregenmortel	1989).		
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Several	antigenically	distinct	viruses	similar	in	morphology	to	NV	were	isolated	from	
outbreaks	matching	the	epidemiological	pattern	of	the	Norwalk	agent,	and	thus	
termed	the	Norwalk-Like	viruses	(NLVs)	(Dolin	et	al.	1982;	Thornhill	et	al.	1977;	
Wyatt	et	al.	1974).	The	newly	discovered	NLVs	were	grouped	with	the	prototype	
virus	by	serology,	or	IEM	and	enzyme	linked-immunosorbent	assay	(ELISA),	or	
partial	genomic	sequencing,	in	the	absence	of	a	virus	culture	system.	However,	
early	grouping	systems	lacked	concordance	due	to	genome	sequencing	of	short	
regions	with	relative	rates	of	mutation,	virus	recombination	and	reagent	variability	
in	serological	assays	(Cubitt	et	al.	1987;	Green	et	al.	1993;	Jiang	et	al.	1995;	Lew,	J	F,	
Kapkian,	A	Z,	Jiang,	X,	Estes,	M	K,	Green	1994;	Treanor	et	al.	1993).	
NV,	and	the	NLVs,	were	classified	into	the	Calicivirdae	family,	defined	by	the	ICTV	in	
1981,	and	its	name	derived	from	the	Latin	calyx,	to	mean	“cup”	or	“goblet”	(Green	
2007).	The	name,	Caliciviridae,	describes	the	cup-shaped	depressions	that	can	be	
observed	on	the	surface	of	the	family	by	EM.	In	2002,	the	ICTV	grouped	these	
viruses	under	the	Genus	Norovirus	(NoV),	which	currently	exists	alongside	
Lagovirus,	Nebovirus,	Sapovirus	and	Vesivirus	(Carstens	and	Ball	2009;	Green	et	al.	
2000;	Mayo	2002;	Pringle	1999).	Noroviruses	are	known	to	infect	both	animals	and	
humans,	whilst	Lagoviruses,	Neboviruses	and	Vesiviruses	infect	animals	and	
Sapoviruses	appear	to	be	restricted	to	humans	(Green	2007).	In	the	family,	
Norovirus	genome	structure	is	most	like	Vesivirus,	with	three	open	reading	frames	
(ORFs)	rather	than	two	(Figure	1.2).	
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Figure	1.2	The	genome	ORF	structures	of	the	Caliciviridae.	The	shaded	region	of	
Vesvivirus	corresponds	to	a	leader	sequence	of	the	capsid	precursor	protein.	
Adapted	from	Field’s	Virology	(Green	2007),	Accession	numbers:	Norovirus	–	
M87661,	Vesivirus	-	M86379,	Sapovirus	–	X86560,	Lagovirus	–	M67473,	Nebovirus	
–	JX018212.	
	
A	definitive	NoV	classification	does	not	currently	exist,	although	interim	grouping	
systems	have	been	proposed	based	on	capsid	sequence	data	(Ando	et	al.	2000;	
Fankhauser	et	al.	2000;	Kageyama	et	al.	2004;	Vinjé	et	al.	2000).	These	systems	
have	applied	genetic	distance	comparisons	to	variants	to	define	genetic	clusters.	
The	most	recent	published	interim-grouping	scheme	defines	7	genogroups	and	41	
genotypes	(Kroneman	et	al.	2013;	Vinje	2015).	In	the	literature,	a	genogroup	is	
expressed	with	roman	numerals	(9	GI,	22	GII,	3	GIII,	2	GIV,	2	GV,	2	GVI	and	1	GVII),	
whilst	an	arithmetic	value	is	appended	to	the	genogroup	to	describe	the	genotype.	
For	example,	a	virus	in	the	NoV	Genus	labelled	GII.4,	would	mean	genogroup	2	and	
genotype	4.	Human	norovirus	(HuNoV)	infection	is	predominantly	caused	by	GI,	GII	
and	to	a	much	lesser	extent	GIV	(Figure	1.3).	
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Figure	1.3	An	unrooted	Maximum-Likelihood	Tree	of	the	NoV	Genus	(Genogroups	I	to	VII)	
based	on	partial	and	complete	nucleic	acid	sequences	of	open	reading	frame	(ORF)	2	
(Green=GI,	Blue=GII,	Yellow=GIII,	Grey=GIV,	Orange=GV,	Black=GVI	and	Purple=GVII).	
1.3 Human	norovirus	diversity	
HuNoVs	are	highly	diverse,	and	there	are	two	main	mechanisms	that	are	
responsible	for	the	promotion	of	this	diversity.	Firstly,	drift	is	the	accumulation	of	
diversity	through	random	mutations,	and	secondly	recombination,	which	is	
reported	to	occur	when	two	or	more	viruses	from	the	same	genogroup	enter	a	cell	
to	form	a	chimeric	progeny	of	viruses	(White	2014).	
1.3.1 Drift	
Drift	is	a	mechanism	by	which	RNA	viruses	randomly	mutate	at	a	rate	of	1	
substitution	in	every	1,000	to	100,000	bases,	and	this	is	largely	due	to	the	RdRp	
	 28	
(RNA	dependent	RNA	polymerase)	lacking	a	proof	reading	mechanism	(Domingo	et	
al.	1997).	The	RdRp	incorporates	nucleotides	at	low	fidelity	and	high	velocity,	and	
these	two	properties	act	in	tandem	to	form	quasispecies,	or	a	population	that	exists	
as	a	mutant	swarm	rather	than	separate	genetic	entities	(Domingo	et	al.	2012;	Eigen	
1971).	
The	principle	of	quasispecies	was	first	introduced	in	1971	by	Eigen	from	
investigating	the	Qβ	replicase	system.	The	use	of	“evolution	in	the	test	tube”	
allowed	for	the	isolation	of	a	variety	of	phage	descendants	with	subtle	changes	to	
RNA	genome	structure	under	different	conditions	(Eigen	1971).	This	term	was	
further	defined	as	an	organised	population	of	species	with	a	defined	probability	
distribution	dependent	upon	selection	(Eigen	and	Schuster	1977).	Experimentally	
each	species	is	not	thought	to	exist	in	a	steady	state,	with	competing	mutants	
constantly	moving	in	and	out	of	existence	under	changing	environmental	selection	
(Domingo	and	Holland	1997).		
Individual	swarms	of	related	viruses	cooperate	with	each	other	allowing	for	less	fit	
mutants	to	become	dominant,	assuming	closely	related	viruses	within	the	swarm	
are	better	adapted	in	comparison	to	other	swarms	that	may	contain	a	more	fit	virus	
(Domingo,	Martin	et	al.	2006).	Populations	of	these	RNA	viruses	are	able	to	rapidly	
explore	sequence	space	expressing	most	of	the	viable	viruses	possible	within	each	
replication	cycle	including	every	point	mutation	and	many	double	mutations	
(Vignuzzi,	Stone	et	al.	2005).	This	can	lead	to	alterations	in	virus	cell	tropism,	
antiviral	nullification	and	antibody	evasion	(Domingo,	Sheldon	et	al.	2012).	
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The	role	of	quasispecies	in	driving	evolution	over	the	course	of	infection	is	well	
studied	in	Human	immunodeficiency	virus	(HIV)	and	members	of	the	Flaviviridae	for	
promoting	evolution	over	the	course	of	infection.	An	example	of	the	impact	of	the	
evolution	of	these	populations	would	be	the	use	of	various	chemokine	receptors	
instead	of	C-C	chemokine	receptor	type	5	(CCR5)	only	by	HIV,	to	prevent	
competition	with	chemokines	and	allow	for	a	broader	tissue	spread	(Connor,	
Sheridan	et	al.	1997).	Both	Hepatitis	C	virus	(HCV)	and	HIV	infections	can	require	
long	term	antiviral	suppression,	potentially	selecting	for	and	establishing	drug	
resistant	mutants	within	virus	populations	(Margeridon-Thermet	and	Shafer	2010).	
In	addition	antibody	selective	pressures	were	found	to	correlate	with	increased	
mutation	rates	of	HCV	quasispecies,	and	this	was	reduced	in	patients	unable	to	
mount	an	adaptive	immune	response	(Di	Lorenzo,	Angus	et	al.	2011).			
Drift	is	believed	to	be	a	major	mechanism	driving	diversity	and	emergence	of	novel	
HuNoVs	and	the	emergence	of	pandemic	strains.	In	the	late	1990’s	the	first	
pandemic	HuNoV	was	detected,	belonging	to	GII.4,	and	since	then	this	genotype	
has	predominated	globally	for	the	last	two	decades	(Kroneman	et	al.	2008b;	Noel	et	
al.	1999).	However,	in	the	GII.4	genetic	cluster,	periodic	strain	replacement	has	
occurred	every	2-3	years	(Figure	1.4).	This	phenomenon,	termed	epochal	evolution,	
and	first	described	in	Influenza	A	viruses,	is	believed	to	be	driven	primarily	via	
selective	pressure	exerted	by	herd	immunity	(Allen	et	al.	2008;	Siebenga	et	al.	
2007).	Such	mutations	therefore	will	lead	to	the	emergence	of	antibody	escape	
mutants	in	waves,	which	will	spread	through	the	population	from	time	to	time	
giving	rise	to	pandemics.	
	 30	
	
Figure	1.4	A	rooted	Maximum-Likelihood	tree	(1000	Bootstrap	replicates)	of	GII.4	
epidemic	strains	based	on	complete	nucleic	acid	sequences	of	the	major	capsid	
protein	adapted	from	(Eden	et	al.	2013).	11S1	corresponds	to	a	GII.7	virus	
sequenced	in	this	study.	
1.3.2 Recombination	
Recombination	occurs	when	two	or	more	different	viruses	infect	the	same	cell	and	
exchange	genetic	material,	and	thus,	can	promote	diversity	in	a	virus	population	
(Pérez-Losada	et	al.	2015).	In	viruses,	recombination	can	expand	the	host	range,	
modify	tissue	tropism,	alter	virulence,	allow	evasion	from	the	host	immune	
response	or	induce	antiviral	resistance	(Pérez-Losada	et	al.	2015).	
HuNoV	recombination	is	postulated	to	occurs	in	a	similar	manner	to	HCV	and	
Poliovirus	(Simmonds	2006),	via	the	copy	choice	model,	or	template	switching,	and	
it	has	been	best	and	more	frequently	described	at	the	ORF1+ORF2	region,	where	
the	highest	degree	of	conservation	exists	(Bull	et	al.	2005;	Bull	et	al.	2007;	Eden	et	
al.	2013;	Lindesmith	et	al.	2008;	Rohayem	et	al.	2005;	Teunis	et	al.	2008;	Waters	et	
al.	2007).	Recombination	occurs	among	HuNoV	of	the	same	genogroup,	and	despite	
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some	potential	inter-genogroup	recombination	having	been	described	(Nayak	et	al.	
2008),	the	evidence	is	to	date	not	sufficiently	robust.	Template	switching	is	
proposed	to	occur	when	the	RdRp	encounters	a	lack	of	contiguous	sequence,	
through	an	RNA	structure	or	a	change	in	genome	composition,	at	which	point	the	
polymerase	jumps	to	a	different	template	(Bull	et	al.	2005;	Rohayem	et	al.	2005).	To	
accurately	detect	a	recombination	event,	complete	sequence	data	is	required	from	
the	ORF,	or	the	two	adjacent	ORFs	if	the	breakpoint	is	in	a	junction.		
1.3.3 Diversity	and	persistence	of	GII.4	strains	in	the	human	population	
It	is	likely	that	the	persistence	of	GII.4	strains	in	the	human	population	is	a	
consequence	of	both	mechanisms,	drift	and	recombination.	Both	mechanisms	may	
lead	to,	as	mentioned	previously,	the	emergence	of	antibody	escape	mutants,	but	
also	the	emergence	of	strains	with	a	broader	range	of	host	binding	specificities	or	
differences	in	replication	rates.	Collectively,	these	factors	are	potentially	
responsible	for	the	successful	establishment	of	GII.4	over	other	genotypes.	The	two	
most	contemporary	replacements,	New	Orleans	2009	and	Sydney	2012,	are	
recombinants	of	older	strains	(2006a/Apeldoorn	2008	&	Osaka	2007/Apeldoorn	
2008,	respectively)	(Eden	et	al.	2013).	Therefore,	drift	and	recombination	
contribute	to	the	selection	of	GII.4	strains	and,	in	an	analogous	manner	to	Influenza	
A	strains,	appear	to	enable	strains	to	undergo	epochal	evolution	and	escape	from	
herd	immunity	(Lam	et	al.	2012;	Lindesmith	et	al.	2008;	Siebenga	et	al.	2007).	
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1.4 Epidemiology	
1.4.1 Burden	
HuNoV	is	an	aetiological	agent	of	sporadic	and	epidemic	GE	in	all	age	groups	
worldwide	(Ahmed	et	al.	2014).	It	is	recognised	as	the	most	common	cause	of	
sporadic	GE,	in	the	community,	and	GE	outbreaks	especially	in	semi-closed	
environments	such	as	health	and	social	care	institutions,	schools	and	nurseries,	
holiday	camps	and	cruise	ships	(Hall	et	al.	2013;	Inouye	et	al.	2000;	Lopman	et	al.	
2003;	Meakins	et	al.	2003;	Tam	et	al.	2012).	However,	data	from	developing	
countries,	with	high	mortality	rates	due	to	diarrhoea,	are	underrepresented	in	the	
literature	(Ahmed	et	al.	2014).	Moreover,	a	recent	study	identified	a	lack	of	data	on	
HuNoV	illness	burden	estimates	in	age	groups	5	years	and	over,	especially	in	low	or	
middle	income	countries	(Bartsch	et	al.	2016).	Nevertheless,	the	limited	data	
available	has	estimated	HuNoVs	to	be	a	significant	cause	of	mortality	in	children	less	
than	5	years	old,	mostly	in	developing	countries	(Bartsch	et	al.	2016;	Lanata	et	al.	
2013;	Patel	et	al.	2008).	In	developed	countries,	the	virus	places	the	greatest	burden	
on	paediatric	populations,	whilst	the	most	severe	clinical	outcomes	tend	to	occur	in	
the	elderly	(Lindsay	et	al.	2015).	Since	the	implementation	of	a	rotavirus	vaccine,	
HuNoV	has	become	the	leading	cause	of	paediatric	hospitalisation	due	to	GE	(Payne	
et	al.	2013).	
The	high	prevalence	of	HuNoV	in	children	or	the	increased	mortality	rate	in	the	
elderly	show	that,	although	all	age	groups	are	susceptible	to	infection,	these	
individuals	are	under	an	increased	risk	of	exposure	or	severe	illness,	respectively.	
Molecular	epidemiology	of	HuNoVs	has	made	it	possible	to	associate	risk	of	
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genotype	infection	to	an	age	group,	setting	or	transmission	route.	Globally,	GII	
HuNoVs	are	more	prevalent	than	GI	in	the	community	and	outbreaks,	whereas	GIV	
infections	are	rare	(Sakon	et	al.	2015;	Vega	et	al.	2014a).	Of	the	existing	GII	viruses,	
GII.4	is	the	most	common	cause	of	HuNoV	related	sporadic	GE	in	children	and	
outbreaks	in	older	age	groups	(>	65	years	old)	(Hoa	Tran	et	al.	2013;	Vega	et	al.	
2014a).	Interestingly,	of	the	HuNoV	sporadic	illness	burden	in	paediatric	
populations,	GII.3	has	been	found	to	be	highly	prevalent,	however	it	is	significantly	
less	prevalent	in	individuals	over	60	years	of	age	(Franck	et	al.	2014).	Of	HuNoVs,	
GII.4	is	a	common	cause	of	foodborne	illness	and	the	most	common	cause	of	
sporadic	illness	in	children,	but	it	is	more	regularly	associated	with	person-to-person	
transmission	and	outbreaks	in	healthcare	environments	than	foodborne	outbreaks	
or	sporadic	illness	(Franck	et	al.	2014;	Sakon	et	al.	2015;	Vega	et	al.	2014a).	The	less	
prevalent	GI	viruses	have	been	reported	to	be	more	significantly	associated	with	
foodborne	outbreaks	than	GII.4	strains	(Franck	et	al.	2014;	Vega	et	xal.	2014a).	GI	
viruses	are	often	detected	in	spring	or	summer	months	in	contrast	to	the	
autumn/winter	seasonality	that	is	driven	primarily	by	GII.4	HuNoVs	(Franck	et	al.	
2014;	Vega	et	al.	2014a).		
The	predominance	of	GII.4,	over	GII.3	and	other	genotypes,	in	institutional	
outbreaks	and	the	community	is	likely	due	to	a	combination	of	factors:	a	higher	
mutation	rate	and	thus	greater	ability	to	evade	the	herd	immunity,	increased	
virulence,	a	broad	host	receptor	binding	specificity,	greater	stability	and	survival	in	
the	environment	and	a	lower	virus	dose	to	cause	disease	(Bull	and	White	2011).		
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It	has	been	demonstrated	that	the	GII.3	polymerase	incorporates	nucleoside	
triphosphates	more	slowly	and	has	a	higher	fidelity	in	comparison	to	the	
corresponding	GII.4	enzyme	(Bull	et	al.	2010).	However,	a	different	study	attributed	
GII.4	predominance	to	an	increase	in	the	fixation	of	amino	acid	substitutions	rather	
than	nucleotide	mutation	rate	(Boon	et	al.	2011).	Therefore,	a	low	GII.3	prevalence	
could	be	a	consequence	of	a	relative	inability	to	evade	herd	immunity,	the	virus	
being	maintained	by	the	replenishment	of	a	susceptible	population,	through	the	
birth	of	immunologically	naïve	children	(Franck	et	al.	2014).	Secondly,	GII.4	HuNoVs	
have	been	associated	with	more	severe	illness	both	in	children	(prolonged	vomiting	
and	diarrhoea)	and	in	the	elderly	(prolonged	diarrhoea	and	higher	levels	of	viral	
shedding)	(Huhti	et	al.	2011;	Lee	et	al.	2007).	Thirdly,	GII.4	can	bind	a	broader	range	
of	Histo-blood	group	antigens	(HBGAs),	a	known	host	attachment	receptor,	and	in	
theory	creating	a	larger	pool	(~80%	of	the	population)	of	susceptible	individuals	
(Boon	et	al.	2011;	Huang	et	al.	2005;	Yang	et	al.	2010).	Fourthly,	during	infection,	an	
immunocompetent	individual	can	shed	stable	virus	3	to	14	hours	prior	to	the	onset	
of	clinical	disease,	and	virus	can	remain	detectable	up	to	4	to	8	weeks	after	the	
resolution	of	symptoms	(Atmar	et	al.	2008;	Duizer	et	al.	2004;	Rockx	et	al.	2002).	
Lastly,	several	human	challenge	studies	have	found	the	infectious	dose	of	HuNoVs	to	
be	low,	but	there	are	variations	between	the	studies.	For	a	disaggregated	GI.1	virus,	
the	infectious	dose	50	(ID50;	which	is	the	dose	required	to	infect	50%	of	a	study	
population)	for	human	volunteers	ranged	from	18	to	1015	genomic	equivalents	
(gEqs)	(Teunis	et	al.	2008).	A	more	recent	study	of	aggregated	virus	estimated	a	
higher	ID50	of	2800	gEqs,	when	all	individuals	of	different	genetic	susceptibilities	
were	included	(Atmar	et	al.	2014).	However,	since	GII	is	distinct	from	GI	it	would	be	
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expected	that	the	infectious	dose	is	different,	and	possibly	lower	given	the	
differences	in	prevalence.	A	GII.4	challenge	study	infected	70%	of	individuals	at	a	
dose	of	50,000	gEqs,	implying	the	ID50	is	below	this	value	(Frenck	et	al.	2012).	
Whether	HuNoV	during	these	latter	stages	of	recovery	from	illness	(or	in	the	
convalescent	phase)	is	infectious	and	can	lead	to	disease	transmission	is	not	known.	
1.4.2 Transmission	
HuNoV	is	transmitted	by	the	faecal-oral	route	with	numerous	transmission	routes	
contributing	to	the	overall	burden	of	HuNoV	(Figure	1.5).	The	virus	can	be	spread	
indirectly,	if	the	environment	or	a	fomite	is	contaminated	(environmental	
transmission),	or	directly,	by	contact	with	a	symptomatic	individual	(person-to-
person	transmission).	A	close	genetic	relatedness	between	human	and	porcine	
NoVs	within	GII,	suggests	the	potential	for	interspecies	transmission.	However,	
zoonotic	or	anthroponotic	transmission	has	not	yet	been	proven	despite	the	ability	
of	HuNoV	to	infect	pigs	in	experimental	conditions	(Cheetham	et	al.	2006).	
Therefore,	the	overall	burden	of	HuNoV	disease	is	known	to	be	sustained	by	
environmental	or	person-to-person	transmission.	
1.4.2.1 Environmental	transmission	
Environmental	transmission	is	sustained	by	the	introduction	of	HuNoV	to	a	water	
source	or	food	source	(usually	by	sewage),	fomite	(i.e	healthcare	equipment)	or	
during	the	preparation	of	complex	foods	(cross-contamination).	A	waterborne	
infection	can	originate	from	drinking	or	recreational	water,	whereas	a	foodborne	
infection	can	occur	when	fruit,	vegetables	(irrigation)	or	shellfish	(bioaccumulation)	
encounter	contaminated	water	(Mathijs	et	al.	2012).	Furthermore,	complex	foods	
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can	be	contaminated	during	the	preparation	process	if	a	food	handler	is	shedding	
virus,	either	from	asymptomatic	infection	or	during	recovery	from	illness	(Parashar	
et	al.	1998).		
	
Figure	1.5	Transmission	route	and	susceptibility	factors	influence	how	HuNoV	cycles	
between	the	community	(sporadic	illness)	and	semi-closed	environments	(outbreaks).		
	
In	the	literature,	although	GII	NoV	is	the	most	common,	the	distribution	of	GI	and	
GII	NoVs	responsible	for	waterborne	outbreaks	is	highly	heterogeneous	(Kroneman	
et	al.	2008b;	Maunula	et	al.	2005).	In	Sweden,	GI	outbreaks	from	a	water	source	
were	predominant,	and	this	is	consistent	with	a	systematic	review	of	published	data	
which	concluded	waterborne	NoV	was	more	likely	to	be	GI	than	GII	(Lysen	et	al.	
2009;	Matthews	et	al.	2012).	The	observed	higher	frequency	of	GI	waterborne	
outbreaks	in	comparison	to	other	transmission	routes,	is	proposed	to	reflect	the	
stability	of	GI	NoV	in	water	(Ngazoa	et	al.	2008;	Seitz	et	al.	2011).	
In	contrast,	NoV	foodborne	outbreaks	are	more	homogenous	in	genotype	(for	both	
GI	&	GII)	distribution.	This	was	highlighted	in	two	studies,	undertaken	over	similar	
time	periods,	in	Europe	and	the	US	which	found	GII	(85%	and	83	%,	respectively)	to	
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be	more	abundant	than	GI	(15%	and	17%,	respectively)	(Hall	et	al.	2012;	Kroneman	
et	al.	2008a).	In	the	US,	foodborne	outbreaks	most	commonly	occur	in	a	restaurant	
setting	and	infected	food	handlers	were	implicated	as	the	main	source	of	
contamination	(Hall	et	al.	2012).	GII	NoV	has	been	identified	to	have	greater	
stability	on	surfaces	(Liu	et	al.	2010),	and	to	be	shed	at	viral	loads	100-fold	higher	
than	GI	(Chan	et	al.	2006)	and	these	factors	are	likely	to	contribute	to	its	prevalence	
in	foodborne	illness.	Interestingly,	GI.1,	and	to	a	lesser	extent	GII.3,	NoVs	were	
found	to	bio-accumulate	in	oysters,	by	specific	binding	of	the	digestive	tissues,	
whereas	GII.4	was	noted	to	be	unstable	and	bind	transiently	(Maalouf	et	al.	2010).	
NoV	water	and	foodborne	transmission	is	more	likely	to	be	associated	with	mixed	
genotype	outbreaks	(GI	and	GII)	and	higher	attack	rates	in	comparison	to	other	
transmission	routes	(Matthews	et	al.	2012).	Those	outbreaks	linked	to	multiple	
genotypes	tend	to	be	linked	to	the	introduction	of	sewage	contaminants	from	
increased	rainfall,	and	flooding,	or	inadequate	wastewater	plant	treatment	(Le	
Guyader	et	al.	2006;	Hewitt	et	al.	2011).	On	the	other	hand,	asymptomatic	or	post-
symptomatic,	food	handler	induced	outbreaks	would	be	associated	with	an	identical	
HuNoV	strain	(Xerry	et	al.	2009).	
1.4.2.2 Person-to-person	transmission	
In	a	semi-closed	environment	(e.g	hospital,	nursing	home,	day-care	centre),	an	
outbreak	is	propagated	primarily	by	person-to-person	transmission.	Transmission	
between	hosts	occurs	directly,	through	contact	with	aerosolized	vomitus	(Green	et	
al.	1998),	or	indirectly	via	the	spread	of	vomitus	or	faecal	material	onto	hands,	
surfaces	or	equipment.	
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In	person-to-person	outbreaks,	GII	NoVs	are	the	most	common,	and	a	large	
proportion	of	these	infections	are	caused	by	the	GII.4	pandemic	strains	(Kroneman	
et	al.	2008b).	Moreover,	the	GII,	and	GII.4,	viruses	are	more	likely	to	be	detected	in	
a	healthcare	or	leisure	setting	and	are	seasonal,	with	a	tendency	of	more	GII	
outbreaks	to	be	detected	in	the	winter	(Kroneman	et	al.	2008b;	Matthews	et	al.	
2012).		
1.4.2.3 Zoonotic	transmission	
It	is	well	established	that	members	of	the	NoV	Genus	are	aetiological	agents	in	pigs	
(GII),	cattle	(GIII),	dogs	(GVI)	and	mice	(GV).	More	distantly	related	members	would	
need	to	jump	the	species	barrier,	although	an	increase	in	seroprevalence	to	GIII	and	
GVI	NoVs	has	been	detected	in	veterinarians	(Mesquita	et	al.	2013;	Widdowson	et	
al.	2005).	HuNoVs	(GII)	have	been	proven	to	replicate	and	cause	disease	in	
gnotobiotic	(Gnc)	pigs	(Cheetham	et	al.	2006),	and	viral	RNA	has	been	detected	in	
pigs,	cattle	and	retail	meat,	which	would	suggest	an	indirect	transmission	route	
through	the	food	chain	(Mattison	et	al.	2007).		
1.5 Norovirus	structure	and	composition	
NoV	is	a	non-enveloped	virus	of	27-32	nm	in	diameter	and	icosahedral	symmetry.	
Due	to	its	appearance	by	EM,	NoVs	were	also	known	as	small	round	structured	
viruses.	The	HuNoV	virion	comprises	a	positive	sense	single	stranded	RNA	(ssRNA)	
genome	of	~7.5-7.7	kb	in	length,	flanked	at	the	5’	end	by	a	protein	structure	(Vpg),	
analogous	to	the	eukaryotic	messenger	RNA	(mRNA)	cap	structure	(Sachs	et	al.	
1997),	and	at	the	3’	end	by	a	poly-(A)	tail	(Figure	1.6)	(Green	2007).	
	 39	
1.5.1 Norovirus	genome	
The	HuNoV	genome	comprises	three	ORFs,	whilst	a	fourth	ORF	is	present	in	murine	
norovirus	(MNV)	(Figure	1.6).	ORF1	encodes	the	non-structural	proteins	p48,	an	
NTPase,	p22,	VPg,	3CLpro	and	the	RdRp	which	are	post-translationally	cleaved	
(Figure	1.6	and	Table	1.1).	Unlike	ORF1,	ORF2	and	3	are	expressed	separately,	and	
encode	the	major,	VP1,	and	minor	structural	proteins,	VP2,	respectively	(Figure	1.6	
and	Table	1.1).	In	MNV	the	fourth	ORF	encodes	a	virulence	factor	(VF1),	which	thus	
far	has	not	been	detected	in	other	NoVs	(Figure	1.6	and	Table	1.1).	
	
Figure	1.6	The	ORF	structure	of	a	NoV	genome,	and	the	proteins	expressed.	
Table	1.1	The	functions	of	proteins	expressed	by	NoVs.	
MNV	 HuNoV	 Function	
NS1/2	 P48	(N-term)	 Replication	complex	formation,	contributes	to	
persistence	in	MNV	infections	
NS3	 NTPase	(2C-
like)	
RNA	helicase/NTPase	
NS4	 P22	(3A-like)	 Replication	complex	formation	
NS5	 VPg	 Genome-linked	protein	involved	in	translation	and	
replication	
NS6	 Pro	(3C-like)	 Protease	
NS7	 Pol/3Dpol	 RdRP	
VP1	 VP1	 Major	capsid	protein	
VP2	 VP2	 Minor	capsid	protein	
VF1	 No	equivalent	 Virulence	factor	
	
	
	
	 40	
Vpg	
The	Vpg	protein	structure	is	covalently	attached	to	the		5’	end	of	the	NoV	genome;	
it	is	analogous	to	the	eukaryotic	mRNA	cap	structure,	and	has	multiple,	integral,	
roles	for	virus	infection	(Herbert,	Brierley	et	al.	1997).	Firstly,	in	MNV	It	was	found	
to	bind	the	eIF3d/eIF4E	sub	units	of	the	eIF3	complex	involved	in	ribosome	
translation	of	mRNA	and	inhibited	the	production	of	host	capped	RNA	
(Daughenbaugh,	Fraser	et	al.	2003).	These	interactions	were	found	to	be	highly	
conserved	been	HuNoV	and	MNV	when	analysing	VPg	AA	sequence	and	comparing	
protein	binding	patterns	in	a	cell	free	system	(Daughenbaugh,	Wobus	et	al.	2006).	
Secondly,	Vpg	undergoes	nucleotidylylation	in	the	presence	of	the	RdRP	or	the	
3CLpro-RdRp	intermediate,	to	act	as	a	primer	for	NoV	replication	(Belliot	et	al.	
2008).	A	Tyrosine	at	position	27	was	found	to	be	the	site	of	nucleotidylylation,	
whereas	groups	of	charged	residues	at	the	N	terminus	were	found	to	be	of	
functional	importance	(Medvedev	et	al.	2017).	Thirdly,	although	no	experimental	
evidence	exists,	Vpg	protein	priming	has	been	postulated	as	a	mechanism	to	avoid	
the	formation	of	5’	triphosphorylated	RNA,	which	would	otherwise	be	detected	by	
innate	immune	mechanisms	in	the	host	cell	(Goodfellow	2011).	
p48	
Investigations	to	elucidate	the	role	of	p48	used	protein	expressing	plasmids	and	cell	
target	VAP-A	in	conjunction	with	yeast	hybrids	(Ettayebi	and	Hardy	2003).	Although	
p48	function	is	unknown,	in	vitro	it	has	been	found	at	the	golgi	apparatus,	and	it	is	
believed	to	promote	both	membrane	rearrangement	and	protein	trafficking	within	
the	host	cell	(Donaldson,	Lindesmith	et	al.	2008).		
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NTPase	
An	NTPase	was	identified	in	early	studies	by	comparing	feline	calicivirus	(FCV)	and	
picornavirus	sequence	alignments	(Neill	1990).	Similar	enzymes	in	both	genera	
were	thought	to	be	putative	SF3	helicases,	but	p41	has	been	found	to	be	unable	to	
unwind	a	DNA-RNA	heteroduplex	and	therefore	is	postulated	to	be	a	structural	
component	in	organising	replication	(Pfister	and	Wimmer	2001).	
p22	
The	NoV	p22	is	similar	to	a	traditional	di-acidic	endoplasmic	reticulum	(ER)	export	
signal	and	antagonises	protein	secretion	via	golgi	apparatus	disassembly	to	inhibit	
the	cell	immune	response	(Sharp,	Guix	et	al.	2010).	This	protein	has	been	labelled	
as	the	most	diverse	protein	amongst	norovirus	strains,	yet	it	contains	a	conserved	
membrane	association	domain	and	a	YXФESDG	motif	(X	is	any	AA	and	Ф	can	be	M,	I	
or	L)	found	only	in	viruses	with	human	tropism	(Sharp,	Guix	et	al.	2010).	
3CLpro	
In	vitro	translation	of	ORF1	demonstrated	the	“3C-like”	protease	(3CLpro)	to	be	
responsible	for	self-cleavage	of	the	virus	polyprotein	product	(Belliot	et	al.	2003).		
The	roles	of	enzyme	AAs	His30	and	Cys139	were	identified	as	proteolytic	activity	
with	Glu54	responsible	for	substrate	specificity	(Someya	and	Takeda	2009).	This	
protease	can	also	inhibit	the	translation	of	cellular	poly-adenylated	mRNAs	to	host	
proteins	through	the	cleavage	of	poly-(A)	binding	protein	(Kuyumcu-Martinez,	
Belliot	et	al.	2004).		
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RdRp	
The	RdRp	protein	utilises	the	parental	viral	RNA	for	de	novo	and	Vpg-dependent	
synthesis	of	negative	sense	genomic	and	subgenomic	RNAs	(Rohayem	et	al.	2006).	
Subsequent	generations	of	viral	positive	sense	RNA	are	formed	by	3’	Vpg	protein	
priming,	where	positive	sense	subgenomic	RNAs	are	generated	by	premature	
termination	or	internal	initiation	(Thorne	and	Goodfellow	2014).	The	RdRp	
functions	in	combination	with	cellular	components	and	comprises	of	palm,	finger	
and	thumb	domains	(Shatskaya	and	Dmitrieva	2013).	Overall	this	forms	a	right	hand	
structure	in	which	two	catalytic	aspartate	AAs	are	contained	in	the	conserved	palm	
domain,	whilst	the	thumb	and	fingers	surround	the	template	to	produce	a	channel	
for	replication	(Ortin	and	Parra	2006).	
1.5.2 Virion	structure	
A	NoV	genome	is	encased	within	a	virion	by	180	major	capsid	molecules	(VP1)	
(Michael	G.	Rossmann	1989;	Prasad	et	al.	1994b).	The	VP1	molecules	interact	to	
form	90	dimers,	and	from	the	centre	can	be	separated	into	a	contiguous	shell	(S	
domain)	and	an	arch-like	protruding	domain	(P	domain)	(Prasad	et	al.	1999;	Prasad	
et	al.	1994b).	The	P	domain	dimers	are	present	at	all	local	and	strict	two	fold	axes,	
generating	a	hollow	at	each	icosahedral	five-	and	threefold	axis	(Prasad	et	al.	1999;	
Prasad	et	al.	1994a;	Prasad	et	al.	1994b)	(Figure	1.7).		
In	the	NV	capsid,	a	single	VP1	molecule	is	531	AA	residues	in	length	(Jiang	et	al.	
1992b).	From	the	N-terminal	to	the	C-terminal	the	S	domain	consists	of	AAs	50-225,	
whilst	the	latter	226-520	residues	form	the	P	domain.		Each	VP1	molecule	is	
identical	but	arranged	into	3	quasi-equivalent	units	(A,	B	and	C)	based	upon	their	
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environment.	Multiple	VP1	dimers	alternate	between	“flat”	and	“bent”	
conformations	to	generate	an	icosahedral	shell	(C/C	and	A/B,	respectively)	(Figure	
1.7)	(Prasad	et	al.	1999).	In	NV,	at	the	N	terminus,	two	of	the	three	quasi-equivalent	
units	are	disordered	(Prasad	et	al.	1999).	The	N	termini,	in	an	unfixed	state,	have	
been	proposed	to	act	as	a	switch	between	conformations,	but	are	not	essential	for	
virus-like	particle	(VLP)	formation	(Bertolotti-ciarlet	et	al.	2002;	Prasad	et	al.	1999).	
A	hinge	region	located	between	the	S	domain	and	P	domain	imparts	flexibility	and	
could	allow	these	interactions	to	influence	the	surface	structure	(Chen	et	al.	2006;	
Prasad	et	al.	1999).	
	
Figure	1.7	The	three-dimensional	structure	of	NV,	the	3	quasi-equivalent	units	and	axes	of	
symmetry	are	labelled.	Used	with	permission	from	V.Prasad	(Prasad	et	al.	1999).	
	
The	S	domain	is	the	most	conserved	capsid	component,	and	folds	into	an	eight-
stranded	anti-parallel	β	sandwich	(Bertolotti-ciarlet	et	al.	2002;	Prasad	et	al.	1999).	
The	primary	function	of	the	S	domain	is	to	form	the	icosahedral	shell,	and	can	
independently	form	smooth	icosahedral	particles,	in	a	baculovirus	expression	
system,	if	the	VP1	molecule	is	truncated	to	remove	the	P	domain	(Bertolotti-ciarlet	
et	al.	2002).		
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The	P	domain	can	be	split	further	into	the	P1	(arch	leg)	and	P2	(globular	head)	
subdomains	(Chen	et	al.	2004;	Prasad	et	al.	1999).	In	the	prototype	NV,	VP1	amino	
acids	279-405	are	an	insertion,	the	P2	subdomain,	surrounded	by	residues	226-278	
&	406-520,	the	P1	subdomain	(Prasad	et	al.	1999).	X-ray	crystallography	of	NV	(GI.I)	
and	VA387	(GII.4)	NoVs	has	shown	the	P2	subdomain	consists	of	6	β	antiparallel	
sheets	(Cao	et	al.	2007;	Prasad	et	al.	1999).		Whereas	the	P1	subdomain	contains	a	
single	α	helix,	a	small	β	sheet	and	a	larger	β	sheet,	forming	a	stem,	with	a	
hydrophobic	core	and	a	globular	head	(Cao	et	al.	2007;	Prasad	et	al.	1999).	
Interactions	between	the	P1	subdomain	and	S	domain	are	determinants	of	particle	
size,	whilst	dimeric	interactions	of	the	P	domain	increase	capsid	stability	(Bertolotti-
ciarlet	et	al.	2002).	The	P2	subdomain	is	responsible	for	interactions	with	the	host	
cell	receptors	and	NoV	antigenicity	(Bertolotti-ciarlet	et	al.	2002;	Cao	et	al.	2007;	
Tan	et	al.	2003).			
A	basic	minor	structural	protein	(VP2)	is	also	present	in	the	prototype	NV,	although	
VLPs	can	be	formed	in	the	absence	of	this	structural	protein,	its	co-expression	
generally	improves	the	yield	and	stability	of	recombinant	VLPs	(Bertolotti-ciarlet	et	
al.	2002;	Glass	et	al.	2000).	VP2	is	hypothesised	to	be	positioned	inside	the	capsid	
and	to	have	roles	in	regulating	assembly	during	replication,	genome	binding	and	
increased	particle	stability	(Bertolotti-Ciarlet	et	al.	2003;	Glass	et	al.	2003;	Glass	et	
al.	2000).	The	number	of	VP2	molecules	per	NV	VLP	has	been	estimated	to	be	~1.5	
(Glass	et	al.	2000).		The	size	of	the	VP2	protein	associated	with	VLPs	is	the	expected	
protein	size	(23	kDa),	but	in	whole	virus	in	stool	it	is	larger	(35	kDa)	and	implies	that	
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the	use	of	an	insect	cell	expression	system	or	the	absence	of	the	NoV	genome	
influences	VP2	gene	regulation	(Bertolotti-Ciarlet	et	al.	2003).		
1.5.2.1 Structure	and	function	of	the	P	domain	
In	the	P	domain,	groups	of	AAs	act	in	concert	to	form	epitopes	on	the	virus	surface.	
Numerous	residues	in	the	P1	and	P2	sub	domains	have	been	proposed	to	influence	
the	surface	structure,	and	most	have	been	mapped	onto	GII.4	NoV	to	understand	
the	role	of	herd	immunity	as	a	driver	of	antigenic	diversity,	emergence	and	spread	
of	variant	strains	(de	Graaf	et	al.	2016)	(Figure	1.8).	The	P2	region	is	the	most	
exposed	region	on	the	surface	of	the	conformational	NoV	capsid,	and	thereby	most	
likely	to	be	involved	in	direct	interactions	between	host	receptors	and	Abs	(Cao	et	
al.	2007;	Prasad	et	al.	1994a).		
	
Figure	1.8	Norovirus	P	domain	of	a	GII.4	consensus	sequence;	the	colours	represent	
protein	subdomains	and	termini	(Blue=N-terminus,	Red=C-terminus,	Yellow=P1	
subdomain,	Grey=P2	subdomain)	mapped	to	X-ray	crystallography	data	from	the	Protein	
Data	Bank	(PDB):	4OOS	(Singh	et	al.	2015).	
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HuNoV	VP1	sequence	data	is	recorded	routinely	by	different	surveillance	systems,	
and	has	been	used	to	identify	conserved	protein	changes	that	could	define	a	
phenotypic	change.	Chakravarty	and	colleagues	utilised	evolutionary	trace	analysis	
which,	unlike	conventional	phylogenetic	methods,	partitions	nodes	on	a	tree	by	
conserved	class	specific	residues	(Chakravarty	et	al.	2005).	This	meant	conserved	
protein	sequence	differences	could	be	identified	between	genus	members	that	
could	influence	host	receptor	binding	patterns	or	epitope	structure	(Chakravarty	et	
al.	2005).	In	HuNoV	GII.4,	15	years	of	capsid	surveillance	data	enabled	the	
identification	of	residue	positions	which	are	hotspots	of	variation,	of	which	
significantly	more	(24%	of	total)	occurred	in	the	P2	domain	(Siebenga	et	al.	2007).	
On	the	other	hand,	sites	of	variability	in	the	HuNoV	structural	genes	have	been	
examined	on	an	individual	level,	mainly	in	immunocompromised	patients	as	a	
putative	reservoir	of	epidemic	variants.	Several	of	these	studies	have	reported	a	
higher	proportion	of	non-synonymous	mutations	in	the	P2	domain,	however	
whether	these	changes	affect	epitopes	would	depend	upon	the	presence	of	
selective	pressure	(Carlsson	et	al.	2009;	Kundu	et	al.	2013;	Nilsson	et	al.	2003).	In	a	
separate	investigation,	the	HuNoV	VP1	gene	was	predicted	to	have	less	positively	
selected	sites	than	VP2	in	the	immunocompromised	host	(Vega	et	al.	2014b).	
However,	in	the	same	investigation,	the	P2	subdomain	had	significantly	more	
mutations,	and	3	of	the	5	sites	with	the	greatest	entropy	corresponded	to	AAs	
which	form	viral	epitopes	recognised	by	specific	antibodies	(Vega	et	al.	2014b).	
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1.5.2.2 Monoclonal	antibody	and	phage	display	mapped	sites	
Several	combinations	of	AAs	have	been	proposed	as	epitopes	of	GII.4	HuNoV,	and	
elucidated	either	in	silico	or	inferred	from	seroepidemiological	studies.	The	biggest	
limitation	for	confirming	such	epitopes	remains	the	lack	of	a	reliable	cell	culture	or	
animal	model	system.	Two	sites	in	the	P2	subdomain,	consisting	of	3	AAs	each	296-
298	and	393-395	(Epitope	A	and	D,	Table	1.2),	were	identified	to	mutate	alongside	
the	emergence	of	GII.4	epidemics	(Allen	et	al.	2008).	Furthermore,	separate	murine	
monoclonal	antibodies	(mAbs),	isolated	after	inoculation	with	parental	GII.4	VLPs	
from	different	epochs,	targeted	their	respective	motifs	at	epitopes	A	and	D	in	
chimeric	VLPs,	implying	both	were	immunogens	(Allen	et	al.	2009).	Another	study	
described	Epitope	D	as	having	an	additional	role	in	HBGA	binding	specificity	by	
measuring	the	affinity	of	time-ordered	VLPs	to	carbohydrates	(Lindesmith	et	al.	
2008).	The	role	of	epitope	D	in	antigenicity	was	further	emphasized	by	
investigations	which	examined	the	ability	of	mAbs,	recovered	from	mice	immunised	
with	GII.4-1987	and	GII.4-2006	VLPs,	to	neutralise	chimeric	VLPs	(Debbink	et	al.	
2012).	In	the	same	study,	assays	measuring	VLP	carbohydrate	binding	affinity,	
demonstrated	the	influence	epitope	A	has	upon	HBGA	binding	patterns	(Debbink	et	
al.	2012).	
Subsequently,	five	groups	of	residues	(epitope	A,	B,	C,	D	and	E)	were	proposed	as	
GII.4	NoV	epitopes,	however	only	two	(A	and	D)	were	antigenically	mapped	by	
human	mAbs	(Lindesmith	et	al.	2012a)	(Table	1.2	and	Figure	1.9).	Epitope	E	was	
demonstrated	to	be	a	strain-specific	(GII.4-2002)	blockade	epitope	by	a	human	mAb	
(Lindesmith	et	al.	2012b).	Most	epitopes	are	situated	near	conserved	receptor-
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binding	sites	or	adjacent	to	residues	that	determine	specificity	(Figure	1.9	and	
1.10),	and	immune	driven	selection	of	epitopes	has	been	proposed	to	generate	
novel	GII.4	strains,	that	escape	herd	immunity,	and	have	altered	binding	patterns	to	
host	receptors	(Cao	et	al.	2007;	Lindesmith	et	al.	2008;	Tan	et	al.	2008).	
Isolation	of	a	human	mAb	capable	of	neutralising	several	GII.4	strains	has	meant	a	
conserved	epitope	across	the	genotype	could	exist,	however	experiments	to	
identify	the	epitope	revealed	a	group	of	residues	(NERK	motif	–	Epitope	N)	that	
could	regulate	conformational	access	to	the	epitope	allosterically	(Lindesmith	et	al.	
2014).	More	recently,	phage	display	was	used	to	demonstrate	an	interaction	
between	a	mAb	and	positions	397	and	447,	whereas	mutation	of	an	adjacent	site,	
396,	altered	VLP	HBGA	recognition	pattern	(Carmona-Vicente	et	al.	2016).	
Table	1.2	Mapped	epitopes	on	the	GII.4	P	domain	in	the	literature	(Each	colour	
corresponds	to	the	epitope	position	on	the	P	domain	model	below).	
	
	
Figure	1.9	Epitope	residue	mapping	of	a	GII.4	P	domain	mapped	to	X-ray	crystallography	
data	from	the	Protein	Data	Bank	(PDB):	4OOS	(Singh	et	al.	2015).	The	arrows	show	sites	
mapped	as	HBGA	interaction	sites	and	epitopes.		
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Table	1.3	Mapped	HBGA	interaction	sites	on	the	GII.4	P	domain	in	the	literature	(Each	
colour	corresponds	to	the	position	of	HBGA	interaction	sites	on	the	P	domain	model	
below).	
	
	
Figure	1.10	HBGA	residue	mapping	of	a	GII.4	P	domain	mapped	to	X-ray	crystallography	
data	from	the	Protein	Data	Bank	(PDB):	4OOS	(Singh	et	al.	2015)	-	(Red=Integral	to	HBGA	
binding,	Blue=Influences	binding	specificity,	Green=Supports	binding	site,	Pink=Second	
binding	cavity).	The	arrows	show	sites	mapped	as	HBGA	interaction	sites	and	epitopes.	
1.6 Virus	replication	
The	lack	of	a	reliable	culture	system	has	hampered	our	understanding	of	the	HuNoV	
replication	cycle.	Most	of	the	information	available	has	been	derived	from	
analogous	systems,	using	virus	relatives	(e.g	FCV	or	MNV).	It	is	noteworthy	that	
MNV	infects	macrophages	and	are	principally	associated	with	pathology	of	the	
neurological	and	immune	systems,	rather	than	enteric	disease	(Karst	et	al.	2003;	
Wobus	et	al.	2004).		
1.6.1 Attachment	and	entry		
Attachment	to	the	host	cell	receptor	is	the	first	stage	of	a	virus	replication	cycle,	
followed	by	internalisation.	NV	binding	and	internalisation	was	demonstrated	first	
in	the	Caco-2	cell	line	(Colon	adenocarcinoma	tissue)	(White	et	al.	1996),	and	led	to	
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the	identification	of	H	type	1	or	type	3	HBGA	expression	as	a	factor	in	virus	binding	
to	Caco-2	cells	or	duodenal	tissue	section	(Marionneau	et	al.	2002).	A	variety	of	
HBGA	binding	patterns	have	been	shown	experimentally	for	different	HuNoV	
genotypes,	and	has	provided	further	evidence	for	their	role	as	receptors	or	co-
receptors	(Huang	et	al.	2005).	Although	HuNoV-HBGA	interactions	are	well	defined	
in	the	literature,	virus	cell	attachment	can	occur	in	their	absence	and	this	is	
evidenced	by	heparan	sulphate	binding	(Murakami	et	al.	2013;	Tamura	et	al.	2003).	
Functional	receptors	and	mechanisms	of	entry	are	more	comprehensively	
understood	in	FCV	and	MNV,	since	tissue	culture	models	were	established	much	
earlier	than	HuNoV	(Kreutz	et	al.	1994;	Wobus	et	al.	2004).	FCV	was	described	to	
bind	N-linked	glycans	on	the	cell	surface,	whilst	Junctional	Adhesion	Molecule	1	
permits	cell	entry	and	clathrin-mediated	endocytosis,	the	virus	genome	is	then	
released	into	the	cytoplasm	by	endosome	acidification	(Kreutz	et	al.	1994;	Makino	
et	al.	2006;	Stuart	and	Brown	2006).	MNV,	strain	CR3,	shares	an	affinity	for	N-linked	
glycans	with	FCV	whilst	other	strains	in	this	genogroup	attach	to	gangliosides	
(Taube	et	al.	2012;	Taube	et	al.	2009).	After	attachment,	entry	can	occur	via	two	
recently	elucidated	functional	receptors	belonging	to	the	CD300	family	(Haga	et	al.	
2016;	Orchard	et	al.	2016).	In	contrast	to	FCV,	MNV	entry	into	the	cytoplasm	is	pH	
independent,	but	reliant	upon	cholesterol	and	dynamin	II	(Gerondopoulos	et	al.	
2010;	Perry	and	Wobus	2010).	
1.6.2 Replication		
Once	a	NoV	genome	is	released	into	the	cytoplasm,	RNA-protein	interactions	occur	
between	the	5’	and	3’	secondary	structures	of	the	viral	genome	and	host	cell	
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factors.	Putative	interactions	with	PTB,	DDX3	and	La	have	been	reported	to	have	
roles	in	viral	translation	and	replication	(Vashist,	Urena	et	al.	2012).	To	begin	
translation	the	5’	covalently	bonded	Vpg	protein	interacts	with	the	eIF4E	
translation	initiation	factor	to	assemble	the	ribosomal	preinitiation	complexes	for	
translation	(Daughenbaugh	et	al.	2003;	Goodfellow	et	al.	2005;	Herbert	et	al.	1997)	
(Figure	1.11).	
The	ORF1	produces	a	polyprotein	that	is	cleaved	into	non-structural	proteins	of	the	
replicase	complex	(Donaldson,	Lindesmith	et	al.	2008).	Viral	3C-like	protease	is	
responsible	for	auto	cleavage	of	this	polyprotein	into	the	RNA-dependent	RNA	
polymerase,	3CLpro,	Vpg,	p22,	NTPase	and	p48	(Hardy	2005).	More	specifically,	
mapped	ORF1	cleavage	sites	include	Q330/G331	and	Q696/G697corresponding	to	the	N	
terminal	region,	NTPase	and	the	p20VPgProPol	precursor	which	is	hydrolysed	into	
its	components	at	E875/G876,	E1008/A1009	and	E1189/G1190	(Belliot,	Sosnovtsev	et	al.	
2003)	(Figure	1.11).		
The	lack	of	tissue	culture	systems	for	HuNoV,	prior	to	the	recently	described	B	cell	
and	enteroid	based	systems	(Ettayebi	et	al.	2016;	Jones	et	al.	2014),	means	that	
most	investigations	into	virus	replication	have	been	performed	in	feline	calicivirus	
(FCV)	and	murine	norovirus	(MNV)	model	systems.	In	the	FCV	model	system,	virus	
infection	induced	internal	membrane	rearrangements	and	vesicle	accumulation	in	
Candell	Reese	Feline	Kidney	(CRFK)	cells	(Green	et	al.	2002).	Further	investigations		
localised	enzymatically	active	replication	complexes	to	the	membranous	pellet	and	
an	increase	in	the	levels	of	negative	sense	templates	of	FCV	genomic	and	
subgenomic	RNA	(Green	et	al.	2002).	Internal	membrane	rearrangements	have	also	
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been	observed,	by	EM,	during	MNV	infection	of	RAW	264.7	macrophage	cells,	
which	led	onto	organelle	displacement	and	a	loss	of	the	golgi	apparatus	(Wobus	et	
al.	2004).	Immunofluorescent	microscopy	demonstrated	the	vesicles	formed	by	
MNV	infection	contained	early	endosome,	golgi	body	and	endoplasmic	reticulum	
markers,	which	indicated	these	organelles	were	sites	of	early	cell	membrane	
recruitment	by	the	virus	(Hyde	et	al.	2009).	Further	investigations,	with		
fluorescently	labelled	b-tubulin,	vimentin,	the	MNV	polymerase	and	dsRNA	
intermediates,	were	able	to	associate	virus	induced	vesicles	with	the	microtubule	
organising	centre;	and	the	role	of	microtubules	in	their	subsequent	accumulation	in	
a	region	adjacent	to	the	nucleus	(Hyde	et	al.	2012;	Hyde	et	al.	2009).	The	
association	of	this	positive-sense	RNA	virus	and	its	replication	complexes	with	
vesicle	structures	is	in	agreement	with	previous	studies,	and	is	thought	to	have	
roles	in	protection,	confinement	and	stability	(Mackenzie	2005).	
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Figure	1.11	Caliciviridae	replication	adapted	from	Antiviral	Research	(Rohayem,	
Bergmann	et	al.	2010).	Virus	attachment	(1),	uncoating	and	entry	(2),	(+)	ssRNA	
translation	into	a	polyprotein	(3),	protease	cleavage	of	the	polyprotein	into	non-
structural	proteins	(4),	assembly	of	the	non-structural	proteins	into	the	replication	
complex	(5),	formation	of	the	anti-genome	from	the	genomic	RNA	(6),	the	anti-genome	is	
utilised	as	a	template	for	both	genomic	and	subgenomic	RNA	synthesis	(7,	8),	the	
subgenomic	RNA	is	then	translated	into	structural	proteins	(9),	non-structural	proteins	
are	released	from	the	polyprotein	and	packaged	alongside	subgenomic	structural	
proteins	and	genomic	RNA.	Genomic	RNA	and	structural	proteins	are	assembled	into	
mature	virions	(10)	which	exit	and	infect	other	cells,	ultimately	to	be	transmitted	(11).	
	
1.7 Host	receptors	and	susceptibility	
HuNoVs	can	bind	to	host	histo-blood	group	antigens	(HBGAs),	and	these	molecules	
are	associated	with	susceptibility	to	infection	and	disease.	These	carbohydrate	
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molecules	are	present	on	the	surface	of	red	blood	cells	and	the	mucosal	epithelium	
(Ravn	and	Dabelsteen	2000).	As	well	as	this,	HBGAs	are	found	as	free	
oligosaccharides	in	saliva,	blood	and	milk	of	other	secretor	individuals	(Ravn	and	
Dabelsteen	2000).	In	the	small	intestine,	these	molecules	are	thought	to	act	as	
receptors	or	co-receptors	for	HuNoV	infection.	HBGAs	are	genetically	variable,	and	
thus	HuNoV	binding	affinity	is	relative	to	type	(Table	1.4).	These	molecules	are	
glycoproteins	formed	from	a	type	1	or	type	2	precursor,	and	the	sequential	addition	
of	a	fucose	or	terminal	galactose/N-acetylgalactosamine	by	fucosyl	transferase	
enzymes	(Figure	1.12)	(Henry	et	al.	1995).	
	
Figure	1.12	Type	1	and	type	2	human	histo-blood	group	antigens	adapted	from	Reviews	in	
medical	microbiology	(Ruvoen-Clouet,	Belliot	et	al.	2013).	
	
Individuals	with	a	nonsense	mutation	within	the	FUT2	gene,	which	encodes	the	
enzyme	responsible	for	synthesising	these	molecules,	are	resistant	to	HuNoV	
infection	due	to	an	absence	of	the	receptor	(non-secretors)	(Marionneau	et	al.	
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2002).	AAs	in	the	HBGA	binding	sites	are	highly	conserved,	though	mapped	
proximal	areas	are	thought	to	influence	antigenicity	implying	receptor	affinity	and	
immune	escape	could	be	related	(Allen	et	al.	2009;	Debbink	et	al.	2014;	de	
Rougemont	et	al.	2011).	
HuNoV	resistant	patient	subsets	were	identified	much	earlier	than	the	relevance	of	
HBGA	molecules	as	potential	norovirus	receptors	(Parrino	et	al.	1977).	In	this	study,	
Parrino	and	colleagues	identified	three	volunteers	that	were	found	to	be	resistant	
to	Norwalk	agent,	with	a	decreased	immune	response	relative	to	other	individuals,	
implying	a	role	for	genetics	(Parrino,	Schreiber	et	al.	1977).	Through	assaying	the	
HBGA	molecules	in	saliva	against	blood	group	it	is	possible	to	identify	structural	
binding	patterns	between	genogroups	and	host	phenotypes	(Huang,	Farkas	et	al.	
2003)	(Table	1.4).	
Susceptibility	to	viruses	is	dependent	upon	tissue	tropism	and	whether	host	cell	
entry	can	occur	via	binding	of	surface	receptors.	A	receptor	type	for	the	
Caliciviridae	was	first	identified	by	applying	Rabbit	haemorrhagic	disease	virus	
(RHDV)	VLPs	to	human	erythrocytes	and	rabbit	tissues	to	deduce	the	importance	of	
HBGA	surface	molecules	(Ruvoen-Clouet,	Ganiere	et	al.	2000).	From	this	basis	it	was	
possible	to	prove	that	H	type	HBGAs	on	the	surface	of	Caco-2	cells	contribute	to	
virus	internalisation	in	secretor	positive	individuals,	and	are	not	decoy	receptors	
(Marionneau,	Ruvoen	et	al.	2002).	
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Table	1.4	HBGA	binding	patterns	of	different	HuNoV	genotypes	adapted	from	Journal	of	
virology	(Huang	et	al.	2005).	
Genogroup	/	
Genotype	
HBGA	binding	pattern	
A/B	 H	 Le	
I	 1	 +++	 ++	 -	
2	 +++	 ++	 -	
3	 -	 -	 -	
8	 -	 ++	 ++	
II	 1	 ++	 +	 -	
2	 +++	 -	 -	
3	 +++	 +	 -	
4	 +++	 ++	 -	
5	 +++	 -	 -	
9	 -	 +	 ++	
21	 -	 -	 ++	
	
1.8 Pathogenesis	
Symptoms	present	during	clinical	norovirus	infection	include	acute	onset	of	
vomiting,	diarrhoea,	nausea,	abdominal	cramps	and	myalgia	(Patel,	Hall	et	al.	
2009).	To	increase	understanding	of	how	the	virus	induces	these	host	responses	
histological,	biochemical	and	physical	studies	have	been	required	in	both	human	
volunteers	and	animal	models	(Karst	2010).		
Early	histological	studies	identified	altered	morphology	of	jejunal	tissues	during	
infection	including	shortening	and	broadening	of	villi,	disorganisation	of	cells	lining	
the	epithelium,	the	presence	of	mucosal	lesions,	inflammatory	cell	infiltrate	and	
widening	of	intercellular	spaces	due	to	oedema	(Agus	et	al.	1973;	Dolin	et	al.	1975).	
Both	asymptomatic	and	clinically	infected	volunteers	show	malabsorption	of	D-
xylose,	lactose	and	lipids	upon	administration	of	virus	inoculum	(Blacklow,	Chanock	
et	al.	1972).	However,	these	results	could	be	influenced	by	intestinal	morphology	or	
variations	within	individual	microbiomes.	
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Immune	cell	infiltrates	have	been	identified	to	be	CD8+	T	cells	expressing	perforin	
leading	to	cell	induced	apoptosis	of	enterocytes	(Karst	2010).	Despite	a	significant	
increase	of	cell	proliferation	biomarkers	(Ki-67)	in	epithelial	cell	tissue,	HuNoV	
infection	alters	gut	physiology	and	could	be	due	to	virus	mediated	apoptosis,	
cytokines	produced	by	CD4+	T	cells,	a	reduction	in	tight	junction	expression	
increasing	permeability	and	a	cyclic	adenosine	monophosphate	(cAMP)	
independent	anion	secretion	mechanism	(Troeger,	Loddenkemper	et	al.	2009).		
Various	animal	models	exist	to	better	understand	the	NoV	disease	process	in	
humans,	including	mice,	humanised	mice,	Gnc	pigs,	calves	and	chimpanzees	(Karst,	
Wobus	et	al.	2003,	Cheetham,	Souza	et	al.	2006,	Bok,	Parra	et	al.	2011).	To	obtain	
an	accurate	reflection	of	pathogenesis	the	animal	model	used	must	be	like	the	host	
of	interest.	This	also	applies	to	the	virus	used,	hence	why	the	discovery	of	MNV-1	
was	an	important	development.	The	discovery	of	MNV-1	allowed	for	the	first	
norovirus	tissue	culturing	system,	and	can	be	applied	to	transgenic	mice	models	
(Wobus,	Karst	et	al.	2004,	Wobus,	Thackray	et	al.	2006).	Mice	do	not	have	an	
emetic	reflex,	instead	gastric	bloating	appears	and	could	correlate	with	gastric	
infection	and	emesis	in	humans	(Kahan,	Liu	et	al.	2011).	An	injury	to	the	digestive	
tract	is	thought	to	be	induced	by	delayed	gastric	emptying,	leading	to	vomiting	in	a	
proportion	of	individuals	(Meeroff,	Schreiber	et	al.	1980).	Other	models	can	remove	
microbial	influence	by	using	Gnc	animals	born	in	aseptic	conditions	with	controlled	
exposure	to	microorganisms.	Infected	Gnc	pigs	and	calves	are	proven	to	shed	GII.4	
viruses	(Cheetham,	Souza	et	al.	2006).	Gnc	calves	infected	with	GII.4	virus	show	less	
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severe	pathologies	when	compared	to	bovine	norovirus	infection	(Souza,	Azevedo	
et	al.	2008).	
Problems	with	these	models	can	include	the	induction	of	morbidities	not	present	
within	human	clinical	infection.	Specifically,	MNV-1	symptomatic	infection	can	only	
occur	in	STAT1-/-	mice,	whereas	infection	of	wild	type	mice	is	limited	to	a	mild	
inflammatory	response	(Mumphrey,	Changotra	et	al.	2007).	After	infection	of	
transgenic	mice,	the	virus	utilises	dendritic	cells	(DC)	to	transport	itself	to	distal	
sites	such	as	the	mesenteric	lymph	nodes	(Elftman,	Gonzalez-Hernandez	et	al.	
2013).	Though	initial	infection	takes	place	in	the	intestine,	the	latter	stages	are	non-
localised,	whereas	HuNoVs	usually	remain	in	the	gut.	
1.9 Detection	and	diagnostics	
Prior	to	the	widespread	availability	of	molecular	or	serological	diagnostic	tools	
(Table	1.5),	the	Kaplan	criteria	were	developed	to	distinguish	HuNoV	infection	from	
other	aetiological	agents	of	GE.	The	Kaplan	criteria	discerns	HuNoV	outbreaks	if	i)	
the	mean	duration	of	illness	is	12-60	hours	ii)	the	mean	incubation	period	is	24-48	
hours	iii)	vomiting	is	present	in	>	50%	of	individuals	and	iv)	bacterial	pathogens	are	
absent	in	stool	(Kaplan	et	al.	1982).	Whilst	this	was	an	effective	and	reasonably	
sensitive	tool	for	the	identification	of	HuNoV	outbreaks,	it	was	not	able	to	identify	
sporadic	cases.	Currently	various	molecular	and	serological	assays	are	available	for	
the	laboratory	diagnostic	of	HuNoV	GE	(Kirby	and	Iturriza-Gomara	2012;	Vinje	
2015).	
During	clinical	manifestation	of	HuNoV	infection,	the	virus	can	be	detected	in	
vomitus,	mouthwashes,	rectal	swabs	or	stool	specimens	(Atmar	et	al.	2008;	Kirby	et	
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al.	2011;	Kirby	et	al.	2010;	Nakanishi	et	al.	2009).	However,	diagnostic	tests	will	
predominantly	be	performed	on	stool	samples	due	to	the	high	viral	load,	virus	
persistence	in	stool	and	the	sporadic	nature	of	vomiting	during	illness	(Kirby	et	al.	
2010;	Rockx	et	al.	2002;	Vinje	2015).	
EM	allows	the	detection	of	virus	in	stool	samples	through	observation	of	the	
characteristic	shape,	and	can	therefore	detect	all	genotypes	and	strains	present	
without	potential	biases.	However,	it	is	a	highly	skilled	and	labour	intensive	method	
that	is	also	relatively	insensitive,	and	its	use	for	diagnostic	purposes	is	currently	
limited	(Costantini	et	al.	2010;	Phillips	et	al.	2009).	EIA	based	assays	have	improved	
upon	the	sensitivity	of	EM	by	utilizing	cocktails	of	pAbs	and	mAbs	raised	against	
different	HuNoV	VLP	strains,	however	cross-reactivity	between	genogroups	and	the	
inability	to	detect	certain	genotypes	has	been	described	(de	Bruin	et	al.	2006;	
Costantini	et	al.	2010).	Numerous	studies	have	identified	cross-reactive	mAbs,	
between	and	within	GI	and	GII,	which	could	further	increase	EIA	sensitivity,	but	
would	decrease	specificity	(Hale	et	al.	2000;	Kitamoto	et	al.	2002;	Li	et	al.	2009b;	
Lindesmith	et	al.	2012b).	EIA	assays	are	limited	further	by	an	antibody	losing	affinity	
to	contemporaneous	strains	via	antigenic	drift	of	HuNoV	strains	and	the	
requirement	for	adequate	sample	storage,	to	prevent	proteolytic	degradation	of	
epitopes	(Bull	et	al.	2010;	Costantini	et	al.	2010).	The	use	of	ELISA	or	other	antigen	
detection	systems	is	particularly	appropriate	in	outbreak	situations	in	which	
numerous	different	samples	are	available	for	testing.	
The	most	widely	used	diagnostic	assays	for	HuNoV	are	based	upon	RT-PCR	(Kirby	
and	Iturriza-Gomara	2012).	Compared	to	EM	and	EIA	based	assays,	PCR	is	able	to	
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detect	much	lower	titres	of	virus	and	therefore	HuNoV	infection	resulting	in	
moderate	shedding	can	be	detected	and/or	quantified	(Amar	et	al.	2007;	Atmar	et	
al.	2008).	Several	conventional	RT-PCR	assays	exist	for	the	detection	of	NoV	(Ando	
et	al.	1995;	Green	et	al.	1995;	Vennema	et	al.	2002;	Vinje	and	Koopmans	1996;	
Wang	et	al.	1994).	However,	these	have	been	largely	superseded	by	second	
generation	qPCR	techniques,	and	the	increase	in	diagnostic	test	sensitivity	has	
meant	thresholds	for	asymptomatic	infection	or	shedding	of	low	viral	loads	prior	to	
or	post-illness	can	be	better	defined	(Kageyama	et	al.	2003;	Phillips	et	al.	2009).	
Other,	less	established,	quantitative	techniques	exist	for	HuNoV	in	clinical	samples.	
LAMP	(Loop-mediated	isothermal	amplification)	and	NASBA	(Nucleic	acid	sequence-
based	amplification),	like	PCR	assays,	quantify	HuNoV	by	amplicon	replication,	
mediated	by	Bst	DNA	polymerase	and	T7	RNA	polymerase,	respectively	(Compton	
1991;	Notomi	et	al.	2000).	Amplicon	replication	by	enzymes,	other	than	Taq	DNA	
polymerase,	can	be	performed	at	lower	isothermic	temperatures,	and	are	less	
susceptible	to	inhibition	(Iturriza-Gomara	et	al.	2008;	Lamhoujeb	et	al.	2009).	
Luminex	technology,	on	the	other	hand,	requires	a	multiplex	PCR	reaction	prior	to	
laser-assisted	quantification	of	oligonucleotide	coated	microspheres,	which	can	
allow	for	high	levels	of	multiplexing	(Dunbar	2006;	Liu	et	al.	2011).	Massively	
parallel	sequencing	(MPS)	also	undergoes	an	amplification	step	to	enrich	nucleic	
acids	prior	to	detection,	and	the	read	data	has	been	shown	to	correlate	with	semi-
quantitative	PCR	measurements	(Nakamura	et	al.	2009).		
NoV	disease	can	also	be	identified	with	qualitative	diagnostic	tests,	which	tend	to	
be	more	rapid.	Gas	chromatography	(GC)	of	volatile	organic	compounds,	in	clinical	
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stool	samples,	and	mass	spectra	of	the	NoV	VLP	spiked	stool	samples,	have	unique	
profiles	which	could	help	inform	the	diagnostic	result	(Colquhoun	et	al.	2006;	
Probert	et	al.	2004).	Microarrays	have	also	been	developed	to	identify	the	presence	
of	different	genotypes	in	a	sample	(Mattison	et	al.	2011).		
Table	1.5	Summary	of	current	HuNoV	diagnostic	methods.	
Diagnostic	
technique	
Sensitivity	 Advantage	 Disadvantage	
EM	 +	
	
Not	pathogen	
specific	
Requires	a	skilled	
technician	
Expensive	
Difficult	to	discern	virus	
	
IEM	 ++	
(Limit:	£	106	
particles/g	faeces)	
(Constantini,	2010)	
Moderate	increase	in	
sensitivity	and	
specificity	
ELISA	 ++	
(Limit:	£	106	gEq/g	
faeces)	(Costantini	et	
al.	2010)	
Low	technical	
requirements	
	
Sensitivity	not	equal	for	
all	genotypes	
Insensitive	for	sporadic	
case	diagnostics		
PCR/qPCR	 ++++	 Detection	limit	of	
one	genomic	copy	
Multiplexing	
Inhibitors	can	generate	
false	negatives	
Does	not	coreelate	with	
symptoms	
Metagenomics	 ?	 Not	pathogen	
specific	
Expensive	
Complex	data	analysis	
Large	capacity	for	data	
storage	required	
No	standard	to	assess	
the	diagnostic	value	of	
result		
	
The	recent	development	of	two	complex	in	vitro	cultivation	methods	for	HuNoV	
have	meant	that	a	diagnostic	assay	to	quantify	infectious	virus	may	be	feasible	
(Ettayebi	et	al.	2016;	Jones	et	al.	2014).	The	first	to	be	described,	can	provide	
relatively	low	yields	of	HuNoV	from	BJAB	cells	(Human	Burkitt	lymphoma	B	cell	
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line),	but	is	reliant	on	the	presence	of	a	cofactor	in	stool	that	is	thought	to	be	H	
antigen	on	the	surface	of	enteric	bacteria	(Jones	et	al.	2014).	In	the	second	
technique,	HuNoV	is	replicated	to	greater	yields	in	enterocytes,	or	intestinal	crypt	
stem	cells,	and	whilst	this	provides	greater	yields	it	also	requires	a	high	level	of	
technical	skill	(Ettayebi	et	al.	2016).	The	enterocyte	system	reflected	more	closely	
the	virus	biology,	as	GII.3	was	shown	to	infect	the	non-secretor	phenotype	whereas	
GII.4	could	not,	but	also	bile	was	found	to	be	either	a	required	cofactor	or	enhancer	
of	virus	replication	for	which	the	mechanism	is	not	well	understood	(Ettayebi	et	al.	
2016).	
1.10 Norovirus	immunity	
In	the	first	NV	and	NLV	human	challenge	studies,	short	term	immunity,	to	a	
homologous	strain,	was	present	9-14	weeks’	post	exposure	(Wyatt	et	al.	1974).	In	
subsequent	experiments,	a	subset	of	individuals	were	not	infected	after	repeat	
inoculations,	whilst	the	remaining	individuals	did	not	appear	to	be	immune	2-3	
years	after	the	initial	challenge	(Parrino	et	al.	1977).	However,	the	inoculum	used	
for	these	challenge	studies	was	found	to	far	exceed	either	of	two	proposed	ID50	
values	for	NV	(Atmar	et	al.	2014;	Teunis	et	al.	2008).		
Correlates	of	innate	immunity	are	not	well	understood	in	HuNoV	infection.	IFN	
expression	has	been	found	to	coincide	with	oral	VLP	inoculation	of	humans	(IFN-g)	
(Tacket	et	al.	2003),	and	decreased	levels	of	NV	RNA	in	a	cell	line	replicon	system	
(IFN-a)	(Chang	et	al.	2006).	Furthermore,	in	the	MNV	model	system,	both	DCs	
(Elftman	et	al.	2013)	and	the	signal	transducer	and	activator	of	transcription	1	
	 63	
(STAT1)	pathway,	influenced	by	IFN	or	extraneous	IFN-l	treatment,	were	shown	to	
control	or	abolish	virus	infection	in	vivo	(Mumphrey	et	al.	2007;	Nice	et	al.	2015).	
An	infected	individual	was	found	to	be	symptomatic	over	a	2	year	period	with	a	low	
cellular	immunity	and	an	intact	humoral	immunity	(Nilsson,	Hedlund	et	al.	2003).	
This	implies	cellular	immunity	is	necessary	and	contributes	to	complete	viral	
clearance.	Another	example	of	the	broad	immune	response	required	was	present	in	
a	volunteer	based	study	that	could	segregate	genetically	susceptible	individuals	
with	varied	norovirus	IgA	specific	responses	relative	to	total	IgA	(Lindesmith	et	al.	
2003).	In	this	study	two	subsets	of	resistant	individuals	were	identified;	those	with	
an	early	IgA	response	above	base	line	during	the	first	five	days	after	infection	
(infection	was	defined	as	the	detection	of	viral	RNA	in	stool	by	RT-PCR	or	≥	4	fold	
increase	in	Norwalk	virus-specific	serum),	and	those	resistant	with	a	lesser	or	no	
secretory	antibody	response,	which	implied	resistance	is	not	solely	dependent	upon	
humoral	immunity	(Lindesmith,	Moe	et	al.	2003).	
1.10.1 Correlates	of	human	norovirus	immunity	
In	the	literature,	further	HuNoV	challenge	studies	and	vaccine	development	trials	
have	been	performed	to	identify	immune	correlates	that	constitute	protection	from	
virus	infection	and	disease	(Ramani	et	al.	2016).	
1.10.1.1 Host	genetics	
In	1977,	Parrino	and	colleagues	proposed	the	presence	of	a	genetic	factor	that	
could	influence	whether	individuals	were	infected	by	NV	(Parrino	et	al.	1977).	The	
risk	of	infection	was	identified	to	be	related	to	the	ABO	group	system	(Hutson	et	al.	
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2002),	and	consequently	investigations	found	an	inactive	a(1,2)fucosyltransferase	
(FUT2)	to	be	an	indicator	of	NV	resistance	(Lindesmith	et	al.	2003).	The	FUT2	
enzyme,	as	described	previously,	is	involved	in	the	synthesis	of	HBGAs	on	the	
surface	of	epithelial	cells	(Henry	et	al.	1995),	however,	whether	HBGAs	function	as	
a	receptor	or	co-receptor	is	not	known.	
1.10.1.2 The	adaptive	immune	system	
Most	of	the	recognised	factors	that	correlate	with	protection	from	HuNoV	are	a	part	
of	the	adaptive	immune	system,	and	this	likely	signifies	its	importance	in	virus	
clearance	(Ramani	et	al.	2016).	In	2003,	Lindesmith	and	colleagues	found	a	more	
rapid	salivary	IgA	response	(response	within	the	first	five	days	in	contrast	to	a	peak	
titre	on	day	14),	after	NV	challenge	to	indicate	protection	in	susceptible	individuals	
(Lindesmith	et	al.	2003).	This	agrees	with	research	from	a	recent	challenge	study,	
which	found	the	presence	of	pre-existing	NV	specific	salivary	IgA,	alongside	specific	
IgG	memory	B	cells,	to	be	associated	with	protection	from	virus	induced	GE	(Ramani	
et	al.	2015).	In	the	same	study,	individuals	with	larger	NV-specific	IgA	titres	in	stool	
tended	to	shed	a	lower	peak	viral	load,	and	on	day	seven	(post-challenge)	this	was	
found	to	correlate	with	a	decrease	in	shedding	duration,	but	it	was	the	presence	of	
NV-specific	IgG	memory	cells	prior	to	challenge	that	correlated	with	protection	
(Ramani	et	al.	2015).	Several	studies	have	noted	a	relationship	between	the	ability	
of	patient	sera,	prior	to	exposure,	to	block	HuNoV	HBGA	interactions	or	virus	
induced	red	blood	cell	(RBC)	haemagglutination	to	correlate	with	an	absence	of	
infection	and	illness	(Atmar	et	al.	2015;	Atmar	et	al.	2011;	Czako	et	al.	2012;	Reeck	
et	al.	2010).	Moreover,	in	one	of	these	studies	GII.4	specific	IgA	in	sera	was	shown	
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to	be	an	indicator	of	resistance	to	infection	and	illness,	in	individuals	receiving	
placebo	rather	than	a	vaccine	(Atmar	et	al.	2015).	
1.11 Treatment	and	prevention	
Several	strategies	exist	to	nullify	HuNoV	infection	and	transmission;	including	
infection	control,	vaccination,	antivirals	and	immunotherapy.	Infection	control	
constitutes	preventing	and	limiting	outbreaks	in	semi-closed	environments	through	
policies	on	organisational	structure,	food-handling,	hygiene,	cleaning	and,	in	
healthcare	settings,	patient	isolation	and	cohorting	(Barclay	et	al.	2014).	The	
development	of	an	efficacious	vaccine	has	the	potential	to	prevent	illness	and	
reduce	secondary	transmission	in	groups	at	high	risk	of	exposure	(Bartsch	et	al.	
2016).	On	the	other	hand,	immunotherapy	and	antivirals	are	a	necessary	
alternative	for	the	treatment	of	immunocompromised	individuals	that	would	be	
unable	to	clear	infection	otherwise,	or	can	provide	a	prophylactic	option	(Gairard-
Dory	et	al.	2014;	Rocha-Pereira	et	al.	2015;	Woodward	et	al.	2015).	
1.11.1 Infection	control	
A	HuNoV	outbreak	is	triggered	by	the	virus	being	introduced	into	a	susceptible	
population,	in	a	semi-enclosed	environment,	by	a	person	or	vehicle;	therefore	food-
handling	and	hygiene	are	important	in	prevention.	To	minimise	the	occurrence	of	
virus	introduction,	individuals	in	healthcare	environments	should	wash	their	hands	
with	soap	and	warm	water	for	at	least	20	seconds,	and	food-handlers	should	avoid	
bare	hand	contact	with	food	(Blaney	et	al.	2011;	Division	of	Viral	Diseases	et	al.	
2011;	US	FDA	2013).	Furthermore,	HuNoV	infected	healthcare	workers	or	food-
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handlers,	should	be	absent	from	work	until	48	hours	after	cessation	of	diarrhoea	
and/or	vomiting	(Hall	et	al.	2012;	Thornley	et	al.	2013).	
If	an	outbreak	occurs,	an	overarching	organisational	structure	is	required	to	
implement	measures	to	identify	and	remove	the	source	of	contamination	and	
decontaminate	the	environment.	In	foodborne	outbreaks	the	source	could	be	a	
food-handler	or	commodity,	whereas	in	a	healthcare	environment	it	is	most	likely	a	
patient	or	healthcare	worker.	In	nosocomial	outbreaks,	secondary	transmission	is	
further	contained	by	disposable	personal	protective	equipment	(PPE),	isolation	of	
infected	cohorts,	designation	of	nurses	to	cohorts	and	limiting	visits	or	patient	
transfers	(Haill	et	al.	2012;	Illingworth	et	al.	2011;	MacCannell	et	al.	2011).	Once	an	
outbreak	has	been	contained,	it	is	necessary	to	disinfect	surfaces,	for	which	freshly	
prepared	1000	parts-per	million	(ppm)	of	sodium	hypochlorite	is	recommended,	
and	has	been	demonstrated	to	be	more	effective	in	comparison	to	alternative	
options	(Tung	et	al.	2013).			
1.11.2 Vaccination	
At	present,	there	is	no	vaccine	available	for	HuNoV	disease	prevention.	However,	
given	the	burden	of	disease	the	development	of	an	effective	vaccine	is	highly	
desirable.	In	the	US	population,	if	development	of	a	HuNoV	vaccine	costed	$25	(50	
%	minimum	efficacy)	Markov	modelling	predicted	cost-effectiveness	in	groups	with	
the	greatest	disease	severity	(>	65	years)	or	burden	(<	5	years),	if	immunity	lasted	at	
least	one	year	(Bartsch	et	al.	2012).	However,	an	efficacious	vaccine	would	need	to	
provide	protection	against	the	continual	divergence	of	GI	and,	more	so,	GII	viruses	
of	which	estimates	on	the	longevity	of	protection	from	vaccination	or	challenge	are	
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highly	variable	(Cubitt	et	al.	1998).	Hence,	a	bivalent	HuNoV	intramuscular	vaccine	
has	been	developed,	which	consists	of	NV	VLP	and	a	consensus	GII.4	VLP	and	can	
elicit	broad	immune	responses	to	different	GII.4	strains	(Parra	et	al.	2012).	
The	duration	of	homologous	immunity	has	been	estimated	to	be	~4	–	8	years	by	
mathematical	modelling,	and	therefore	could	be	a	viable	intervention	method	
(Simmons	et	al.	2013).	This	observation	markedly	differs	from	experimental	
evidence,	which	have	described	the	duration	of	immunity	to	be	greater	than	six	
months	but	less	than	two	years	(Johnson	et	al.	1990;	Parrino	et	al.	1977),	which	is	
further	supported	by	epidemiological	studies	in	infants	(Blazevic	et	al.	2016).	
In	total,	two	delivery	routes	have	been	trialled	in	HuNoV	immunogenicity	clinical	
trials;	VLPs	have	been	administered	intranasally	or	intramuscularly	to	cohorts	aged	
between	18	and	50	with	superior	results	obtained	with	the	intramuscular	
administration	(Atmar	et	al.	2011;	Bernstein	et	al.	2015).		
In	a	challenge	clinical	trial,	Atmar	and	colleagues	could	reduce	disease	severity	by	
intranasal	immunisation	with	a	homologous	VLP	prior	to	NV	challenge	(Atmar	et	al.	
2011).	A	subsequent	study	significantly	reduced	disease	severity,	but	not	infection	
rate,	in	volunteers	immunised	intramuscularly	with	a	mixture	of	NV	and	a	GII.4	
consensus	VLP	(Bernstein	et	al.	2015).	The	adjuvants	present	in	the	most	recently	
developed	HuNoV	vaccine,	aluminium	hydroxide	and	monophosphoryl	lipid	A	
(MPL),	could	increase	antibody	titre	and	the	number	of	B	cells	in	the	human	
papilloma	virus	vaccine	(HPV)	(Schwarz	and	Leo	2008).	However,	the	data	provided	
by	these	trials	is	limited,	as	vaccine	induced	immune	responses	have	not	yet	been	
examined	in	the	age	groups	that	would	benefit	most	(infants	and	the	elderly).	
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1.11.3 Antivirals	
An	antiviral	can	provide	a	prophylactic	or	immediate	treatment	option	for	
individuals	that	have	not	been	vaccinated	or	those	that	are	not	capable	of	
mounting	an	adequate	immune	response	to	clear	HuNoV.	The	mechanism	of	an	
antiviral	can	target	a	host	factor,	which	would	have	a	higher	genetic	barrier	for	
antiviral	resistance,	or	a	virus	encoded	protein,	which	will	minimise	inhibition	of	
ongoing	processes	in	the	cell.	In	the	literature,	libraries	of	compounds	have	been	
screened	in	silico	or	in	vitro	for	affinity	to	a	NoV	protease	or	polymerase	(Eltahla	et	
al.	2014).		
Suramin	and,	the	analogous	compound,	NF023	were	found	to	have	an	affinity	for	
the	MNV	and	HuNoV	RdRps	by	in	silico	analysis,	and	thus	inhibited	virus	replication	
in	vitro	(Mastrangelo	et	al.	2012).	Fragments	of	these	molecules	were	used	to	
identify	a	novel	target	site	in	the	RdRp	thumb	domain	(Tarantino	et	al.	2014).	This	
led	to	the	development	of	PPNDs	(pyridoxal-5ʹ-phosphate-6-(2ʹ-	naphthylazo-6ʹ-
nitro-4ʹ,8ʹ-disulfonate)	tetrasodium	salt),	a	molecule	which	inhibits	the	RdRp	by	
double	stacking	in	the	thumb	domain	(Croci	et	al.	2014).	Instead	of	screening	for	
novel	inhibitors,	existing	antivirals	for	other	RNA	viruses	can	be	tested	for	efficacy	
against	NoVs.	Favipiravir	and	Ribavirin,	which	could	also	be	an	immunomodulator,	
increase	the	rate	of	mutagenesis	in	RNA	virus	quasispecies	to	induce	an	error	
catastrophe	event,	of	which	Ribavirin	has	been	shown	to	clear	HuNoV	chronic	
infection	(Arias	et	al.	2014;	Woodward	et	al.	2015).	Another	example	is	2’-C-methyl-
cytidine,	a	nucleoside	analogue	which	has	been	proven	to	clear	MNV	infection,	and	
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as	a	phrophylactic	prevent	transmission	to	susceptible	mice	(Rocha-Pereira	et	al.	
2015;	Rocha-Pereira	et	al.	2013).	
A	dipeptidyl	compound	(GC376),	developed	by	Takahashi	and	colleagues,	was	
shown	to	covalently	bond	to	the	catalytic	cysteine	residue	within	the	NoV	3CL	
protease	and	form	several	hydrogen	bonds	to	inhibit	function	(Takahashi	et	al.	
2013).	Further	work	on	dipeptidyl	compounds	has	identified	macrocylic	molecules	
to	have	differential	activity	against	MNV,	in	contrast	to	host	proteases	(Damalanka	
et	al.	2016;	Galasiti	Kankanamalage	et	al.	2015).	
1.12 Context	and	contribution	of	this	research	
	
As	the	scientific	literature	over	the	last	two	decades	emphasizes,	HuNoVs	are	the	
most	common	cause	of	sporadic	cases	and	outbreaks	of	acute	gastroenteritis	
worldwide.	Their	persistence	in	the	human	population	is	driven	by	a	number	of	
factors	such	as	virion	stability,	low	infectious	dose,	a	broad	host	binding	specificity,	
a	lack	of	long	term	immunity	in	the	host	and	a	high	evolutionary	rate	(Bull	and	
White	2011).	GII.4	HuNoV	is	the	most	diverse	HuNoV	genotype	and	the	most	
persistent;	this	genotype	undergoes	strain	replacement	via	antigenic	drift	in	a	
similar	manner	to	Influenza	A	viruses.		
HuNoV	infection	of	immunocompromised	individuals	is	widely	considered	to	be	a	
reservoir	for	the	emergence	of	novel	virus	strains.	In	chronic	HuNoV	infection,	virus	
shedding	can	persist	for	long	periods,	and	the	virus	population	will	undergo	random	
mutations	leading	to	the	formation	of	quasispecies.	However,	epidemiological	
surveillance	data	would	suggest	HuNoVs	mutate	at	a	much	faster	rate	in	the	
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population.	Therefore,	the	overarching	aim	of	this	thesis	is	to	identify	the	presence	
of	quasispecies	and	generation	of	HuNoV	diversity	in	acute	infections,	in	which	
immune	pressure	could	direct	the	emergence	antibody	escape	novel	strains.	
1.13 The	aims	of	chapter	2	
The	aim	of	this	series	of	investigations	was	to	optimise	a	protocol	for	the	absolute	
quantification	of	GII	HuNoV	from	clinical	stool	samples	by	second	generation	qPCR.		
• To	establish	a	reliable	method	for	absolute	quantification	of	HuNoV	genome	
copy	number	in	stool	samples.	
• To	evaluate	the	impact	of	the	use	of	a	plasmid	vs	RNA	standard	for	
quantification	of	HuNoV	in	stool	samples.	
• To	evaluate	the	impact	of	one	vs	two	step	RT-PCR	and	specific	vs	randomly	
primer	RT-steps	on	quantification	of	HuNoV	in	stool	samples.	
1.14 The	aims	of	chapter	3	
• To	evaluate	the	porcine-gastric	mucin	based	HuNoV	capture	method	as	an	
enrichment	tool	for	HuNoV	in	clinical	samples,	prior	to	MPS.	
• To	measure	the	effects	of	PGM-MB	capture	and	random	PCR	amplification	
cycles	on	the	detection	and	quantification	of	HuNoV	minority	variants	on	
HiSeq	(Illumina)	sequence	data.	
1.15 The	aims	of	chapter	4	
• To	identify	virus	populations	and	mutations	in	whole	genome	sequence	data	
in	clinical	samples	collected	longitudinally	from	acute	HuNoV	infection	
through	to	convalescence,	and	map	any	changes	to	the	protein	structure.	
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• To	accurately	detect	the	presence	of	minority	variants,	in	acute	HuNoV	
infection,	and	identify	whether	regions	of	the	genome	are	under	selective	
pressure.	
• To	investigate	the	relationship	between	the	presence	of	HuNoV	specific	
copro-antibodies	and	any	changes	identified	in	the	HuNoV	whole	genome	
sequence	data	over	the	course	of	acute	infection.	
1.16 The	aims	of	chapter	5	
• To	validate	P2	domain	sequencing	in	HuNoV	seeding	events	and	outbreaks	
as	a	tool	to	discern	the	introduction	of	a	single	HuNoV	strain	or	multiple	
virus	strains	in	an	outbreak	using	different	sequencing	technologies:	Sanger	
and	MPS.	
• To	identify	the	analytical	advantages	and	disadvantages	between	a	partial	
sequencing	and	whole	genome	sequencing	approach	to	tracking	HuNoV	
transmission	within	outbreaks.	
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2 Absolute	quantification	of	GII	
Norovirus	in	clinical	specimens	
	
2.1 Introduction	
2.1.1 Molecular	biology	and	pathogen	quantification	
Accurate	detection	and	monitoring	virus	titres	is	essential	to	various	applications	in	
clinical	virology	and	environmental	virology.	Traditional	methods	have	measured	
viral	titres	via	virus-antibody	(Ab)	interactions,	plaque	forming	units	(pfu)	in	vitro	or	
by	high-resolution	microscopy.	These	quantitative	techniques	can	be	limited	by	the	
availability	of	reagents,	such	as	antibody’s	or	a	tissue	culture	model,	changes	in	
virus	antigenicity	over	time,	or	the	low	sensitivity	of	microscopy	and	the	level	of	
experience	needed	to	visually	discern	different	viruses	in	a	sample	(Goldsmith	and	
Miller	2009).		
The	discovery	of	polymerase	chain	reaction	(PCR)	and	it’s	wide	dissemination	
between	laboratories	led	to	the	development	of	highly	sensitive	and	specific	
molecular	assays	for	virus	quantification	(Mullis	and	Faloona	1987;	Saiki	et	al.	
1985).	The	first	generation	of	quantitative	PCR	(qPCR)	assays	differed	on	whether	
the	proportion	of	a	target	was	determined	at	the	log	phase	of	PCR	or	by	direct	
competition	with	a	separate	nucleic	acid	at	different	concentrations	(Competitive	
PCR).	Quantification	in	the	log	phase	of	PCR	compares	the	sample	against	known	
standards	to	deduce	the	copy	number	of	a	target,	whereas	the	use	of	a	directly	
competing	nucleic	acid	meant	target	abundance	could	be	estimated	by	how	it’s	
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replication	is	inhibited	(JD	1993;	Kellogg	et	al.	1990;	Pang	et	al.	1990;	Wang	et	al.	
1989).	
An	inherent	disadvantage	of	first	generation	qPCR	assays	was	the	requirement	of	
post	amplification	processing,	and	led	to	the	development	of	second	generation	
qPCR	assays	(Heid		Stevens,	J.,	Livak,	K.J.,	and	Williams,	P.M.	1996).	The	principle	of	
second	generation	qPCR	assays	was	first	introduced	In	1996,	which	utilized	the	5’	→	
3’	exonuclease	activity	of	Taq	DNA	polymerase	to	generate	fluorescence	when	
target	molecules	were	replicated	in	a	closed	system	(Heid		Stevens,	J.,	Livak,	K.J.,	
and	Williams,	P.M.	1996).		
Third	generation	qPCR	assays,	or	digital	PCR,	partition	a	sample	to	amplify	single	
genome	copies	in	individual	wells,	the	copy	number	can	then	be	inferred	by	
counting	the	number	of	wells	with	a	fluorescent	signal	(Vogelstein	and	Kinzler	
1999).	Utilization	of	this	technology	in	clinical	laboratories	has	been	limited	by	
dynamic	range	and	cost,	however	theoretically	it	is	more	sensitive	than	second	
generation	assays	and	is	less	susceptible	to	inter-assay	variability	and	inhibitors	of	
amplification	(Dingle	et	al.	2013;	Sedlak	et	al.	2014).	
The	use	of	second	generation	qPCR	assays	is	widespread	amongst	laboratories	and	
has	led	to	the	need	for	standardization	and	quality	controls	between	assays	to	
generate	meaningful	results	(Bustin	et	al.	2009;	Huggett	et	al.	2005).	To	produce	
meaningful	data	that	can	be	published,	it	is	important	to	normalise	the	nucleic	acid	
input,	optimise	amplification,	monitor	inefficiencies	and	quantify	against	validated	
standards	of	known	concentrations	(Bustin	et	al.	2009).	
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2.1.1.1 Normalization	
Prior	to	qPCR,	samples	can	be	normalized	by	the	sample/nucleic	acid	quantity	or	an	
endogenous	host	reference	gene.	To	normalize	by	sample	volume	or	weight	the	
nucleic	acid	target	must	be	evenly	distributed	in	the	sample.	On	the	other	hand,	
copy	number	of	a	target	nucleic	acid	can	be	normalized	to	an	endogenous	
reference	gene,	on	the	assumption	it	is	expressed	at	a	baseline	level	and	is	not	
influenced	by	experimental	parameters	(Brouwer	et	al.	2003).	
2.1.1.2 Internal	process	controls	
A	qPCR	internal	process	control	(IC)	is	an	endogenous	or	exogenous	nucleic	acid	
that	can	be	concurrently	extracted,	reverse	transcribed	(when	the	target	is	RNA)	
and	amplified	with	the	target	to	produce	a	distinct	signal,	and	thus	can	be	
examined	for	inefficiencies	in	the	process.		
An	exogenous	internal	control	(EIC)	can	be	designed	to	compete	with	the	qPCR	
target	for	primer	binding,	a	competitive	internal	control	(CIC),	or	undergo	
amplification	via	a	separate	set	of	primers,	non-competitive	internal	control	(NIC)	
(Hoorfar	et	al.	2004).	A	CIC	would	more	closely	reflect	amplification	of	the	target	
sequence;	however,	the	template	should	be	present	at	a	lower	copy	number	in	
comparison	to	the	target	and	generate	a	longer	amplicon	to	maintain	assay	
sensitivity	(Hoorfar	et	al.	2004).	A	NIC	could	compete	indirectly,	for	enzyme	and	
dNTPs,	but	this	can	be	avoided	if	the	reaction	is	not	performed	in	a	multiplex.	
Simultaneously,	the	structure	of	an	EIC	is	equally	important	to	mimic	the	stability	of	
the	target	at	each	stage	of	the	qPCR	process,	and	can	be	exposed,	as	nucleic	acid,	or	
encased,	as	armoured	RNA,	a	recombinant	virus	or	an	animal	virus	surrogate	
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(Schrader	et	al.	2012).	The	concept	of	an	armoured	EIC	was	first	introduced	in	1998	
(Pasloske	et	al.	1998).	A	portion	of	the	HIV	gag	gene	was	expressed	in	E.	coli,	with	
an	operator	sequence	to	allow	the	self-assembly	of	MS2	capsid	subunits	around	the	
fragment	(Pasloske	et	al.	1998).	The	efficient	expression	of	an	encased	RNA	
fragment	was	limited	to	500	bases,	but	the	MS2	capsid	provided	resistance	to	
nuclease	degradation	and	greater	stability	in	plasma	(Pasloske	et	al.	1998).	A	
protocol	to	produce	recombinant	PR8	Influenza	A	virus,	containing	a	HCV	gene	
fragment,	as	an	EIC	was	recently	described	and	found	to	be	more	stable	and	
cheaper	than	armoured	RNA	(Wang	et	al.	2016).	However,	live	virus	can	be	
genetically	unstable	and	infectivity	would	require	nullification	before	use	as	an	EIC,	
therefore	closely	related	animal	viruses	tend	to	be	evaluated	instead	(Gentry-
Shields	and	Jaykus	2015).	
2.1.1.3 External	standards	
The	quantity	of	a	qPCR	target	can	be	measured	by	a	comparative	cycle	threshold	
(Ct)	or	a	standard	curve	method.	A	comparative	Ct	method	assesses	the	quantity	of	
a	target	relative	to	others	whilst	a	standard	curve	method	measures	absolute	copy	
numbers,	and	hence	requires	an	external	standard	(ES)	of	known	concentration.	
An	ES	is	a	nucleic	acid	template,	consisting	of	identical	priming	sites	to	the	qPCR	
target,	which	is	quantified	in	parallel.	In	the	literature,	live	virus,	plasmids	
(linearized	and	circular),	amplicons,	in	vitro	transcribed	RNA	and	synthetic	
deoxyribonucleic	acid	(DNA)	standards	have	been	validated	(Bermúdez	de	León	et	
al.	2013;	Bowers	and	Dhar	2011;	Dhanasekaran	et	al.	2010;	Fu	et	al.	2009;	Hartnell	
et	al.	2012;	Lima	et	al.	2017).	
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A	validated	ES	should	undergo	reverse	transcription	(RT)	and/or	qPCR,	depending	
upon	the	target	of	interest,	and	remain	stable	for	long	periods	to	prevent	
misinterpretation	of	sample	copy	number.	An	RNA	ES	will	detect	RT	inefficiencies,	
and	therefore	sample	copy	number	can	be	accurately	determined	retrospectively	
(Bowers	and	Dhar	2011).	On	the	other	hand,	plasmid	standards,	and	less	so	
amplicons,	have	greater	stability	at	more	moderate	temperatures,	although	there	is	
evidence	of	an	in	vitro	transcribed	RNA	ES	showing	no	significant	variability	over	9	
months	(Bermúdez	de	León	et	al.	2013;	Dhanasekaran	et	al.	2010).	Alternatively,	
lenticules,	or	control-dried	plano-convex	discs,	are	reference	materials	that	contain	
live	virus	and	are	used	for	quality	control	and	quantitative	purposes	(Hartnell	et	al.	
2012).	Lenticules	have	been	demonstrated	to	have	short	(1	week)	and	moderate	
(52	weeks)	stability	at	room	temperature	and	below	-15	degrees	Celsius,	
respectively	(Hartnell	et	al.	2012).	
2.1.2 HuNoV	diagnostics	
Early	RT-PCR	methods	to	detect	HuNoV	were	mostly	used	qualitatively,	but	several	
semi-quantitative	protocols	exist	for	first	generation	qPCR	of	HuNoV,	and	some	are	
still	used,	however	this	has	largely	been	superseded	by	second	generation	
techniques	(Vennema	et	al.	2002).	Third	generation	qPCR	assays	exist	for	HuNoV,	
but	these	have	been	used	sparingly	in	research,	and	hence	second	generation	
assays	are	considered	the	“gold	standard”	for	diagnostics	(Coudray-Meunier	et	al.	
2016;	Coudray-Meunier	et	al.	2015;	Fraisse	et	al.	2017;	Polo	et	al.	2016).	Although	
PCR	based	assays	are	the	most	common	diagnostic	tool,	there	are	three	inherent	
limitations	to	this	technology.	Firstly,	PCR	relies	on	a	molecular	process	that	can	
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generate	false	negative	results	in	the	presence	of	polymerase	inhibitors;	these	have	
been	comprehensively	described	in	stool	specimens	and	can	be	carried	forward	
after	the	nucleic	extraction	stage	(Schrader	et	al.	2012).	Secondly,	the	high	
sensitivity	of	the	RT-PCR	methods	means	that	the	presence	of	HuNoV	in	a	clinical	
sample	can	be	detected	in	asymptomatic	infection	or	for	an	extended	period	
following	infection	and	recovery	due	to	prolonged	shedding;	this	problem	may	be	
overcome	by	the	establishment	of	an	assay	cut-off	as	a	proxy	for	viral	load	when	
there	is	evidence	that	load	is	inversely	related	to	the	presence	or	severity	of	
symptoms	(Phillips	et	al.	2009).	Thirdly,	quantification	of	a	genome	cannot	discern	
non-infectious	HuNoV	from	viable	virus,	which	can	only	be	ascertained	with	a	valid	
tissue	culture	system.	This	is	still	a	limitation	for	HuNoV	despite	the	recent	
description	of	two	in	vitro	systems	that	sustain	virus	replication	(Ettayebi	et	al.	
2016;	Jones	et	al.	2014).	Whilst	the	ability	to	reproduce	these	methods	more	widely	
is	a	promising	development	for	the	HuNoV	research	field,	at	present	they	do	not	
offer	a	realistic	diagnostic	tool	due	to	their	complexity	and	cost,	in	addition	to	the	
limited	sensitivity	to	date.	
2.2 Materials	and	methods	
2.2.1 Sample	preparation,	RNA	isolation	and	application	of	the	exogenous	
internal	control	
For	protocol	optimization	purposes,	a	collection	of	stool	samples,	positive	for	GII	
HuNoV,	were	gifted	to	this	project	from	a	previous	study	(Table	2.1).	The	protocol	
was	then	applied	to	stool	samples	collected	from	patients	diagnosed	with	clinical	
HuNoV	disease	in	the	Royal	Liverpool	University	Hospital	(RLUH).	Seven	patients	
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were	recruited	in	total,	and	three	of	these	had	two	or	more	samples	collected	
(Table	2.2).	
Table	2.1	GII	HuNoV	archived	samples	used	in	the	optimisation	of	an	absolute	
quantification	methodology	(NA	–	Not	applicable).	
Sample	
ID	
Genogroup	 Year	of	
detection	
Ct	value	
A	 GII	 2012	
	
21.71	
B	 23.36	
C	 35.31	
N	 NA	 Negative	
	
Table	2.2	GII	HuNoV	positive	clinical	samples	collected	for	absolute	quantification	
with	the	optimised	protocol.	
Patient	
ID	
Genotype	 Year	of	
detection	
Day	
collected	
post	
recruitment	
GII	HuNoV	Ct	
value	
D	 GII.4	 2017	 1	 24.45	
2	 24.76	
E	 GII.16P/GII.4	 0	 20.03	
1	 18.94	
1	 19.82	
F	 GII.4	 0	 25.95	
1	 18.10	
2	 20.08	
3	 22.54	
	
Stool	samples	were	suspended	in	sterile	phosphate	buffered	saline	(PBS)	(Sigma,	
Dorset,	UK)	at	2-12%	(w/w);	each	preparation	was	shaken	vigorously	and	
centrifuged	at	14800	rpm	for	10	minutes.	An	aliquot	of	250	µL	of	the	suspension	
supernatant	was	collected	for	nucleic	acid	extraction	by	guanidium	
isothiocyananate/silica	method	(Gn	silica)	(Boom	et	al.	1990).	At	the	first	stage	of	
extraction,	the	lysis	buffer	was	spiked	with	EIC	template	RNA	(PrimerDesign,	
Hampshire,	UK),	as	recommended	by	the	manufacturer.	
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For	lenticule	validation,	2	or	3	Genogroup	II	Lenticule	Discs	(PHE-
RMNOROG2/231415)	were	rehydrated	per	experiment,	and	this	was	performed	
three	times	to	give	seven	replicates	overall.	A	disc	was	rehydrated	in	100	μL	of	
sterile	distilled	water	(SDW)	for	10	minutes	and	vortexed	thoroughly.	Each	disc	was	
serially	diluted	from	1.1	×	104	copies	to	1.1	×	10-2	copies	and	the	nucleic	acids	
extracted	as	described	above.		
2.2.2 Plasmid	standard	curve	
An	E.coli	transformant	of	pCRGII3-3	containing	partial	ORF1+ORF2+ORF3	of	a	GII.3	
HuNoV	genome	(Figure	2.1)	was	kindly	gifted	by	Dr	D	Allen	(PHE).	The	transformant	
was	grown	overnight	at	37°C	in	ampicillin	supplemented	(100	µg/mL)	Luria-Bertani	
broth.	The	plasmid	was	extracted	from	the	overnight	culture	using	the	Qiaprep	Spin	
Miniprep	Kit	(Qiagen,	West	Sussex,	UK),	following	the	manufacturer’s	instructions.	
The	concentration	of	the	plasmid	eluate	was	measured	using	the	Qubit®	DNA	BR	
Assay	Kit	(Fisher	Scientific,	Leicestershire,	UK),	and	then	a	dilution	series	was	
generated	in	the	range	of	6×107	copies/µL	to	6×10-2	copies/µL.				
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Figure	2.1	pCRGII3-3	plasmid	map.	
2.2.3 In	vitro	transcribed	RNA	curve	
Primers	were	designed	to	produce	an	amplicon	consisting	of	a	T7	RNA	polymerase	
promoter	upstream	of	the	ORF1/2	in	pCRGII3-3	(Table	2.3).		A	touchdown	PCR	was	
performed	using	the	Expand	High	Fidelity	System	(Roche,	West	Sussex,	UK)	to	
amplify	the	ORF1/2	region	in	1	ng	of	pCRGII3-3	with	0.4	µM	of	the	RNA	SC	primers	
(Table	2.3).	The	touch	down	PCR	thermal	profile	was	as	follows:	95°C	for	5	min,	
followed	by	3	cycles	of	95°C	for	1	minute,	60°C	for	30	seconds	(decreasing	by	2°C	
every	3	cycles,	with	an	additional	23	cycles	at	50°C),	72°C	for	3	minutes	and	a	final	
extension	step	of	72°C	for	5	minutes.	
The	PCR	product	was	gel-purified	on	a	0.9%	(w/v)	agarose	gel	(Appendix	A),	using	
the	QIAQuick	gel-extraction	kit	(Qiagen,	West	Sussex,	UK),	and	pure	amplicon	
provided	a	template	for	in	vitro	transcription	with	the	MEGAscript	T7	High	Yield	
Transcription	Kit	(Fisher	Scientific,	Leicestershire,	UK).	The	in	vitro	transcribed	RNA	
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was	treated	with	Turbo	DNase	(Fisher	Scientific,	Leicestershire	UK)	and	precipitated	
using	lithium	chloride,	as	recommended	by	the	MEGAscript	T7	High	Yield	
Transcription	Kit	(Fisher	Scientific,	Leicestershire,	UK).	The	purified	RNA	was	then	
re-suspended	in	30	µL	DEPC-treated	water	(Fisher	Scientific,	Leicestershire,	UK).	
The	concentration	of	transcribed	RNA	and	remaining	DNA	template	were	measured	
using	Qubit®	RNA	BR	and	DNA	HS	Assay	Kits	(Fisher	Scientific,	Leicstershire,	UK).	
Subsequently,	the	RNA	was	diluted	to	a	range	of	6×105	copies/µL	to	6×10-2	
copies/µL.		
2.2.4 RT,	One	step	and	two	step	qPCR	
RT	reactions	were	performed	using	the	SuperScriptTM	III	Reverse	Transcriptase	
System	(Fisher	Scientific,	Leicstershire,	UK).	The	RT	reaction	mixture	(35	µL)	
contained	7	µL	of	5	×	First-Strand	Buffer,	1.4	mM	DTT,	5	mM	MgCl2,	0.29	mM	
dNTPs,	200	units	of	SuperScriptTM	III	reverse	transcriptase	and	5	µL	of	RNA.	Primer	
concentrations	for	the	conversion	of	RNA	to	cDNA	were	as	follows:	for	a	random	
RT,	0.29	µM	of	random	hexamers;	for	a	specific	RT,	0.29	µM	of	the	COG	II	primers	
(Table	2.3);	for	EIC	RNA,	1	µL	of	the	Internal	Control	RNA	RT	primer	mix	
(Primerdesign,	Hampshire,	UK).	The	thermal	profile	for	first	strand	synthesis	
consisted	of	25°C	for	10	minutes,	37°C	for	60	minutes	and	95°C	for	5	minutes.	
A	Rotor	Gene	6000	(Qiagen,	West	Sussex,	UK)	instrument	was	used	for	one	and	
two-step	qPCR.	One-step	qPCR	assays	were	performed	using	the	2´Precision	
OneStepTM	qRT-PCR	Mastermix	(Primerdesign,	Hampshire,	UK).	A	final	reaction	
mixture	(20	µL)	included	10	µL	Precision	OneStepTM	qRT-PCR	Mastermix	
(Primerdesign,	Hampshire,	UK)	and	5	µL	of	RNA.	Primer	and	probe	concentrations	
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for	single	and	multiplex	reactions	were	as	follows:		for	the	GII	assay,	0.5	µM	of	COG	
II	primers	and	0.125	µM	of	the	Ring	2	P	probe	(Table	2.3);	for	the	GADPH	assay,	0.5	
µM	of	primers	and	0.25	µM	of	probe	(Table	2.3);	for	the	IC	assay	1	µL	of	the	IC	
primer/probe	mix	(Primerdesign,	Hampshire,	UK).	The	thermal	profile	for	the	one-
step	assay	consisted	of	55°C	for	10	minutes,	95°C	for	8	minutes	followed	by	40	
cycles	of	95°C	for	15	seconds	and	60°C	for	60	seconds.		
Two-step	qPCR	assays	were	performed	using	the	PrecisionPLUS	Mastermix	
(Primerdesign,	Hampshire,	UK).	A	final	reaction	mixture	(20	µL)	included	10	µL	
PrecisionPLUS	mastermix	(Primerdesign,	Hampshire,	UK),	5	µL	of	DNA,	0.4	µM	of	
COG	II	primers	and	0.1	µM	of	Ring	2	P	probe	or	1	µL	of	the	IC	primer/probe	mix	
(Primerdesign,	Hampshire,	UK).	The	thermal	profile	for	the	two-step	assay	
consisted	of	95°C	for	2	minutes	followed	by	40	cycles	of	95°C	for	10	seconds	and	
60°C	for	60	seconds.	Probe	fluorescence,	for	the	one	and	two-step	assays,	was	
acquired	on	the	green	channel	during	annealing	and	extension.	 	
For	the	plasmid	template,	a	single	standard	curve	was	run	with	the	one-step	qPCR	
assay,	6	replicates,	and	three	independent	standard	curves	with	the	two-step	qPCR	
assay,	20	replicates	overall.		
For	the	ssRNA	template,	three	independent	standard	curves	were	run	with	the	one-
step	qPCR	assay,	14	replicates	overall.	A	one-step	(no	RT	control)	and	two-step	
qPCR	assay	were	performed	on	each	dilution	to	detect	the	presence	of	residual	
DNA.	
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For	each	respective	template,	the	mean	Ct	value	and	calculated	copy	number	were	
averaged	for	each	10-fold	dilution,	the	slope	and	y-intercept	could	then	be	
calculated	by	linear	regression	analysis.	
Table	2.3	Primer	and	probe	oligonucleotides.	
	
	 	
F:Forward,	R:Reverse,	P:Probe,	References	–	GADPH	set:	(Miyamoto	et	al.	2011),	COG	set:	
(Kageyama	et	al.	2003).	
aGuanidine	/	Cytosine	content.	
b	Melting	temperature	(20	µM	-	Basic).	
c	FAM	reporter	dye	coupled	to	the	5’/TAMRA	quencher	dye	coupled	to	the	3’	end	of	the	
oligonucleotide.	
2.3 Results	
2.3.1 The	commercial	EIC	is	suitable	to	assess	the	efficiency	of	clinical	stool	
extraction	
To	use	the	EIC	in	experiments,	it	was	necessary	to	measure	the	consistency	of	
template	detection	during	clinical	sample	extraction,	with	and	without	the	presence	
of	GII	Nov.	The	one-step	qPCR	assay	measured	the	IC	to	be	suitable	for	monitoring	
the	recovery	of	RNA	during	extraction	in	the	presence	or	absence	of	virus	
(Table	2.4).		
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Table	2.4	EIC	validation	between	a	HuNoV	positive	and	negative	sample.	
	 Ct	value	
Sample	 HuNoV		 IC		
A	 20.03	 30.27	
N	 Negative	 30.8	
	
2.3.2 Duplex	quantification	of	the	commercial	IC	and	GII	HuNoV	influences	virus	
quantification	efficiency		
The	effect	of	an	IC	and	GII	HuNoV	duplex	was	evaluated	by	one-step	qPCR	of	the	
virus	in	the	presence	and	absence	of	IC	amplification.	Relative	quantification	of	the	
virus	in	the	presence	of	the	spiked	RNA	template	was	inhibitory	toward	GII	HuNoV	
quantification	in	most	reactions	(7/8)	(Table	2.5).	The	mean	increase	in	the	HuNoV	
Ct	value	was	1.07	and	ranged	from	0.1	to	3.0;	therefore,	assays	hereafter	would	
amplify	both	in	separate	reactions	(Table	2.5).	
Table	2.5	GII	HuNoV	quantification	in	single	reactions	and	an	EIC	multiplex.	
Sample	 Experiment	 HuNoV	Ct	value	
without	IC	
HuNoV	Ct	
value	with	IC	
A	 1	 18.76	 18.93	
2	 20.19	 21.65	
3	 19.44	 21.17	
4	 19.36	 19.98	
B	 1	 19.64	 18.75	
2	 19.36	 19.46	
3	 18.23	 18.66	
4	 18.62	 21.62	
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2.3.3 Weight	normalization	of	faecal	samples	provides	greater	consistency	than	
an	endogenous	housekeeping	gene	
Two	methods	of	stool	sample	normalisation	were	compared;	these	were	weighing	
the	amount	of	stool	used	for	extraction	or	quantifying	the	endogenous	reference	
gene,	glyceraldehyde-3-phosphate	dehydrogenase	(GADPH),	in	parallel	one-step	
qPCR	reactions.		
The	average	log10	of	viral	load	for	two	different	sets	of	repeated	sample	
preparations,	deduced	from	the	validated	RNA	standard	(Figure	2.2),	were	9.7±0.3	
for	A	and	9.9±0.25	for	B	(Table	2.6).	These	results	demonstrate	the	reproducibility	
of	HuNoV	sample	preparation,	nucleic	acid	extraction	and	one-step	qPCR.	
Moreover,	the	results	from	one-step	quantification	in	the	same	sample	were	
indicative	of	a	homogenous	distribution	of	virus	in	the	HuNoV	positive	stool	
samples	tested.	
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Table	2.6	Weight	normalisation	of	faecal	suspensions	from	two	samples.	
Sample	 Experiment	 Weight	(g)	 HuNoV	
Ct	value	
Viral	load	(genome	
copies/g)	
Log10	viral	
load	
A	 1	 0.05	 18.76	 1.1	×	1010	 10.1	
2	 0.09	 20.19	 0.26	×	1010	 9.4	
3	 0.10	 19.44	 0.37	×	1010	 9.6	
4	 0.11	 19.36	 0.36	×	1010	 9.6	
B	 1	 0.02	 19.64	 1.6	×	1010	 10.2	
2	 0.10	 19.36	 0.36	×	1010	 9.6	
3	 0.09	 18.23	 0.89	×	1010	 9.9	
4	 0.11	 18.62	 0.57	×	1010	 9.8	
	
Detection	of	the	reference	gene,	GADPH,	in	stool	samples,	with	or	without	GII	
HuNoV,	was	consistently	low	between	experiments;	ranging	from	35.99-38.35	Ct	
values	(Table	2.7).	Quantification	of	the	reference	gene	was	more	variable	with	
standard	deviations	ranging	from	0.05-1.67,	in	comparison	to	GII	HuNoV	in	weight	
normalised	samples,	0.59-0.65.	
Table	2.7	Reference	gene	normalisation.	
Sample	 Weight	(g)	 GADPH	Ct	value	 HuNoV	Ct	value	
A	 0.05	 Negative	 18.78	
0.04	 36.29	 19.12	
B	 0.13	 38.35	 25.94	
0.11	 35.99	 26.1	
C	 0.07	 36.36	 Negative	
0.05	 36.29	 Negative	
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2.3.4 A	HuNoV	primer	specific	two-step	qPCR	approach	showed	the	greatest	
sensitivity	for	GII	HuNoV	detection		
To	further	develop	an	assay	for	GII	HuNoV	quantification	from	clinical	samples,	
experiments	were	undertaken	to	amplify	a	dilution	series	of	the	virus	in	sample	A,	
using	one	and	two-step	qPCR	with	random	or	HuNoV-specific	RT	reactions.	A	two-
step	qPCR	with	a	virus	targeting	RT	step	was	the	most	sensitive	of	all	the	PCR	assays	
tested	(Table	2.8).	In	contrast	a	randomly	primed	RT,	that	shouldn’t	discriminate	
between	sequences	prior	to	RNA	conversion,	was	the	least	sensitive	for	detection	of	
GII	HuNoV	of	all	three	assays	performed.	The	one-step	qPCR	assay	(RT	and	PCR	
combined)	showed	an	intermediate	level	of	sensitivity,	but	at	the	highest	dilution	
factor	the	reaction	was	in	the	limits	of	detection	for	the	virus	(Table	2.8).	
Table	2.8	GII	HuNoV	positive	stool	sample	RT-PCR	results	using	different	
PCR/priming	strategies.	
Sample	 PCR	reaction	 Dilution	
factor	
HuNoV	Ct	
value	
Random	hexamer	
Ct	value	
A	
		
		
		
		
		
		
		
		
		
		
One-step	 100	 19.25	 		
		 	10-1	 21.33	 		
		 	10-2	 24.24	 		
		 	10-3	 28.39	 		
		 	10-4	 37.90	 		
Two-step	 100	 17.20	 21.57	
		 	10-1	 20.52	 24.58	
		 	10-2	 22.75	 28.16	
		 	10-3	 27.58	 31.72	
		 	10-4	 29.82	 34.56	
		 	10-5	 33.28	 37.37	
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To	examine	whether	differences	in	sensitivity	could	be	observed	in	a	different	type	
of	template	these	experiments	were	repeated	to	quantify	the	in	vitro	transcribed	
RNA	standard	curve.	The	in	vitro	transcribed	curve	was	assayed	in	triplicate	from	
3×106	to	3×103	copies,	and	the	sensitivity	increased	consecutively	from	the	two-step	
assay	with	a	randomly	primed	RT,	to	the	one-step	assay	and	further	to	the	targeted	
two-step	qPCR,	with	the	exceptions	of	3×104	and	3×103	copies	for	this	assay	
(Figure	2.2).	From	3×104	to	3×103	copies	the	targeted	two	step	lost	the	ability	to	
detect	GII	HuNoV,	whilst	the	two-step	with	a	randomly	primed	RT	became	
increasingly	variable	(Figure	2.2).	In	contrast,	the	one	step	assay	did	not	become	
undetectable	from	3×104	to	3×103	copies	and	was	much	less	variable	within	this	
range	than	a	two-step	with	a	randomly	primed	RT	(Figure	2.2).	
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Figure	2.2	Standard	curves	generated	in	one	and	two-step	qPCR	using	two	
template	preparation.	
	
2.3.5 Absolute	quantification	with	a	plasmid	standard	can	underestimate	viral	
load	
Comparison	of	the	two	different	standards,	in	vitro	transcribed	RNA	and	plasmid,	
after	validation	highlighted	that	the	RNA	standard	generated	a	higher	Ct	value	at	an	
identical	predicted	copy	number	to	the	DNA	(Figure	2.2).		
To	investigate	this,	standardized	and	published	reference	materials,	lenticules,	
containing	a	geometric	mean	of	4.04	log10	GII	HuNoV	genome	copies/disc	were	
diluted	and	quantified	with	the	RNA	and	DNA	standards.	Lenticule	dilutions	101,10-1	
and	10-2	were	estimated	to	be	at	log10	copy	numbers	3.39±0.17,	2.78±0.14	and	
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1.57±0.089	against	the	DNA	standard,	whereas	the	RNA	template	estimated	
greater	viral	titres	of	5.31±0.17,	4.72±0.13	and	3.57±	0.082	(Figure	2.3).	The	batch	
of	lenticules	measured	had	an	expected	range	of	1.65	to	4.46,	which	was	in	close	
agreement	with	the	plasmid	standard,	and	hence	the	HuNoVs	in	the	disc	were	
quantified	with	a	DNA	standard	(Figure	2.3	-	A).	If	quantification	of	the	reference	
material	was	performed	with	the	DNA	standard,	the	log	genome	copy	number	
appeared	to	be	underestimated	when	compared	to	the	RNA	standard	(Figure	2.3	-	
B).		
	
Figure	2.3	Quantification	of	lenticule	reference	material	with	different	standards	
A)	Plasmid	B)	in	vitro	transcribed	RNA	(Dashed	lines	=	Upper	and	lower	expected	
range	of	the	lenticule	batch).	
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2.3.6 Application	of	the	absolute	quantification	of	GII	HuNoV	method	to	
quantify	HuNoV	present	in	samples	collected	longitudinally	from	the	acute	
phase	of	infection	to	convalescence		
Longitudinal	samples	from	three	different	patients	(D,	E	and	F)	were	weight	
normalised	and	quantified	in	triplicate	by	one-step	qPCR,	in	parallel	with	the	two	
standards	(Figure	2.4).	Where	samples	were	available	from	the	day	of	symptom	
onset,	peak	viral	load	was	observed	approximately	24	hours	from	onset,	with	
decreasing	titres	subsequently	(Figure	2.4).	The	data	shows	that	this	method	is	
highly	reproducible,	and	the	use	of	a	DNA	standard	for	HuNoV	load	estimation	
consistently	underestimates	the	amount	of	virus	present	in	the	clinical	samples	by	
nearly	3	logs	of	magnitude.	
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Figure	2.4	Quantification	of	longitudinal	GII	HuNoV	samples	with	the	optimised	
method.	
	
2.4 Discussion		
In	this	series	of	investigations,	methods	for	consistent	HuNoV	quantification	in	
clinical	samples	have	been	optimized.	
Firstly,	a	commercially	available	EIC	to	monitor	the	extraction	efficiency	of	viral	RNA	
from	stool	was	validated.	Multiplexing	the	target	virus-specific	and	EIC	PCRs	
	 93	
together	resulted	in	increasing	Ct	values	for	the	target	PCR	in	most	reactions.	This	
inhibitory	effect	could	be	due	to	competition	between	the	two	templates;	directly	
for	primer	binding	or	indirectly	as	reagents	become	limiting	in	the	PCR	reaction.	The	
concept	of	a	bias	toward	the	amplification	of	one	template	over	another	is	
documented	in	the	literature,	and	can	be	split	into	PCR	selection	and	drift	(Polz	and	
Cavanaugh	1998;	Suzuki	and	Giovannoni	1996;	Wagner	et	al.	1994).	Overall,	the	
experimental	results	would	suggest	the	presence	of	PCR	selection	rather	than	drift,	
as	the	inhibitory	effect	was	reproducible.	However,	PCR	selection	is	multifactorial;	
and	can	be	influenced	by	primer	GC	content,	template	length,	template	accessibility	
and	the	number	of	primer	binding	sites	in	a	template	(Polz	and	Cavanaugh	1998).	
Secondly,	normalization	and	quantification	by	stool	weight	was	established	as	the	
most	reliable	method	when	compared	to	the	use	of	a	house	keeping	gene,	GADPH.	
The	use	of	housekeeping	gene	amplification	for	relative	quantification	is	common	
practice	in	clinical	virology,	where	the	method	has	been	validated	for	tissue	
samples	and	blood	primarily	(Dong	and	Wang	2012;	Gra	et	al.	2003;	Jabs	et	al.	
2001;	Kuchipudi	et	al.	2012).	However,	the	validity	of	this	approach	for	use	with	
stool	samples	is	far	less	clear.	Stool	samples	are	heterogeneous,	and	will	contain	
varying	proportions	of	host	cell	material,	microorganisms	(bacteria,	virus	and	
potentially	protozoa),	partially	digested	foods	(of	animal	or	plant	origin,	and	hence	
may	also	contain	pathogens	or	symbionts	of	those	organisms).	Therefore,	accurate	
normalization	of	quantification	is	severely	challenged	by	the	enormous	diversity	
from	sample	to	sample	not	only	depending	on	the	individual	but	also	on	the	
severity	of	the	symptoms	when	samples	are	being	investigated	for	GE,	the	duration	
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of	symptoms	and	the	degree	of	injury	to	the	gut.	Although	some	reports	have	
suggested	that	GADPH	or	other	human	housekeeping	genes	can	be	applied	for	
relative	quantification	purposes	(Miyamoto	et	al.	2011);	the	data	presented	here	
suggest	that	this	is	unreliable	due	to	the	levels	detected,	when	present,	being	low	
and	close	to	the	assay’s	limit	of	detection.	Another	challenge	is	that	viruses	form	
clumps	either	because	they	are	attached	to	cell	debris	or	linked	by	antibodies,	
particularly	as	infection	and	recovery	progress.	The	experiments	presented	here	
clearly	indicate	that	normalization	by	stool	weight	is	a	reproducible	approach	in	
acute	HuNoV	infection,	and	furthermore,	that	in	this	environment	the	virus	is	
represented	homogenously,	hence	making	norovirus	quantification	using	this	
approach	robust	and	reproducible.	
Thirdly,	for	HuNoV	RNA	amplification,	a	two-step	RT-PCR	approach	using	HuNoV	
specific	primers	in	the	RT	step	was	established	as	the	most	sensitive	approach	for	
detection	and	quantification.	By	separating	the	RT	conversion	step	and	DNA	
amplification,	both	reactions	can	be	optimized	without	limiting	substrate	or	
reaction	conditions.	In	contrast,	a	two-step	with	random	hexamer	priming	in	the	RT	
reaction	reduced	sensitivity	although	this	was	within	the	instrumental	error.	
Therefore,	a	random	RT	could	be	viable	in	obtaining	cDNA	across	the	breadth	of	a	
sample	without	having	a	significant	influence	on	detection	sensitivity.	The	
advantage	of	the	latter	approach	is	that	the	cDNA	produced	could	be	used	for	the	
detection	of	multiple	targets	that	may	be	other	RNA	viruses,	transcripts	of	interest,	
and	other	regions	of	the	genome	of	interest.	A	random	RT	of	a	HuNoV	positive	
clinical	sample	could	be	used	to	amplify	the	major	capsid	gene	that	may	be	
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necessary	for	virus	characterization	and	for	outbreak	investigation	and	tracking	
(Iturriza-Gomara	et	al.	1999).	Furthermore,	in	sequencing	projects	it	is	important	to	
analyse	an	even	distribution	of	a	virus	population,	without	bias	toward	a	single	
genotype.	HuNoV,	an	RNA	virus,	can	mutate	readily	in	a	cloud	of	quasispecies	
leading	to	variants	and	eventually	generation	of	novel	genotypes	(Domingo	et	al.	
1985);	the	use	of	random	priming	can	maintain	the	detection	of	diversity	with	a	
reduction	in	bias	in	diagnostics	and	virus	characterization	assays	used	in	reference	
laboratories	and	research.	
Finally,	development	and	the	use	of	an	RNA	standard	curve	demonstrated	
quantitative	methods	using	DNA	standard	curves	underestimate	viral	load,	which	
are	widely	used	in	HuNoV	detection	(https://www.iso.org/standard/65681.html).	
This	is	an	important	observation,	and	is	particularly	pertinent	and	relevant	to	the	
quantification	of	virus	in	foods	and	the	environment,	where	assumptions	may	be	
made	on	the	risk	to	users	and	consumers	from	contaminated	food	or	water	based	
on	viral	load	measurements.	
We	have	optimised	methods	for	GII	HuNoV	quantification	by	qRT-PCR,	and	applied	
this	methodology	to	clinical	HuNoV	samples.	First,	we	have	validated	a	
commercially	available	EIC	to	monitor	the	extraction	efficiency	of	viral	RNA	from	
stool.	Second,	stool	samples	can	be	normalised	by	weight	more	efficiently	and	
reproducibly	than	with	a	housekeeping	gene	(GADPH),	for	virus	quantification.	
Third,	a	GII	HuNoV	specific	RT	followed	by	PCR	was	the	most	sensitive	for	viral	load	
quantification	in	clinical	samples.	
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3 The	development	of	an	unbiased	
capture	method	for	HuNoV	
3.1 Introduction	
Several	nucleic	acid	sequencing	technologies	have	been	invented	in	the	past	half-
century,	which	have	increased	the	amount	of	molecular	data	available,	and	further,	
the	applications	and	different	types	of	analyses	that	can	be	performed.	The	first	
assays,	to	determine	the	order	of	a	nucleic	acid	sequence,	consisted	of	specific	
enzymatic	or	chemical	degradation	of	very	short	oligonucleotides	and	product	
separation	by	chromatography,	electrophoresis	or	both	(2D	fractionation),	to	
resolve	each	fragment	(Holley	et	al.	1964;	Sanger	et	al.	1965).	Over	a	decade	later,	
the	concept	of	sequencing	by	DNA	polymerase	extension	was	introduced,	which	
required	individual	radiolabeled	nucleotides	to	be	added	sequentially	for	step	wise	
extension,	and	chromatographic	separation	of	each	product	(Padmanabhan	et	al.	
1972).	Thereafter,	Sanger	published	a	methodology	to	determine	50	nucleotides,	
the	‘Plus-Minus	system’,	by	combining	5’	to	3’	nucleotide	addition	of	DNA	
polymerase	and	3’	to	5’	cleavage	of	T4	polymerase,	which	immediately	predates	
widely	used	1st	generation	sequencing	technologies	(Sanger	and	Coulson	1975).		
In	1977,	two	1st	generation	sequencing	assays	were	published,	which	detected	
deoxyribonucleic	acid	(DNA)	strand	fragments	radiolabeled	on	the	phosphate	group	
at	the	5’	end	by	electrophoresis.	Firstly,	the	‘Chemical	sequencing’	method	(50-100	
nucleotides)	which	chemically	degraded	a	specific	nucleotide	base,	which	was	
followed	by	strand	scission,	to	produce	fragments	at	each	position	of	the	DNA	
strand	(Figure	3.1	-	A)	(Maxam	and	Gilbert	1977).	Secondly,	‘Sanger	method’	(~1000	
	 97	
nucleotides)	which	combined	primer	directed	DNA	replication	with	radiolabelled	
dideoxynucleotides	(ddNTPs)	to	limit	strand	extension	at	each	position	(Figure	3.1	-	
B)	(Sanger	et	al.	1977).	
	
Figure	3.1	The	process	of	(A)	Maxam-Gilbert	sequencing	
(https://commons.wikimedia.org)	and	(B)	Sanger	sequencing	to	discern	
nucleotide	sequences	(https://www.slideshare.net/ueb52/introduction-to-next-
generation-sequencing-v2).	
	
The	‘Sanger	method’	became	the	first	widely	used	1st	generation	sequencing	
technology,	and	further	improvements	to	this	methodology	such	as	the	use	of	
fluorophores	and	the	detection	of	fluorescence	by	a	laser	allowed	the	sequencing	
to	take	place	in	a	single	reaction	(Figure	3.1	-	B).	Sequencing	then	became	
accessible	to	many	laboratories	through	reduced	economic	costs,	due	to	vastly	
reduced	running	times,	and	simplified	protocols	after	the	introduction	of	capillary	
sequencing	machines	coupled	with	the	ability	to	obtain	sequence	for	increasingly	
longer	fragments.	This	marked	the	beginning	of	the	“genomic	revolution”,	the	
exponential	increase	in	DNA	sequence	data	availability,	and	the	routine	application	
of	sequencing	to	a	wide	range	of	research	and	medicine	areas.	These	improvements	
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have	been	carried	forward	to	subsequent	sequencing	technologies	(Hunkapiller	et	
al.	1991).	The	sequencing	technologies	currently	available	can	be	separated	into	1st	
(e.g	Sanger	sequencing),	2nd	(Massively	parallel	sequencing	platforms)	and	3rd	
(Single	molecule	sequencing	platforms)	generation	technologies	(Heather	and	Chain	
2016).	
3.1.1 Massively	parallel	sequencing	
Massively	parallel	sequencing	(MPS)	is	a	process,	provided	currently	by	multiple	
platforms,	that	allows	sequencing	of	all	DNA	in	a	sample	with	high	redundancy.	The	
process	can	be	split	into	three	stages:	library	preparation,	sequencing	and	data	
analysis.			
At	the	library	preparation	stage,	nucleic	acids	are	fragmented	and	indexed.	
Fragmentation	can	be	achieved	mechanically	(nebulization	or	hydrodynamic	
shearing),	enzymatically	(transposase	or	nuclease)	or	chemically	(heating	with	a	
divalent	cation).	Individual	fragments	are	then	labelled	with	a	unique	index	
sequence	to	allow	for	sample	pooling	in	the	latter	stages.	At	this	point,	if	necessary,	
the	library	can	be	amplified	by	polymerase	chain	reaction	(PCR),	depending	upon	
the	amount	of	template	available.	
At	the	sequencing	stage,	if	the	library	is	not	already	immobilized	(such	as	via	
emulsion	PCR),	the	library	is	bound	to	a	solid	surface	by	oligonucleotides	
complementary	to	the	index	or	by	the	presence	of	an	immobilized	polymerase.	The	
different	platforms	available	can	then	be	separated	into	the	following	categories	
based	on	sequencing	chemistry:	cyclic	reversible	termination	(CRT),	single-
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nucleotide	addition	(SNA),	sequencing	by	ligation	(SBL)	and	real-time	sequencing	
(RTS)	(Table	3.1).	
3.1.2 The	Massively	Parallel	Sequencing	platforms	
Different	types	of	MPS	platform	exist;	each	varies	in	sample	preparation,	
throughput,	read	length,	read	accuracy	and	the	amount	of	data	produced	
(Table	3.1).		The	aims	of	a	project	should	dictate	the	choice	of	platform;	for	
example,	a	project	attempting	to	identify	quasispecies	in	a	population	of	small	
genomes	would	not	require	long	reads	but	would	need	a	high	base	call	accuracy.	
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Table	3.1	Types	of	MPS	platforms	and	their	specifications.	
Manufacturer	 Sequencing	
chemistry	
Approximate	
read	length	
(bases)	
Approximate	
maximum	
amount	of	
data	per	run	
Strength	 Weakness	 Reference	
Study	or	
Review	
Illumina	
(HiSeq/MiSeq)	
CRT	 36-600	 540-15,000	
Mb	
High	
throughput	
with	a	low	
error	rate	
Sequencing	
AT-GC	rich	
regions	is	a	
challenge	
(Radford	
et	al.	
2012)	
Thermo	
Fisher	
Scientific	
(SOLiD)	
SNA	 200-400	 30-2,000	Mb	 Fastest	
throughput	
and	
shortest	
run	time	
Poor	
performance	
with	
homopolymers	
Roche	(454)	 SNA	 400-700	 450-700	Mb	 Long	reads	 Difficult	to	
distinguish	
signal	for	
homopolymers	
of	6	
nucleotides	
and	above	
Pacific	
Biosciences	
(PacBio)	
RTS	 0-60,000	 500-1,000	
Mb	
Long	reads	 Accuracy	83%	
on	one	run	
(can	increase	
with	repeated	
sequencing	
runs)	
(Metzker	
2010)	
Thermo	
Fisher	
Scientific	(Ion	
Torrent)	
SBL	 50-75	 80,000-
320,000	Mb	
Positions	
sequenced	
twice	–	
high	
accuracy	
Instrument	
has	difficulty	
sequencing	
AT-GC	rich	
regions	
Oxford	
Nanopore	
Technologies	
(MinION)	
RTS	 10,000-
100,000	
40,000	Mb	 Longest	
reads	
Difficulty	
sequencing	GC	
rich	
regions/High	
error	rate	
(Laver	et	
al.	2015)	
Approximate	read	length	and	maximum	amount	of	data	per	run	obtained	from	manufacturer’s	
website	(2016)	
	
3.1.2.1 Bridge	amplification	(2nd	generation)	
Bridge	amplification	is	a	sequencing	process	provided	by	the	HiSeq	and	MiSeq	
platforms	(Illumina).	Fragmented	nucleic	acids	are	bound	to	a	lawn	of	
oligonucleotides	on	a	flow	cell	via	adapters,	and	the	complementary	sequence	
generated.	Each	adapter,	present	on	the	5’	and	3’	can	then	form	a	bridge	with	their	
corresponding	adapter	on	the	flow	cell	for	clonal	amplification.	Once	clusters	are	
generated	the	3’	ends	are	blocked	and,	firstly,	forward	strands	are	sequenced	with	
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fluorescently	labeled	reversible	terminators,	followed	by	the	reverse	strand	in	the	
next	stage	(Figure	3.2	-	F)	(Bentley	et	al.	2008).	
3.1.2.2 Oligonucleotide	ligation	and	detection	or	SOLiD	sequencing	(2nd	
generation)	
Oligonucleotide	ligation	and	detection	sequencing	requires	nucleic	acid	fragments	
to	be	bound	to	beads	covered	with	adapter	sequence,	which	are	then	clonally	
amplified	and	further	aggregated	to	larger	polystyrene	beads	for	fixation	to	a	glass	
slide.	Sixteen	different	fluorescently	labelled	primers	are	introduced	(octamers),	
corresponding	to	four	colours,	and	successively	ligated	via	the	first	two	nucleotides.	
The	latter	six	nucleotides	of	the	primer	are	universal,	of	which	the	final	three	are	
bound	to	the	fluorophore,	and	chemically	cleaved	after	laser	excitation.	However,	
as	two	nucleotides	on	the	probe	dictate	binding,	and	the	following	three	are	
universal	bases	which	are	not	cleaved,	the	sequence	must	be	offset	by	1-5	positions	
to	obtain	the	complete	sequence	data	(Figure	3.2	-		B)	(McKernan	et	al.	2009).	
3.1.2.3 Pyrosequencing	(2nd	generation)	
The	concept	of	measuring	the	production	of	inorganic	phosphate	in	biological	
reactions	was	published	in	1985	(Nyren	1987).	Nyren	and	colleagues	demonstrated	
inorganic	phosphate	could	be	sequentially	converted	to	adenine	triphosphate	
(ATP),	by	ATP	sulfurylase,	and	then	used	as	a	substrate	for	bioluminescence,	by	
luciferase	(Nyren	1987).	A	platform,	the	454	instrument,	was	then	manufactured	
(Roche)	that	could	measure	the	release	of	organic	phosphate	after	the	correct	
incorporation	of	a	nucleotide	by	DNA	polymerase,	by	cycling	through	the	four	
different	options	(Figure	3.2	-	E)	(Margulies	et	al.	2005).	
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3.1.2.4 Semiconductor	sequencing	(2nd	generation)	
In	semiconductor	sequencing,	provided	by	the	Iontorrent	platform	(Life	
technology),	nucleic	acid	fragments	are	bound	to	beads	and	clonally	amplified.	
After	amplification,	each	bead	occupies	a	single	well	in	a	chip	and	an	individual	
nucleotide	is	added	for	incorporation	by	DNA	polymerase;	if	the	correct	nucleotide	
is	added	a	proton	is	released	which	can	be	detected	as	a	pH	change	(Figure	3.2	-	D)	
(Rothberg	et	al.	2011).	
3.1.2.5 Single	molecule	real-time	sequencing	(3rd	generation)	
Single	molecule	real-time	sequencing,	provided	by	the	PacBio	platform	(Pacific	
Biosciences),	does	not	require	clonal	amplification.	This	platform	detects	strand	
extension	as	the	fluorophore	present	on	labeled	nucleotides	is	cleaved	by	DNA	
polymerase	in	real-time	(Figure	3.2	-	C)	(Braslavsky	et	al.	2003).	
3.1.2.6 Direct	strand	sequencing	-	Nanopore	(3rd	generation)	
In	a	similar	manner	to	the	PacBio,	nucleic	acids	prepared	for	direct	strand	
sequencing	are	not	clonally	amplified,	and	can	be	performed	with	the	MinION	
platform	(Nanopore	technology).	Direct	strand	sequencing	requires	an	
electrophoretic	gradient	separated	by	a	bilayer	which	contains	pores,	such	as	a-
hemolysin.	A	strand	of	ribonucleic	acid	(RNA)	or	DNA	diffuses	through	the	pore,	
down	the	gradient,	and	each	base	blocks	an	electric	current	running	across	the	
bilayer	to	produce	a	characteristic	signal	disruption	in	the	electric	current	
(Figure	3.2	-	A)	(Kasianowicz	et	al.	1996).	
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Figure	3.2	The	types	of	sequencing	chemistries	currently	available	–	(A)	Direct	
strand	sequencing	(https://commons.wikimedia.org),	(B)	Oligonucleotide	ligation	
and	detection	sequencing	(Voelkerding	et	al.	2009),	(C)	Single	molecule	real	time	
sequencing	(http://data-science-sequencing.github.io/lectures/lecture6/),	(D)	
Semi-conductor	sequencing	(https://commons.wikimedia.org),	(E)	
Pyrosequencing	(Voelkerding	et	al.	2009),	(F)	Bridge	amplification	
(https://www.slideshare.net/AndorKiss/new-technologies-at-the-center-for-
bioinformatics-functional-genomics-at-miami-university).	
	
3.1.3 Massively	parallel	sequencing	vs	Sanger	sequencing	
Traditional	Sanger	sequencing	is	limited	by	the	requirement	of	targeted	
amplification	to	initiate	sequencing	and	the	small	volume	of	sequence	data	
produced	in	comparison	to	MPS	methods.	A	Sanger	sequencer	can	detect	a	second	
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allele	in	a	mixed	population	at	a	frequency	of	>20%	at	best	(Bar-Eli	et	al.	1989).	In	
contrast,	an	Illumina	platform	can	generate	sufficient	depth	of	sequence	data	to	
reliably	call	minority	variants	present	with	a	frequency	of	>	1%	and	above	(Thys	et	
al.	2015).	Furthermore,	prior	to	MPS,	amplification	of	the	target	by	PCR	is	not	an	
absolute	requirement,	and	hence	selection	and	bias	during	amplification	can	be	
reduced	(Wagner	et	al.	1994).	
3.1.4 Massively	parallel	sequencing	in	virology	
The	introduction	of	MPS	platforms	has	enabled	de	novo	unbiased	sequencing,	and	
is	considered	an	ideal	tool	for	investigations	of	metagenomes,	viromes	and	
pathogen	discovery.	Furthermore,	the	ability	of	MPS	to	detect	minority	species	has	
provided	great	potential	to	survey	virus	diversity.	An	increase	in	the	resolution	of	
minority	species	has	meant	virus	evolution	can	be	measured	within	or	between	
hosts	in	transmission	studies,	and	has	allowed	for	the	early	detection	of	emergent	
antiviral	resistance.	
However,	apart	from	direct	strand	sequencing	(Kasianowicz	et	al.	1996),	MPS	
platforms	are	limited	by	the	requirement	of	a	reverse	transcription	(RT)	step	for	
library	preparation	and	further	downstream	processing	of	RNA	molecules.	
Therefore,	investigations	into	viruses	with	RNA	genomes	require	an	additional	RT	
conversion	step,	which	can	vary	in	efficiency.	The	efficiency	of	an	RT	step	is	
influenced	by	the	total	amount,	or	fragment	size,	of	nucleic	acids	in	a	sample,	and	is	
a	significant	contributor	to	sequence	error	if	coupled	with	a	high-fidelity	
polymerase	in	PCR	(Arezi	and	Hogrefe	2007;	Nolan	et	al.	2006;	Ståhlberg	et	al.	
2004).		
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3.1.4.1 Viral	metagenomics	
Viral	metagenomics	is	the	indiscriminate	examination	of	all	the	nucleic	acids	
present	in	a	sample,	often	following	a	universal	virus	particle	enrichment	protocol,	
to	identify	undiscovered	viruses	and	novel	roles	for	those	viruses	already	identified.	
Notable	viral	metagenomic	discoveries,	by	MPS,	include	the	discovery	of	
Schmallenberg	virus	in	cattle	(Hoffmann	et	al.	2012a)	or	the	strong	association	of	
IAPV	(Israeli	Acute	Paralysis	Virus)	as	a	marker	for	Colony	Collapse	disorder	in	
Honey	Bees	(Cox-Foster	et	al.	2007).		
3.1.4.2 Virus	surveillance	
Virus	surveillance	is	commonly	applied	in	epidemiological	studies,	to	understand	
transmission	patterns	on	a	local	and	global	scale,	or	in	a	clinical	setting	for	the	
detection	of	antiviral	resistance	in	hosts	undergoing	therapy.		
MPS	can	be	applied	to	environmental	or	clinical	samples	to	track	the	transmission	
of	a	mutant	virus	that	exists	in	a	virus	population	at	low	frequency,	but	becomes	
the	dominant	haplotype	after	a	bottleneck	transmission	event	(Bull	and	White	
2011).	Once	the	source	of	an	outbreak	or	zoonotic	transmission	event	is	mapped	
the	information	can	be	used	to	implement	preventative	measures.	The	ability	to	
identify	the	source	of	an	emergent	variant	has	been	important	when	tracking	cross	
species	barrier	jumps	of	Influenza	A,	which	could	lead	to	the	introduction	of	a	
novel,	more	pathogenic,	virus	(Croville	et	al.	2012).	
In	a	clinical	setting,	MPS	has	been	used	to	identify	the	presence	of	underlying	
antiviral	resistant	variants	in	a	virus	population	that	could	be	selected	for	during	
therapy.	In	the	literature,	the	454	(Roche)	MPS	platform	has	been	used	to	detect	
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the	appearance	of	antiviral	resistant	variants	early	in	chronic	Hepatits	C	virus	(HCV)	
infection,	or	to	measure	the	population	diversity	(and	receptor	usage)	in	HIV	
positive	hosts	to	better	inform	on	the	most	effective	therapeutic	option	(Abbate	et	
al.	2011;	Newman	et	al.	2013).	
3.1.5 HuNoV:	Partial	and	whole	genome	sequencing	
The	field	of	HuNoV	molecular	epidemiology	has	benefited	from	the	development	of	
RT-PCR	methodologies	to	detect	and	sequence	short	regions	of	the	genome.	
Diagnostic	RT-PCR	assays	were	meant	to	be	highly	sensitive	for	detecting	diverse	
HuNoV	for	national	surveillance,	and	hence	targeted	the	most	conserved	region	of	
the	genome	(Ando	et	al.	1995;	Green	et	al.	1995;	Vinje	and	Koopmans	1996;	Wang	
et	al.	1994).	
	
Figure	3.3	HuNoV	primer	regions	used	for	diagnostic	and	surveillance	RT-PCRs	
mapped	to	the	Norwalk	virus	genome	(M87661).	
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Table	3.2	HuNoV	diagnostic	primer	positions	mapped	to	the	Norwalk	virus	
genome	(M87661).	
	
To	characterise	HuNoV	strains,	amplification	and	sequencing	of	more	diverse	
regions	of	the	genome	has	been	routinely	used	in	reference	laboratories.	Partial	
sequencing	of	regions	of	the	virus	capsid	and	RNA	dependent	RNA	polymerase	
(RdRp)	have	been	used	for	virus	characterisation,	strain	surveillance	and	
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transmission	studies.	Furthermore,	studies	in	which	regions	of	the	ORF1	as	well	as	
the	ORF2	have	often	identified	potential	recombinant	strains	(Waters	et	al.	2007).	
However,	such	findings	need	to	be	confirmed	through	sequencing	of	contiguous	
sequence	spanning	both	ORFs.	
3.1.6 Massively	Parallel	Sequencing	of	HuNoV	and	enrichment		
MPS	provides	the	opportunity	to	obtain	information	from	the	entire	genome,	the	
ability	to	detect	minority	variant	strains	and	virus	mixtures	in	dual	or	multiple	
infections.	HuNoV	cannot	be	readily	propagated	in	cell	culture	(Duizer	2004),	and	
therefore	virus	detection	and	characterisation	is	typically	done	directly	from	clinical	
samples	(stool).	Whilst	this	is	advantageous,	as	it	precludes	virus	selection,	several	
disadvantages	exist	in	the	application	of	MPS	directly	to	nucleic	acids	extracted	
from	stool	samples.	
HuNoV	RNA	will	represent	a	very	small	proportion	of	the	total	nucleic	acids	present	
in	a	stool	sample	(Nakamura	et	al.	2009).	Therefore,	prior	to	library	preparation	it	is	
necessary	to	isolate	or	at	least	enrich	the	HuNoV	RNA	against	host,	bacterial	and	
other	viral	nucleic	acids	to	ensure	sequencing	of	the	genome	of	interest.	A	handful	
of	HuNoV	MPS	studies	exist	in	the	literature;	in	these	studies,	the	availability	of	the	
virus	genome	for	sequencing	has	been	maximized	by	PCR,	specific	or	non-specific	
virus	RNA	enrichment	or	a	combination.	
3.1.6.1 Ribosomal	RNA	depletion	
A	complex	microbiota	is	a	significant	component	of	the	gut,	and	it	is	shed	as	a	
component	of	stool	alongside	host	cells	by	movement	of	the	digestive	tract	
(Eckburg	et	al.	2005).	Bacterial	and	host	cell	ribosomes	are	comprised	of	protein	
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and	non-coding	RNA.	Therefore,	after	total	nucleic	acid	extraction	of	a	stool	sample,	
a	large	proportion	of	the	RNA	isolated	will	inevitably	be	ribosomal.	To	increase	the	
representation	of	HuNoV	RNA,	oligonucleotide	probes	have	been	adapted	to	bind	
the	non-coding	RNA,	and	then	double	stranded	nucleic	acids	can	then	be	removed	
with	magnetic	beads	(Bavelaar	et	al.	2015;	Hasing	et	al.	2016).	The	removal	of	
excess	non-target	RNA	allows	for	enrichment	of	the	viral	RNA	of	interest,	and	
enhances	virus	sequencing.	
3.1.6.2 Polyadenylated	tail	selection	
Polyadenylated	tail	selection	has	commonly	been	applied	to	separate	non-coding	
RNA	from	mRNA	in	transcriptomics,	prior	to	RNA-seq	(Wilhelm	and	Landry	2009).	
The	presence	of	a	polyadenylated	tail	at	the	3’	end	is	a	structural	feature	of	the	
HuNoV	genome.	Therefore,	the	methodologies	used	to	select	for	messenger	RNA	
(mRNA)	from	other	nucleic	acid	extracts	can	be	applied	to	the	HuNoV	genome.	
Polyadenylated	RNAs	can	be	selected	for,	from	the	total	extract,	by	using	d(T)	
oligonucleotides	to	physically	separate	out	molecules	with	a	poly-A	tail	or	to	initiate	
RT	(Batty	et	al.	2013;	Fonager	et	al.	2017;	Wong	et	al.	2013).		
3.1.6.3 RNA	baits	
A	library	of	RNA	baits	is	a	collection	of	120-mer	oligonucleotide	fragments	used	to	
capture	complimentary	target	sequences.	A	HuNoV-specific	library	is	sufficiently	
diverse	to	capture	multiple	genotypes	prior	to	MPS.	This	technique	has	been	
applied	to	a	panel	of	507	stool	samples,	comprising	four	and	ten	different	GI	and	GII	
HuNoV	genotypes,	respectively	(Brown	et	al.	2016).	The	RNA	bait	library	could	
generate	complete	genomes	in	89%	of	the	stool	samples,	with	>	80%	of	genome	
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coverage	from	clinical	samples	containing	high	and	low	viral	loads	(Brown	et	al.	
2016).	The	intermediate	level	of	specificity	of	this	technique	is	more	advantageous	
than	targeted	PCR.	However,	RNA	baits	could	still	generate	a	bias	or	would	be	
unable	to	detect	novel	HuNoVs	or	recombinants	in	contrast	to	total	RNA-
sequencing.	
3.1.6.4 Physical	methods	for	virus	concentration:	Ultracentrifugation	
Virions	in	a	clinical	sample	can	be	separated	from	other	components	by	size	and	
physico-chemical	properties.	HuNoV	size	selection,	prior	to	MPS,	has	been	achieved	
by	sequential	filtration,	centrifugation	and	ultracentrifugation	through	a	density	
barrier	(Vega	et	al.	2014b).	Isolation	of	HuNoV	by	physical	separation	can	provide	a	
sample	fraction	of	the	highest	purity,	however	the	process	is	highly	time-consuming	
and	not	suitable	for	high-throughput	(Vega	et	al.	2014b).	Moreover,	sucrose	
gradient	ultracentrifugation	can	cause	damage	to	Respiratory	syncytial	virus	(RSV)	
particles,	although	HuNoV	VLPs	have	been	shown	to	maintain	capsid	integrity	and	
HBGA	binding	after	undergoing	a	similar	purification	method	(Huhti	et	al.	2010;	
Trépanier	et	al.	1981).	
3.2 Materials	and	methods	
3.2.1 Optimisation	of	HuNoV	capture	from	clinical	samples	
3.2.1.1 Clinical	sample	preparation	
A	10-20%	(v/v)	stool	stock	suspension	was	made	up	to	40	mL	in	sterile	PBS	(Sigma,	
Dorset,	UK)	from	pooling	two	high	titre	clinical	samples,	due	to	an	insufficient	
amount	of	patient	stool	sample.	The	stock	suspension	was	diluted	(1	in	100)	to	
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correspond	to	a	lower	titre	clinical	sample	(Table	3.3).	The	neat	stock	and	diluted	
suspension	were	used	to	optimise	PGM	capture	and	poly-(A)	tail	enrichment.	
A	high	titre	and	a	low	titre	stool	stock	suspension	were	used	to	examine	the	effects	
of	PGM-MB	capture	and	non-specific	amplification	on	sample	metagenomics	and	
the	frequency	of	minority	variants	detected	(Table	3.3).		
Table	3.3	The	stock	stool	suspensions	used	to	optimise	capture	and	enrichment	
methods	or	examine	the	effects	of	capture	and	non-specific	PCR	on	variant	calling	
frequencies.		
Sample	
ID	
Sample	
name	
Ct	value	 Viral	copy	
number/g	
15-13	 13-IP-01	 15.85	 2.7´109	
15-IP-01	
17	 17-IP-01	 35.31	 1.2´104	
	
A	collection	of	archived	stool	samples,	positive	for	GII	HuNoV,	were	gifted	to	this	
project	from	a	previous	study	(Table	3.3).	Stool	samples	were	obtained	from	
symptomatic	individuals	at	the	Royal	Liverpool	University	Hospital	(RLUH)	in	
Liverpool.	National	Health	Service	(NHS)	ethical	approval	for	sample	collection	was	
provided	by	the	Research,	Development	and	Innovation	department	(RD&I)	of	
RLUH,	which	required	patient	consent	to	collection	and	use	of	stool	for	research	
purposes.	
3.2.1.2 Preparation	of	PGM-MBs	
MagnaBind™	carboxyl	derivatized	beads	(Fisher	Scientific,	Leicestershire,	UK)	were	
prepared	as	described	in	the	manufacturer’s	instructions,	pooled	and	stored	at	4°C.	
PGM	III	(Sigma,	Dorset,	UK)	or	BSA	as	control	(Sigma,	Dorset,	UK)	were	dissolved	in	
conjugation	buffer	to	a	concentration	of	7.5	mg/mL	for	the	coupling	reaction.	
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3.2.1.3 Optimization	of	GII	HuNoV	capture	from	clinical	stool	samples	
Prior	to	enrichment,	the	stool	suspension	was	centrifuged	at	5000	rpm	for	15	
minutes	and	the	PGM-MB	stock	was	reconstituted	by	pipetting.	For	each	
optimization	experiment	100	µL	of	homogenous	PGM-MBs	was	added	to	1	mL	of	
capture	mixture	containing	stock	stool	suspension	and	sterile	PBS	(Sigma,	Dorset,	
UK)	in	a	ratio	1:3.	The	mixture	was	kept	under	constant	mixing	on	an	SB2	rotator	
shaker	(Fisher	Scientific,	Leicestershire,	UK)	for	15	minutes.	After	mixing	the	PGM-
MBs	were	isolated	by	the	DynaL	magnetic	separation	(MS)	rack	(Fisher	Scientific,	
Leicestershire,	UK)	and	washed	to	homogeneity	with	1	mL	sterile	PBS	(Sigma,	
Dorset,	UK)	or	0.1	M	citric	acid-sodium	citrate	buffer;	this	was	repeated	a	further	
two	times.	The	PGM-MBs	were	then	eluted	into	60	µL	sterile	PBS	(Sigma,	Dorset,	
UK)	and	transferred	to	a	sterile	microcentrifuge	tube.	
Various	conditions	were	altered,	in	triplicate,	to	optimize	PGM-MB	virus	capture	
and	recovery	as	follows:		
Binding	dynamics		
• pH	-	Sterile	PBS	(Sigma,	Dorset,	UK)	in	the	capture	mixture	was	replaced	by	
0.1	M	citric	acid-trisodium	citrate	buffer	at	pH	3.6.	
• Incubation	time	–	The	duration	of	capture	incubation	was	extended	to	30	
and	60	minutes.	
• Temperature	–	The	capture	mixture	was	incubated	at	4	or	37°C.	
• Receptor	saturation	–	The	ratio	of	stool	suspension	was	altered	(3:1,	1:1,	
1:3)	or	the	volume	of	PGM-MBs	added	was	altered.	
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Nucleic	acid	recovery	
• Virus	extraction	–	Nucleic	acids	were	extracted	from	the	PGM-MB	eluate	by	
either	heat	release,	as	described	previously	(Tian	et	al.	2010),	or	the	
guanidium	isothiocyanate	(Gn)	silica	method	(Boom	et	al.	1990).	Lysis	buffer	
extraction	entailed	the	addition	of	L6	buffer	(Severn	Biotech	Limited,	
Worcestershire,	UK)	or	RLT	buffer	(Qiagen,	West	Sussex,	UK)	directly	to	the	
eluate,	and	MS	to	separate	the	buffer	from	the	PGM-MBs.	The	remaining	
steps	of	the	extraction	were	performed	as	described	previously	(Boom	et	al.	
1990)	or	according	to	the	manufacturer’s	instructions.	An	Internal	RNA	
extraction	control	(PrimerDesign,	Hampshire,	UK)	was	spiked	into	each	
sample	prior	to	HuNoV	nucleic	acid	extraction	per	the	manufacturer’s	
instructions.	
In	PGM-MB	virus	capture	experiments	after	optimisation,	sterile	PBS	was	replaced	
by	0.1	M	citric	acid-sodium	citrate	buffer	and	reactions	were	performed	at	25	°C	for	
15	minutes.	The	captured	viral	RNA	was	purified	using	a	Gn	silica	method	(Boom	et	
al.	1990).	
3.2.2 Oligo	(dT)	selection	of	HuNoV	RNA	
Nucleic	acids	were	extracted	from	0.25	mL	of	stool	stock	suspension	using	the	Gn	
silica	method	(Boom	et	al.	1990).	Poly-(A)	RNA	in	the	extraction	eluate	was	
captured	using	the	Poly-(A)	Purist	Kit	(Invitrogen,	Renfrewshire,	UK).	The	protocol	
used	for	Oligo	(dT)	selection	was	performed	following	the	manufacturer’s	
instructions,	except	for	two	differences.	Firstly,	the	volume	of	the	extraction	eluate	
was	increased	to	0.25	mL	with	DEPC-treated	water	(Fisher	Scientific,	Leicestershire,	
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UK).	Secondly,	poly-(A)	RNA	was	centrifuged	from	the	column	in	a	volume	of	20	µL	
DEPC-treated	water	(Fisher	Scientific,	Leicestershire,	UK).	
3.2.3 DNase	treatment	
Prior	to	library	preparation	extracted	RNA	was	DNase	I	(Sigma,	Dorset,	UK)	treated	
and	column	purified	using	the	Qiaquick	gel	extraction	kit	(Qiagen,	West	Sussex,	UK),	
following	the	manufacturer’s	instructions.		
3.2.4 One-step	quantitative	PCR	of	GII	HuNoV	RNA	
Quantitative	(Taqman)	real-time	RT-PCR	(qPCR)	was	performed	on	a	Rotor	Gene	
6000	(Qiagen,	West	Sussex,	UK)	using	the	Rotor-Gene	Multiplex	RT-PCR	Kit	(Qiagen,	
West	Sussex,	UK).	The	qPCR	targeted	the	ORF1/2	junction	of	the	GII	HuNoV	genome	
to	monitor	enrichment	and	library	preparation	steps	(Table	3.2	and	Figure	3.3).	
Each	reaction	contained	10	µL	of	2x	Rotor-Gene	Multiplex	RT-PCR	Master	Mix	
(Qiagen,	West	Sussex,	UK),	0.2	µL	Rotor-Gene	RT	Mix	(Qiagen,	West	Sussex,	UK),	1	
µM	COG	2F/COG	2R	(Sigma,	Dorset,	UK)	[Sequence:	Chapter	2	Table	1],	0.5	µM	Ring	
2	probe	(Sigma,	Dorset,	UK)	[Sequence:	Chapter	2	Table	1],	5	µL	of	RNA	sample	and	
DEPC-treated	water	(Fisher	Scientific,	Leicestershire,	UK)	to	a	total	volume	of	20	µL.	
Quantitative	real-time	RT-PCR	cycling	conditions	were	as	follows:	50°C	for	15	
minutes,	95°C	for	2	minutes,	and	then	45	cycles	of	95°C	for	15	seconds	and	56°C	for	
60	seconds.	Fluorescence	was	detected	at	the	56°C	extension	step.	
3.2.5 MPS	Library	preparation	
Each	Library	was	prepared	using	the	ScriptSeq	v2	RNA-Seq	Library	Preparation	Kit	
(Illumina,	Essex,	UK)	with	one	slight	modification	to	the	manufacturer’s	instructions.	
	 115	
HuNoV	RNA	was	denatured	at	95°C,	and	subsequently	placed	on	wet	ice,	before	
library	preparation.	At	the	amplification	stage,	Illumina-compatible	barcodes	
replaced	the	reverse	primer	to	allow	for	sample	multiplexing.	Prior	to	sequencing	
on	the	HiSeq2500	Illumina	platform	at	the	Centre	for	Genomic	Research,	University	
of	Liverpool,	library	size	and	concentration	was	analysed	with	the	2100	Bioanalyzer	
(Agilent	Technologies)	and	Qubit	dsDNA	High	Sensitivity	assay	(Fisher	Scientific,	
Leicestershire,	UK),	respectively.	A	sample	with	an	insufficient	amount	of	library	
present	after	12	cycles	of	non-specific	PCR	amplification	was	amplified	for	a	further	
10	cycles.	If	additional	amplification	was	performed,	amplicons	were	purified	with	
AMPure	beads	(Beckman	Coulter,	Buckinghamshire,	UK)	at	0.7x	the	volume	of	the	
total	PCR	reaction,	to	minimise	the	presence	of	primer	dimer.	
3.2.6 Data	analysis	
Perl	and	R	scripts	used	in	the	bioinformatics	pipeline	(Figure	3.4	and	Table	3.4)	to	
detect	and	analyse	minority	variants	are	available	at:		
https://www.dropbox.com/sh/9gw8ub4fyxh2pdf/AAABMJlYyR6oW96jLFeP1uqca?d
l=0	
	 116	
3.2.6.1 Consensus	mapping	and	calling	minority	variants	
	
	
Figure	3.4	Bioinformatics	pipeline	for	generating	a	consensus	sequence	and	calling	
minority	variants.	Perl	script	to	reformat	the	data	is	available	online	at:	
https://github.com/riverlee/pileup2base.	
	
	
	
	
	
	
	
	
	
	 117	
Table	3.4	References	to	software	used	in	the	consensus	generation	and	minority	
variant	calling	pipeline.	
Software	
name	
Version	 Function	 Reference	
SPAdes	 v.3.5.0	 De	novo	
assembly	
(Bankevich	et	al.	2012)	
Blastn	 2.2.27+	 Reference	
search	
(Zhang	et	al.	2000)	
Trimmomatic	 0.36	 Quality	
control	
(Bolger	et	al.	2014)	
FastQC	 V0.10.1	 Diagnostics	 (Andrews	2010)	
Burrows-
Wheeler	
Aligner	
0.5.9-
r16	
Aligner	 (Li	and	Durbin	2009)	
SAMtools		 0.1.18-
r580	
Sequence	
alignment	
map	
processing	
and	variant	
calling	
(Li	et	al.	2009a)	
Picard	tools	 2.1.1	 Remove	
duplicate	
reads	
Available	online	at:	
http://broadinstitute.github.io/picard/	
	
3.2.6.2 Metagenomic	analysis	
To	compare	the	effectiveness	of	the	PGM	treatment	for	HuNoV	enrichment	
metagenomic	analytical	approaches	were	used.	The	Genome	Relative	Abundance	
and	Average	Size	(GAAS	version	0.17	–	available	online	at:	
https://sourceforge.net/projects/gaas/files/gaas/GAAS-0.17/)	software	was	used	
(Angly	et	al.	2009)	for	this	purpose.	Firstly,	fastq	files	were	converted	to	fasta	
format	with	Seqtk	(https://github.com/lh3/seqtk).	Similarities	in	each	fasta	file	
were	examined	against	a	RefSeq	database	(2012)	for	protozoa,	microbes	and	
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viruses.	The	database	was	manipulated	to	add	HuNoV	consensus	sequences	from	
each	positive	stool	sample.	
3.2.6.3 Statistical	analysis	
PGM-MB	enrichment	optimization	data	was	analysed	by	a	one-way	ANOVA.	
3.3 Results	
3.3.1 PGM-MBs	can	capture	GII	HuNoV	from	clinical	samples	at	high	viral	loads	
The	Ct	value	obtained	in	NoV	specific	amplification	of	the	high	titre	stool	
suspension	before	and	after	PGM-MB	capture	was	not	significantly	different	(<	3	Ct	
values),	despite	a	slight	decrease	after	capture	(Table	3.5).	
Table	3.5	Capture	of	GII	HuNoV	from	clinical	samples	with	PGM-MB.	
Sample	ID	 Ct	value	
No	PGM	
enrichment	
PGM	
enrichment	
15-13	 25.55	 24.2	
	
3.3.2 A	low	pH	environment	increases	the	affinity	of	PGM-MBs	to	GII	HuNoV	
PGM-MB	capture	of	a	neat	GII	HuNoV	clinical	sample	had	a	lower	average	Ct	when	
performed	in	acidic	conditions	(23.2±1.2)	rather	than	in	a	neutral	pH	(24.5±0.27).	
This	effect	was	significantly	more	pronounced	(32.0	±1.9	to	27.5	±0.97)	when	the	
sample	was	diluted	100-fold	(Figure	3.5,	p	=	<	0.05).	
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3.3.2.1 The	rate	of	PGM-MB	capture	was	similar	at	room	or	physiological	
temperature	
The	PGM-MBs	captured	GII	HuNoV	from	the	neat	clinical	sample	at	a	similar	rate,	
whether	incubated	at	room	temperature	(Ct	24.2±0.44)	or	at	physiological	
temperature	(37°C)	(Ct	24.7±0.092).	However,	when	the	temperature	was	
decreased	to	4°C	there	was	a	significant	loss	in	virus	yield	of	more	than	10-fold	(Ct	
29.6±0.92),	in	comparison	to	the	room	temperature	and	37°C	treatments	(p	=	
<0.05).	Temperature	of	PGM-MB	enrichment	had	a	lesser	effect	on	the	virus	yield	
obtained	with	a	more	dilute	sample:	Ct	32.7±2.6,	Ct	31.4±0.70	and	Ct	30.7±0.99,	at	
temperatures	4,	25	or	37°C,	respectively	(Figure	3.6).		
3.3.2.2 Increasing	the	incubation	time	during	capture	did	not	increase	virus	
capture	
If	the	incubation	period	of	the	PGM-MB	capture	was	doubled	or	quadrupled	the	GII	
GII	HuNoV	yield	didn’t	change	(Figure	3.7).	Much	of	GII	HuNoV	capture	took	place	in	
the	first	15	minutes	and	did	not	increase	further	at	30	or	60-minute	incubation	
periods,	this	effect	could	be	seen	if	the	clinical	sample	was	neat	or	dilute	(Ct:	
26.6±1.1,	26.5±1.2,	26.3±1.1	or	30.8±0.77,	30.9±1.6,	31.1±1.0,	respectively).	
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Figure	3.5	The	effects	of	an	acidic	pH	on	PGM-MB	binding	of	GII	HuNoV.	
	
	
Figure	3.6	The	effects	of	temperature	on	PGM-MB	binding	of	GII	HuNoV.	
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Figure	3.7	The	effects	of	incubation	time	on	PGM-MB	binding	of	GII	HuNoV.	
	
3.3.3 Optimization	of	HuNoV	genome	extraction	after	or	prior	to	capture	or	
enrichment	
	
Three	different	types	of	nucleic	acid	extraction	methods	were	assessed	to	remove	
the	HuNoV	genome	from	the	PGM-MB	complex	(Figure	3.8).	There	were	no	major	
differences	in	the	GII	HuNoV	Ct	value	measurements	obtained	for	a	column	
extraction	(28.00±0.19),	Gn	silica	extraction	(27.6±0.81)	or	heat	release	method	
(27.36±0.59).		
A	quantitative	RT-PCR	was	performed	to	examine	which	extraction	method	to	use	
prior	to	oligo	(dT)	cellulose	selection.	The	Ct	value	obtained	after	enrichment	was	
not	significantly	different	when	column	extraction	was	applied	to	the	clinical	
sample	(24.69),	instead	of	a	Gn	silica	extraction	(25.18).	
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Figure	3.8	HuNoV	genome	extraction	from	PGM-MBs.	
	
3.3.4 Enrichment	is	limited	by	the	buffer	used	in	wash	steps,	the	ratio	of	PGM-
MB	to	GII	HuNoV	and	the	volume	of	sample	available	
To	examine	capture	efficiency	and	whether	captured	virus	is	lost	during	the	wash	
stages,	the	stool	suspension	after	enrichment,	the	PGM-MBs	and	the	subsequent	
washes	were	extracted	and	quantified	for	GII	HuNoV.		
If	a	PBS	wash	buffer	was	applied,	the	PGM-MBs	captured	the	GII	HuNoV	more	
efficiently,	but	a	loss	of	viral	load	was	observed	at	each	wash	step	(Table	3.6).	When	
this	experiment	was	repeated,	but	the	wash	was	performed	with	the	capture	buffer	
(Citric	acid-sodium	citrate	buffer),	less	GII	HuNoV	was	lost	and	in	less	wash	steps	
(Table	3.6).	
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Table	3.6	The	effects	of	different	wash	buffer	on	PGM-MB	capture	efficiency	
measured	in	triplicate.	
Sample	
A	
Enrichment	stage	 Ct	value	
PBS	wash	(pH	
7.2)	
	Citric	acid-sodium	citrate	
buffer	wash	(pH	3.6)	
100	µL	PGM-MBs	 200	µL	
PGM-MBs	
Stool	suspension	after	
enrichment	
29.1±0.39	 25.2±0.28	 25.6±0.28	
PGM-MBs	 26.4	 26.4	 25.8	
Wash	stage	I	 28.9±0.38	 37.4	 37.9±2.16	
Wash	stage	II	 27.9±0.27	 37.2	 Negative	
Wash	stage	III	 29.5±0.78	 Negative	 34.1	
	
To	investigate	the	binding	dynamics	of	the	PGM-MBs	further,	serial	dilutions	of	a	
stool	suspension	were	enriched	using	different	sample	and	PGM-MB	volumes.	If	
the	volume	of	the	stool	suspension	was	doubled	the	Ct	value	tended	to	decrease	
proportionally,	but	there	were	two	exceptions	to	this	trend	(Table	3.7).	When	100	
µL	of	PGM-MBs	was	used	to	enrich	200	µL	of	diluted	suspension	the	cycle	
threshold	increased	in	contrast	to	the	corresponding	dilutions	at	100	µL	of	stool	
suspension.	These	two	treatments	were	the	only	two	examples	of	an	increase	in	
virus	yield	after	halving	the	volume	of	PGM-MBs.	
If	100	µL	of	stool	suspension	was	used,	doubling	the	PGM-MB	volume	caused	the	
enrichment	effect	to	become	more	pronounced	as	the	sample	was	diluted	
(Table	3.7).	However,	the	same	effect	could	not	be	seen	for	all	dilutions	when	the	
volume	of	stool	suspension	was	doubled.	
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Table	3.7	Binding	dynamics	of	PGM-MB	and	GII	HuNoV	in	clinical	samples.	
Stool	
suspension	
volume	(µL)	
Dilution	
factor	
Ct	value	 	
	
	
Difference	
50	µL	PGM-MBs	 100	µL	PGM-MBs	
100	 1×101	 27.85	 26.97	 -0.88	
1×10-2	 30.9	 28.26	 -2.64	
1×10-4	 34.69	 31.39	 -3.25	
200	 1×101	 26.8	 25.32	 -1.48	
1×10-2	 29.03	 29.59	 0.56	
1×10-4	 30.32	 32.81	 2.49	
	
To	identify	whether	any	relationship	existed	between	the	amount	of	virus	that	could	
be	enriched	from	a	sample	and	the	viral	load	remaining	after	enrichment,	a	panel	of	
4	different	clinical	samples	were	enriched	and	a	comparison	was	made	between	the	
Ct	values	of	the	stool	suspension,	the	suspension	after	enrichment	and	the	PGM-
MBs	after	capture	(Table	3.8).	For	each	sample	an	increase	in	Ct	value	was	observed	
from	the	stool	suspension	to	the	amount	of	virus	captured	by	the	PGM-MBs,	and	a	
further	increase	in	the	Ct	value	from	the	captured	PGM-MBs	to	the	stool	suspension	
supernatant	after	capture	(Table	3.8).	The	increase	in	Ct	value	from	the	stool	
suspension	to	the	PGM-MBs	agrees	with	the	binding	dynamics	investigation	
(Table	3.7),	and	likely	implies	receptor	saturation	with	virus.	The	Ct	value	of	12-IP-01	
had	a	much	larger	Ct	value	after	PGM-MB	treatment	in	comparison	to	the	other	
samples,	which	could	indicate	an	inability	to	access	the	virus	or	a	loss	in	titre	during	
the	wash	steps	(Table	3.8).	
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Table	3.8	The	effects	of	sample	variability	on	PGM-MB	virus	binding	(ND	–	not	
detectable).	
Sample	
Untreated	
stool	
suspension	
Ct	value	
PGM-MB	Capture	
Ct	value	
Supernatant	(after	capture)	Ct	
value	
11-IP-01	 19.92	 22.88	 ND	
12-IP-01	 20.53	 28.63	 29.15	
13-IP-01	 24.94	 25.42	 31.07	
13-IP-02	 23.3	 24.23	 30.65	
	
3.3.5 PGM-MB	pooling	can	concentrate	HuNoV	from	clinical	stool	samples		
If	the	amount	of	clinical	sample	enriched	with	PGM-MBs	was	increased	3	or	10-fold,	
and	pooled	for	extraction,	the	HuNoV	yield	increased	(Table	3.9).	An	increase	of	10-
fold	corresponded	to	~2	decrease	in	the	Ct	value	(Table	3.9).	
Table	3.9	Clinical	stool	sample	pooling	strategies.	
	 No.	of	sample	aliquots	pooled	by	PGM-MBs	
Sample	
A	
1	 2	 3	 10	
22.3	 22.43	 21.94	 20.31	
	
3.3.6 RNA-sequencing	of	enriched	HuNoV	clinical	samples	
The	qPCR	Ct	value	decreases	in	a	linear	relationship	as	the	virus	target	sequence	
increases	(Heid		Stevens,	J.,	Livak,	K.J.,	and	Williams,	P.M.	1996),	and	treatment	of	
the	high	titre	clinical	sample	with	PGM-MB	capture	and	pooling	(P10)	generated	a	
library	with	the	lowest	Ct	value,	therefore,	this	library	likely	contained	the	most	
HuNoV	sequencing	reads	(Table	3.10).		
Two	of	the	four	prepared	libraries	required	further	non-specific	amplification	to	
have	sufficient	DNA	to	be	pooled	prior	to	MPS;	these	were	the	samples	that	had	no	
enrichment	(NE)	and	that	from	a	single	PGM-MB	capture	(P1)	(Table	3.10).	This	
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meant	additional	random	amplification	became	an	enrichment	method	to	be	
compared	in	further	experiments.	In	all	the	libraries	prepared,	a	lower	Ct	value	
correlated	with	a	greater	percentage	of	reads	mapped	to	the	GII	HuNoV	genome	
and	a	greater	mean	coverage	(Table	3.10).	If	less	library	preparation	PCR	cycles	
were	performed	a	lower	Ct	value	meant	a	higher	concentration	of	DNA	(Table	3.10).	
Enrichment	of	the	high	titre	sample	generated	a	complete	GII	HuNoV	genome	(PA,	
P1,	P10)	after	MPS,	and	for	no	enrichment	(NE)	the	genome	was	near	complete	
(99.98%).	The	mean	coverage	and	percentage	of	reads	mapped	was	greatest	if	the	
sample	had	undergone	poly-A	tail	selection	(PA)	or	PGM-MB	pooling	(P10)	
(Table	3.10).	The	Ct	value	obtained	after	a	single	PGM-MB	capture	(P1)	was	not	
significantly	different	from	the	sample	that	had	not	undergone	PGM-MB	
enrichment,	with	a	potential	loss	of	half	of	the	DNA	target	as	indicated	by	the	
increase	of	approximately	1	Ct	value	(Ct:	17.4	vs	16.57).	Also,	the	PGM-MB	(P1)	
sample	had	lower	mean	coverage	in	comparison	to	the	sample	without	enrichment	
(2302.74	vs	3599.58).	
Table	3.10	Depth	and	breadth	of	GII	HuNoV	genome	coverage	in	the	enrichment	
optimisation	investigation	(NE=No	enrichment,	PA=Poly-A	tail	selection,	P1=Single	
PGM-MB	enrichment,	P10=Pooling	of	ten	PGM-MB	reactions).	
Sample	
(Treatment)	
Library	
PCR	
cycles	
Library	
Ct	
value	
DNA	
(ng/µL)	
Reads	
mapped	
to	
genome	
(%)	
Percent	
genome	
(%)	
Coverage	
Mean	 Standard	
deviation	
15-13	(NE)	 27	 16.57	 1.07	 25.7	 99.98	 3599.58	 1461.43	
15-13	(PA)	 12	 14.56	 5.46	 46.38	 100	 4009.15	 1653.85	
15-13	(P1)	 27	 17.4	 1.62	 14.02	 100	 2302.74	 1091.33	
15-13	(P10)	 12	 10.13	 7.21	 61.94	 100	 5224.45	 1769.75	
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3.3.7 Deviations	in	HuNoV	consensus	genome	coverage	between	treatments	
In	this	pilot	investigation,	enrichment	methods	were	optimised	using	a	single	
sample	of	high	HuNoV	titre.	The	coverage	plots	of	sample	A	were	similar	in	shape	
after	alignment	to	the	GII	HuNoV	consensus,	regardless	of	the	treatment	used	
(Figure	3.9).		
To	understand	the	influence	of	sequence	composition	on	HuNoV	library	
preparation,	a	50-base	sliding	window	of	GC	content	was	plotted	against	mapped	
read	coverage	to	the	HuNoV	consensus	genome	for	all	sample	treatments	
(Figure	3.10).	In	the	graph,	coverage	decreased	gradually	from	30-66%	GC	content,	
but	there	were	two	exceptions	at	28	and	68%	where	coverage	dropped	off	sharply	
(Figure	3.10).	
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Figure	3.9	HiSeq	read	coverage	plots	of	the	HuNoV	consensus	genome	for	sample	
A	(Red	line:	250	base	sliding	window	of	GC	content,	blue	line:	Coverage	of	base	
position	and	shaded	regions	are	above	or	below	one	SD	of	the	mean	coverage).	
	
GC	ratio
GC	ratio
GC	ratio
GC	ratio
1
2
3
1
2
3
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Figure	3.10	HiSeq	read	coverage	plotted	against	GC	ratio	(Black	line:50	bp	sliding	
window,	grey	areas:	Standard	deviation).	
	
Different	regions	in	the	genome	(³	100	bases)	were	examined	more	closely	for	
abnormalities	in	coverage	(over	1	SD).	The	read	coverage	dropped	for	all	samples	at	
the	start	and	end	of	the	HuNoV	consensus	genome	(Figure	3.9	and	Table	3.11).	In	
ORF	1,	there	were	four	internal	regions	of	the	genome	with	read	coverage	
abnormally	higher	than	the	mean	(over	1	SD),	however	only	region	B	followed	this	
trend	in	all	sample	treatments	(Table	3.11).	In	contrast,	none	of	the	regions	in	ORF2	
deviated	above	or	below	the	mean,	and	region	F	in	ORF3	showed	a	deviation	above	
the	mean	in	three	quarters	of	the	sample	treatments.	The	majority	of	regions	that	
had	an	abnormally	high	coverage	had	a	lower	average	GC	ratio	in	comparison	to	the	
mean	content	of	the	whole	consensus	genome	(50.1	%),	which	was	used	to	align	
the	reads	of	the	different	sample	treatments	(Table	3.11).	
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Table	3.11	Deviations	in	coverage	across	the	GII	HuNoV	genome	(Ne=Non-
enrichment,	PA=Poly-A	tail	selection,	P1=	PGM	×	1,	P10=	PGM	×	10).	
Region	 Region	
position	range	
in	different	
libraries	
ORF	 GC	
content	
(%)	
Above/Below	
standard	
deviation	
Sample	
A	 1-694	 1	
	
51.6	 Below	 NE,	PA,	P1,	
P10	
B	 2458-2727	 48.8	 Above	 NE,	PA,	P1,	
P10	
C	 2766-2893	 52.1	 Above	 NE,	PA,	P1	
D	 3110-3216	 48.9	 Above	 NE,	PA,	P1	
E	 4830-4969	 48.1	 Above	 NE,	PA	
F	 6756-6931	 3	
	
42.0	 Above	 NE,	PA,	P1	
G	 7233-7509	 53.3	 Below	 NE,	PA,	P1,	
P10	
	
3.3.8 Metagenomics	of	PGM	enriched	samples	
Molecular	quantification	proved,	in	agreement	with	the	literature,	that	GII	HuNoV	
could	bind	PGM	on	the	surface	of	MBs.	However,	binding	to	carbohydrate	
molecules	and	PGM	is	not	HuNoV	specific,	and	other	enteric	pathogens	such	as	
rotavirus	and	Campylobacter	species	can	also	bind	to	this	class	of	molecules	(Hu	et	
al.	2012;	Ruiz-Palacios	et	al.	2003).	Further	investigations	were	performed,	aimed	at	
examining	the	metagenome	of	the	clinical	samples	subjected	to	PGM-MB	capture.	
The	samples	used	for	this	included	clinical	stool	samples,	positive	for	GII	HuNoV,	
collected	from	three	patients	on	different	days.	The	collection	of	samples	
underwent	PGM-MB	capture	and	MPS	in	parallel	with	a	separate	GII	NoV	positive	
clinical	sample	which	received	no	PGM-MB	treatment.	A	similar	number	of	reads	
were	generated	in	all	but	one	of	the	samples,	the	exception,	sample	11-3,	had	a	
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read	count	three	magnitudes	lower	and	could	be	a	result	of	failure	during	library	
preparation	or	sequencing	(data	not	shown).		
In	the	remaining	samples,	the	largest	number	of	the	reads	mapped	to	viruses,	of	
which	a	greater	proportion	were	non-bacterial	viruses	(Figure	3.11).	In	most	of	the	
samples	collected	PGM-MB	capture	was	effective,	and	the	greatest	proportion	of	
the	non-bacterial	virus	group	mapped	to	each	respective	HuNoV	sample	consensus	
sequence	(Figure	3.12).	However,	3	out	of	10	PGM-MB	treated	samples	(4-3,	13-4	
and	13-5),	which	did	not	appear	to	fail	library	preparation	or	sequencing	had	below	
2%	of	the	reads	mapped	to	their	GII	HuNoV	consensus	sequence	(Figure	3.11).	The	
PGM	untreated	stool	contained	very	little	HuNoV,	and	therefore	corresponded	
closely	to	another	sample	which	was	considered	to	have	failed	library	preparation	
(Figures	3.11	and	3.12).	
	
Figure	3.11	MPS	reads	(Illumina)	mapped	and	grouped	by	a	RefSeq	database,	from	
longitudinal	HuNoV	clinical	samples	positive	for	GII	HuNoV,	with	or	without	PGM	
capture.	
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Figure	3.12	MPS	reads	(Illumina)	mapped	and	typed	by	a	RefSeq	database,	from	
longitudinal	HuNoV	clinical	samples	positive	for	GII	HuNoV,	with	or	without	PGM	
capture.	
	
The	effects	of	PGM-MB	enrichment	or	additional	PCR	cycling	upon	the	
metagenomics	of	GII	positive	stool	samples	was	investigated.	The	high	(15-13)	and	
low	(17)	titre	clinical	samples	were	compared	directly,	under	the	influence	of	PGM-
MB	enrichment	and	additional	PCR	cycling	(Figure	3.13).	The	greatest	enrichment	
effect	was	observed	in	the	high	titre	sample	with	PGM-MB	capture,	whilst	a	
combination	of	PCR	and	PGM-MB	capture	led	to	less	reads	in	comparison	
(Figure	3.13).	Interestingly,	a	decrease	in	the	proportion	of	HuNoV	reads	was	
detected	if	additional	PCR	cycling	was	performed	in	contrast	to	no	treatment	
(Figure	3.13).	In	the	weak	titre	sample,	both	PGM-MB	capture	and	additional	PCR	
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cycling	were	unable	to	enrich	the	proportion	of	HuNoV	reads	above	2%	
(Figure	3.13).	
	
	
Figure	3.13	MPS	reads	(Illumina)	mapped	and	grouped	by	a	RefSeq	database,	from	
a	high	(Sample	A=15-13)	and	low	(Sample	B=17)	titre	HuNoV	clinical	sample	
positive	for	GII	HuNoV,	with	or	without	a	combination	of	PGM	capture	and	
additional	PCR	cycling.	
	
3.3.9 The	effects	of	enrichment	and	PCR	on	variant	bias	
In	the	initial	experiments	to	investigate	the	effects	of	poly-A	tail	enrichment	and	
PGM-MB	capture	on	GII	HuNoV,	a	subset	of	clinical	samples	required	additional	
non-specific	amplification	for	even	nucleic	acid	pooling	prior	to	MPS.	Investigations	
thus	far	have	shown	several	PGM-MB	captures	were	more	effective	than	poly-A	tail	
enrichment	at	increasing	the	availability	of	GII	HuNoV	reads	(Table	3.10),	and	
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therefore	further	experiments	were	performed	to	understand	the	effects	of	capture	
and	non-specific	amplification	on	library	quality	and	minority	variant	frequency.	
In	the	high	titre	sample	(15-13),	each	treatment	recovered	a	near	complete	
consensus	genome	(Table	3.12).	However,	the	greatest	mean	coverage	was	
obtained	by	PGM-MB	capture,	which	was	followed	by	capture	and	additional	non-
specific	amplification	(Table	3.12	and	Figure	3.14).	If	the	number	of	library	
preparation	cycles	doubled,	with	or	without	PGM-MB	capture,	the	total	DNA	
concentration	decreased	alongside	the	mean	GII	HuNoV	coverage	(Table	3.12).			
In	the	lower	titre	sample	(17),	PGM-MB	capture	did	not	increase	the	fraction	of	the	
consensus	genome	recovered	in	comparison	to	no	treatment	(Table	3.12).	
Enrichment	by	additional	non-specific	amplification	increased	genome	recovery	by	
16.2%,	and	a	combination	of	capture	and	additional	cycling	recovered	a	near	
complete	consensus	genome	(Table	3.12	and	Figure	3.15).	The	recovery	of	a	near	
complete	genome	coincided	with	the	greatest	mean	coverage	for	the	low	titre	
sample	(Table	3.12).	However,	in	the	low	titre	sample	with	PGM-MB	capture,	and	
the	high	titre	sample	with	no	treatment,	a	high	library	DNA	concentration	did	not	
correlate	with	HuNoV	mean	coverage	(Table	3.12).	
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Table	3.12	The	effects	of	non-specific	amplification	and	PGM-MB	capture	on	the	
total	DNA	concentration	after	the	library	preparation	stage,	the	GII	HuNoV	read	
coverage	(IQR=Interquartile	range)	and	differences	in	read	mapping.	
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Figure	3.14	HiSeq	read	coverage	plots	of	a	high	titre	GII	HuNoV	clinical	sample	
after	PGM-MB	and/or	non-specific	PCR	treatment.	
	
Figure	3.15	HiSeq	read	coverage	plots	of	a	low	titre	GII	HuNoV	clinical	sample	
after	PGM-MB	and/or	non-specific	PCR	treatment.	
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The	fold	increase	in	percentage	of	total	reads	mapped	for	the	higher	titre	clinical	
sample	(15-13)	reflected	the	pattern	observed	in	mean	coverage	(Table	3.12).	If	
PGM-MB	was	applied	the	proportion	of	reads	mapping	to	the	consensus	increased	
3-fold,	whilst	additional	PCR	cycles	with	or	without	capture	decreased	the	fold	
difference	to	1.3	or	0.5,	respectively.	On	the	other	hand,	PGM-MB	capture,	PCR	or	
both	led	to	a	decrease	in	the	relative	proportion	of	HuNoV	reads	when	compared	to	
the	untreated	low	titre	sample	(Table	3.12).	
The	high	and	low	titre	sample,	and	each	of	their	treatments,	were	sequenced	on	
the	same	Illumina	flow	cell	and	given	error	rates	are	constant	between	each	sample	
it	should	be	possible	to	assess	the	effects	of	capture	and	non-specific	amplification	
on	the	frequency	of	minority	variant	base	calls.	
To	assess	whether	any	skewing	existed	in	the	frequency	of	minority	variants,	a	
subset	of	positions	in	the	sequence	data	of	the	high	titre	sample	were	examined.	A	
position	was	considered	for	comparison	if,	firstly,	a	minority	base	was	present	in	
more	than	one	sample	treatment	and,	secondly,	if	the	base	had	been	called	twice	
or	more	(Figure	3.16).	Most	positions	increased	in	variant	frequency	in	the	presence	
of	PGM-MB	capture	treatment,	and	if	it	was	combined	with	extra	PCR	cycling	
(Figure	3.16).	Therefore,	further	analysis	was	performed	to	measure	whether	any	
skew	existed	between	each	untreated	sample	(15-13	and	17-1),	and	each	treatment	
(Figure	3.17).	
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Figure	3.16	The	skew	of	minority	variants	at	a	subset	of	positions	across	the	
consensus	sequence	obtained	from	the	high	titre	sample.	
	
If	the	high	titre	sample	underwent	PGM-MB	capture	or	additional	PCR	cycling	
combined	with	capture	the	frequency	of	minority	variants	at	each	respective	
position	appeared	to	be	even	(Figure	3.17).	But	if	extra	PCR	cycling	was	applied	
solely,	the	frequency	of	variants	became	skewed	toward	the	untreated	sample,	
implying	additional	non-specific	amplification	decreases	the	ability	to	detect	of	
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minority	variants	at	each	position	(Figure	3.17).	In	the	lower	titre	sample	a	limited	
number	of	variants	were	present,	presumably	due	to	the	low	coverage	and	the	
absence	of	a	complete	genome	in	most	samples	(Table	3.12	and	Figure	3.17).	
	
	
Figure	3.17	The	frequency	of	variants	called	after	treatment	(y-axis)	against	the	
frequency	of	variants	present	in	the	non-enriched	sample	(x-axis).	A	and	D	=	PGM-
MB	capture,	B	and	E	=	Additional	PCR	amplification,	C	and	F	=	PGM-MB	capture	
and	additional	PCR	amplification.	
	
	
	 140	
3.4 Discussion	
	
3.4.1 Optimisation	of	PGM	GII	HuNoV	capture	
In	a	clinical	stool	sample,	HuNoV	represents	a	very	small	proportion	of	the	total	
nucleic	acid	material	(Nakamura	et	al.	2009).	To	examine	the	whole	genomes	of	a	
HuNoV	population	in	this	environment	it	is	necessary	to	increase	the	virus	
representation	or	remove	the	‘contaminants’.	These	investigations	demonstrate	
the	validity	of	a	HuNoV	enrichment	method	that	relies	on	capturing	viral	particles,	
and	is	based	on	the	well	described	interactions	between	the	virus	capsid	and	
HBGAs.	One	advantage	of	this	method	is	that	PGM	can	capture	HuNoV	strains	
regardless	of	genogroup	or	genotype	specificity,	and	therefore	provides	a	
universally	applicable	method	(Tian	et	al.	2010).		
3.4.2 The	PGM-MB	metagenome	
HuNoV	has	a	proven	affinity	for	the	HBGA	structures	on	the	villus	surface,	and	as	
amply	described	in	the	literature,	the	expression	of	different	HBGA	influences	host	
susceptibility	to	the	virus	(Huang	et	al.	2005;	Marionneau	et	al.	2002).	PGM	is	a	
mixture	of	over	30	diverse	glycosylated	protein	structures;	but	some	of	these	are	
analogous	to	the	HBGAs	in	humans,	and	this	has	been	shown	by	reactivity	with	a	
mAb	known	to	recognise	a	HBGA	type	A	conformational	structure	(Karlsson	et	al.	
1997).	Subsequently,	the	ability	of	the	purified	PGM	(Glenister	et	al.	1988)	to	
compete	with	HBGA	for	HuNoV	VLP	binding,	in	a	dose	dependent	manner,	was	
proven	by	Tian	and	colleagues	(Tian	et	al.	2005).	The	HBGA	structures	present	in	
commercial	PGM	type	III	were	further	characterised	by	Lindesmith	and	colleagues,	
and	shown	to	contain	H,	A	and	Lewis	Y	antigens,	which	further	explained	the	broad	
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binding	affinity	of	this	mixture	to	HuNoVs	(Huang	et	al.	2005;	Lindesmith	et	al.	
2012b).	This	mixture	of	proteins	can	be	coated	onto	MBs	and	used	to	concentrate	
HuNoV	(Tian	et	al.	2008).		
PGM-MB	capture	experiments	of	GII	HuNoV	were	optimised,	under	different	
environmental	parameters,	on	two	serial	dilutions	of	a	clinical	sample,	
corresponding	to	strong	and	weak	viral	loads.	At	a	low	pH,	there	was	a	trend	of	
increased	PGM-MB	capture	efficiency,	which	was	significant	when	applied	to	a	
sample	with	low	viral	load	(p	=	<	0.05).	When	the	duration	of	PGM-MB	exposure	to	
the	virus	was	increased,	there	was	no	change	in	the	yield,	which	indicates	the	GII	
HuNoV	capture	occurs	shortly	after	being	in	contact	with	the	HBGA-like	molecules,	
and	extension	of	incubation	time	does	not	have	an	impact	on	capture	efficiency.	
Both	findings	agree	with	previous	work	(Tian	et	al.	2010)	in	which	PGM-MB	capture	
of	GII.4	HuNoV	was	found	to	be	rapid,	and	a	significant	increase	in	virus	binding	was	
observed	from	a	sample	of	weak	viral	load	at	pH	3.6.	Tian	and	colleagues	postulated	
that	this	increase	in	affinity	is	due	to	the	overall	charge	of	PGM	(negative)	and	the	
GII.4	HuNoV	VLP	(positive)	at	low	pH	(Tian	et	al.	2010).	On	the	other	hand,	if	the	
temperature	was	altered	from	4°C	to	37°C,	no	significant	change	in	virus	yield	
occurred	at	high	viral	load,	but	for	the	diluted	sample,	incubation	at	4°C	
significantly	decreased	the	yield	of	GII	HuNoV	(p	=	<	0.05).	A	reduction	in	HuNoV	
yield	at	lower	temperatures	could	be	a	result	of	a	reduced	reaction	rate	between	
the	virus	surface	receptor	and	PGM.	
There	was	some	variability	in	the	results	obtained	with	PGM-MBs	capture	applied	
to	different	clinical	samples,	which	did	not	necessarily	correlate	with	differences	in	
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viral	load.	Stool	samples	comprise	a	complex	matrix;	in	addition	to	the	virus	of	
interest,	which	may	be	found	clumped,	free	or	in	a	cell	associated	form,	it	will	
comprise	unabsorbed	food,	luminal	secretions,	the	host	microbiota	and	the	host	
virome.	A	loss	of	capture	was	observed	in	sample	13-4	and	13-5	(Figure	3.12)	and	
could	have	been	due	to	progression	of	the	infection	to	the	convalescent	stages.	In	
the	convalescent	stages	of	infection,	various	factors	in	addition	to	the	decreasing	
viral	load	are	likely	to	hamper	the	HuNoV	capture	efficacy.	Secretions	into	the	
lumen	will	comprise	of	host	mucins,	secretory	antibodies	and	cell	debris	from	
regular	epithelial	cell	shedding	(Bullen	et	al.	2006).	The	cell	debris	and	mucins	will	
be	partially	composed	of	glycosylated	proteins,	or	HBGAs	with	affinity	for	HuNoV	
particles	present	in	the	stool.	In	addition,	if	the	host	has	seroconverted,	the	
secreted	antibodies	will	mask	or	neutralise	the	virus	surface	receptors,	making	
them	unavailable	to	the	mucin	bait.	
HBGA-like	structures	are	found	on	the	surface	of	gram-negative	bacteria,	and	
therefore	the	microbiota	of	some	individuals	may	bind	and	capture	HuNoV	to	
interfere	with	a	mucin	based	capture	method.		Bacterial	HBGA-like	structures	were	
first	described	in	1961,	and	provided	an	explanation	for	non-self-blood	group	Ab	
activity	(Springer	et	al.	1961).	These	HBGA-like	structures	were	more	recently	found	
on	Escherichia	coli,	Escherichia	fergusonii,	Enterobacter	cloacae	and	Shigella	flexneri	
by	screening	bacterial	isolates	or	stool	samples	for	reactivity	to	anti-blood	group	
specific	Abs	(Li	et	al.	2015;	Miura	et	al.	2013).	Furthermore,	it	was	possible	to	
elucidate	a	direct	interaction	between	the	extracellular	polymeric	substance	of	
E.cloacae	and	HuNoV	VLPs	(Miura	et	al.	2013).	Subsequently,	the	rescue	of	HuNoV	
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GII.4	Sydney	infection	of	BJAB	B	cells	after	incubation	with	E.cloacae	is	in	
agreement	with	these	bacterial	HBGA-like	molecule-HuNoV	interactions	(Jones	et	
al.	2014).		
Despite	the	efficacy	of	mucin,	and	HBGA-like	molecules	within,	for	capturing	
HuNoV,	this	is	not	an	exclusive	interaction,	and	other	viruses	and	various	bacteria	
are	also	known	to	bind	HBGA.	The	data	presented	here	demonstrated	PGM-MB	
capture	provided	greater	proportions	of	various	bacteriophages,	mobile	genetic	
elements	and	other	eukaryotic	viruses,	but	effectively	reduced	the	detection	of	
bacterial	DNA.	The	proportion	of	reads	that	were	mapped	to	HuNoV	were	
significantly	higher	in	the	stool	samples	subjected	to	the	mucin	capture	method	
than	in	those	sequenced	without	prior	mucin	capture.	The	impact	of	this	
enrichment	is	especially	significant	when	dealing	with	samples	of	low	viral	load.	
Therefore,	due	to	PGM-MB	interactions	not	being	strictly	confined	to	HuNoV	and	
the	above	factors,	this	method,	whilst	providing	a	reasonable	enrichment	of	HuNoV	
from	clinical	samples,	is	subject	to	a	degree	of	interference	and	variability	that	
cannot	be	entirely	controlled.	However,	this	technique	can	increase	the	
representation	of	HuNoV	nucleic	acid	over	other	‘contaminant’	sequences,	prior	to	
MPS,	even	if	it	does	not	exclude	other	organisms	entirely	or	serve	to	concentrate	
the	virus	effectively,	unless	used	in	parallel	(PGM-MB	pooling).	
The	method	described	here	offers	numerous	advantages	over	the	use	of	PCR	before	
library	preparation	and	MPS.	Firstly,	PGM-MBs	should	exclude	most	components	in	
the	clinical	samples	unable	to	bind	to	the	receptor.	Secondly,	clinical	samples	with	
very	low	HuNoV	titres	can	be	enriched,	by	pooling,	without	the	use	of	PCR	which	
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could	introduce	a	bias.	This	means	that	the	efficacy	of	this	method	should	not	be	
impacted	by	the	emergence	of	new	HuNoV	genotypes	or	variants,	and	will	also	
capture	and	sequence	mixtures	of	HuNoVs	in	a	sample.	
3.4.3 Limitations	of	enrichment	protocols	
Several	effective	enrichment	protocols	for	HuNoV,	prior	to	MPS,	have	been	
published	in	the	literature.	However,	protocols	can	be	limited	by	an	inability	to	
discriminate	between	viral	and	non-viral	nucleic	acids	(poly-A	tail	enrichment),	or	
by	targeting	a	single	virus	type	(RNA	bait	enrichment).	If	a	nucleic	acid	extraction	is	
performed	on	stool	samples,	host	mRNAs	can	compete	with	the	viral	genomic	RNA	
during	poly-A	tail	enrichment,	and	reduce	the	availability	of	HuNoV	sequence	data	
downstream.	On	the	other	hand,	RNA	baits	are	short	oligonucleotide	fragments	
designed	prior	to	MPS,	to	enrich	for	a	virus	after	extraction.	However,	if	the	sample	
contained	a	mixture	of	HuNoVs	or	a	virus	recombinant,	the	whole	virus	population	
will	not	be	selected	by	enrichment	and	be	unavailable	for	downstream	analysis	
(Brown	et	al.	2016).	RNA	bait	enrichment	may	particularly	underrepresent	minority	
species.	
3.4.4 The	effects	of	library	preparation	and	NGS	on	GII	HuNoV	read	mapping	
In	this	pilot	investigation,	a	deviation	away	from	the	mean	coverage	could	be	seen	
in	several	regions	(>	100	bases),	and	the	sizes	ranged	from	~106	to	694	bases.	The	
deviation	in	coverage	was	below	average	at	the	start	and	end	of	the	genome	for	all	
library	preparations	(Figure	3.9).	There	are	two	variables	that	are	likely	contributors	
to	this	observation.	Firstly,	the	Illumina	library	preparation	process	is	limited	by	an	
inability	to	recover	short	dsDNA	fragments	that	would	be	generated	at	the	start	and	
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end	of	the	genome,	and	this	has	been	described	previously	for	HuNoV	(Batty	et	al.	
2013).	Secondly,	the	5’	end,	ORF1/2	junction	and	the	3’	end	have	been	predicted	to	
form	secondary	structures,	which	could	induce	a	steric	hindrance	prior	to	cDNA	
synthesis	or	PCR	amplification	(Simmonds	et	al.	2008).	The	ORF1/2	junction	is	not	
completely	highlighted	in	this	analysis	(Figure	3.9),	but	a	sudden	decline	in	coverage	
did	occur	from	positions	4944-4971	(>	1	SD	above	the	mean)	to	positions	5020-
5023	(>1	SD	below	the	mean)	in	all	library	preparations.	Simmonds	and	colleagues	
conservatively	predicted	the	presence	of	secondary	structures	at	three	regions	
across	the	genomic	sense	strand	of	different	viruses	within	the	Caliciviridae,	which	
included	GII.4,	by	multiple	bioinformatics	algorithms	(Simmonds	et	al.	2008).	The	
algorithms	detected	a	drop	in	synonymous	site	variability	and	a	change	in	the	
minimum	free	energy	difference,	when	compared	against	randomly	scrambled	
subsequences,	at	the	3’	and	5’	region	of	each	genome,	as	well	as	upstream	of	the	
ORF1/2	junction	(Simmonds	et	al.	2008).	Moreover,	the	algorithms	agreed	with	
secondary	structure	prediction	software	at	the	ORF1/2	junction	and	5’	end	of	the	
GII.4	genome	(Simmonds	et	al.	2008).	
In	the	remaining	regions,	there	was	an	overrepresentation	of	reads	(>1	SD	above	
the	mean)	in	the	first	(4	regions)	and	third	(1	region)	ORFs	(Table	3.11).	The	
unusually	high	coverage	in	these	regions	could	be	attributed	to	an	absence	of	
predicted	secondary	structures	or	a	bias	in	the	library	preparation	process,	which	
can	be	induced	by	extremes	of	GC	content,	and	was	lower	than	average	in	four	of	
five	regions	(Simmonds	et	al.	2008).	During	library	preparation,	the	source	of	bias	
could	be	fragmentation,	if	the	reaction	is	not	sequence	independent,	at	a	primer	
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annealing	stage,	if	the	affinity	is	not	random,	or	because	of	stochasticity	in	the	PCR	
step.	The	fragmentation	step	in	the	ScriptSeq	(Illumina)	kit	is	chemical,	and	in	
contrast	to	enzymatic	methods	likely	to	be	sequence	independent	(Hansen	et	al.	
2010).	The	subsequent	RT	step	is	initiated	by	random	hexamers	which,	in	
transcriptomics,	have	been	shown	to	bind	selectively	to	regions	adjacent	to	specific	
nucleotide	profiles	of	13	nt	(Hansen	et	al.	2010).	Moreover,	those	RNA	fragments	
converted	to	cDNA	have	undergone	PCR	enrichment,	and	this	step	has	been	
identified	as	a	significant	source	of	base-composition	bias	(Aird	et	al.	2011).	Aird	
and	colleagues	found	base	composition	did	influence	coverage,	and	regions	with	a	
higher	than	average	GC	content	were	amplified	less	efficiently	during	the	library	
preparation	stage	(Figure	3.10).	After	PCR	enrichment,	the	relative	abundance	of	
amplicons	with	a	GC	content	of,	12%	or	below,	or,	greater	than	65%,	decreased	to	
~1	tenth	or	~1	hundredth	of	the	expected	abundance,	respectively	(Aird	et	al.	
2011).	The	bias	was	largely	attributed	to	differences	between	thermocyclers	and	
the	ramp	rate,	and	by	slowing	the	ramp	rate,	to	allow	for	more	denaturation	time,	
it	was	possible	to	recover	the	relative	abundance	of	templates	with	a	high	GC	
content	(Aird	et	al.	2011).	Therefore,	if	the	GC	ratio	is	high,	the	dsDNA	does	not	
separate	efficiently	and	the	hexamer	cannot	bind	to	amplify	the	template,	but	if	the	
ratio	is	too	low	there	is	inefficient	annealing	and	extension.	The	peak	of	average	
base	coverage	at	different	GC	contents	was	34%	GC,	and	this	could	reflect	the	
lesser	number	of	hydrogen	bonds	between	bases	needed	to	be	denatured	in	an	AT	
rich	template	(Figure	3.10).	Other	investigations	have	found	a	correlation	of	
increasing	read	coverage	with	an	increase	in	the	GC	ratio	of	reads.	However,	this	
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finding	was	generated	with	the	Solexa	instrument	(Illumina),	which	produces	
shorter	reads	(Dohm	et	al.	2008;	Hillier	et	al.	2008).	
3.4.5 The	effects	of	random	PCR	amplification	bias	on	the	frequency	of	variants		
	
A	PGM-MB	capture	method	is	effective	in	a	high	titre	stool	sample,	however	can	be	
limited	if	the	viral	load	is	low	or	inaccessible	(Figure	3.12).	If	extra	non-specific	PCR	
cycling	or	PGM-MB	capture	were	applied	to	the	low	titre	sample	the	fraction	of	
HuNoV	genome	recovered	was	54.1%	or	27.9%,	respectively.	In	contrast,	when	the	
low	titre	sample	underwent	PGM-MB	capture	and	non-specific	amplification	the	
virus	genome	recovery	increased	to	99.2%,	and	implies	synergy	between	the	two	
different	methodologies.	On	the	other	hand,	capture	recovered	near	complete	virus	
genomes	in	a	stool	sample	of	high	viral	load.	Moreover,	additional	non-specific	
amplification	constrained	the	sequence	diversity	available	in	a	sample	of	high	
HuNoV	viral	load	in	comparison	to	PGM-MB	capture.	This	is	likely	due	to	PCR	
selection	and	drift	leading	to	the	high	efficiency	exponential	amplification	of	a	
subset	of	templates	in	relation	to	others	(Wagner	et	al.	1994).	The	effects	of	
amplification	skew	on	MPS	has	been	observed	previously	by	the	assignment	of	
unique	primer	identifiers	to	a	known	number	of	HIV	cDNA	templates	through	
degenerate	priming,	prior	to	454	(Roche)	MPS	(Jabara	et	al.	2011).	
3.4.6 Limitations	of	metagenomics	analysis	
	
A	limitation	of	this	metagenomics	analysis	would	be	the	lack	of	positive	and	
negative	controls.	In	a	shotgun	metagenomics	experiment	negative	controls	are	
“blanks”	during	sampling,	nucleic	acid	extraction	and	library	preparation	(Kim	et	al.	
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2017).	Therefore,	to	eliminate	any	contaminating	sequences	during	a	HuNoV	PGM-
MB	capture,	it	would	be	necessary	to	perform	MPS	on	PGM-MBs	without	a	clinical	
sample,	on	the	eluate	from	the	extraction	procedure	and	on	a	library	preparation	
without	template.	Similarly	a	positive	control	could	have	been	included	in	all	
experiments	prior	to	nucleic	acid	extraction	and	library	preparation	to	ensure	
efficiency	at	each	stage	(Kim	et	al.	2017).	A	lack	of	negative	controls	has	been	a	
significant	issue	in	metagenomics	studies	of	low	biomass	samples,	and	misleading	
results	have	been	directed	by	the	nucleic	acid	extraction	kit	chosen	rather	than	the	
experimental	variables	(Salter	et	al.	2014;	Turner	et	al.	2012).	However,	
contaminant	nucleic	acid	sequences	originating	from	reagents	can	also	be	detected	
in	high	biomass	samples,	which	cannot	be	arbitrarily	discarded	without	a	negative	
control	(Glassing	et	al.	2016;	Laurence	et	al.	2014).	To	avoid	misleading	results	due	
to	contamination	negative	controls	can	be	introduced,	to	remove	contaminant	
nucleic	acids	during	bioinformatics	analysis,	or	laboratory	reagents	can	be	treated	
with	ultraviolet	(UV)	light,	enzymes	or	ethidium	monoazide	(EMA)	to	minimise	the	
contaminant	nucleic	acids	carried	forward	to	MPS	(Corless	et	al.	2000;	Glassing	et	
al.	2016).	The	stool	samples	used	in	these	investigations	would	be	considered	high	
biomass,	and	less	likely	to	be	influenced	by	contamination.	However,	further	
experiments	should	investigate	whether	contamination	is	present	prior	to	capture,	
which	could	have	an	influence	on	receptor	saturation	on	the	surface	of	the	PGM-
MBs.	
Another	limitation	to	consider	is	the	potential	for	“spreading-of-signals”	or	
“adapter	leakage”	directly	prior	to	MPS	of	the	pooled	samples.	“Spreading-of-
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signals”	has	been	described	on	the	HiSeq	platform	and	causes	5-10%	of	reads	to	be	
assigned	to	the	incorrect	sample	index	(Sinha	et	al.	2017).	This	is	due	to	low	levels	
of	free	index	primers,	which	are	carried	forward	by	AMPure	XP	beads	(Beckman	
Coulter)	and	complementary	to	other	indices	in	regions	other	than	the	barcode.	
These	primers	allow	DNA	polymerase	to	extend	the	library	at	the	3’	end	to	generate	
an	identical	library	strand	with	a	different	index	(Sinha	et	al.	2017).	The	
metagenomics	investigations	performed	were	on	the	same	flow	cell,	and	therefore,	
5-10%	of	reads	in	a	sample	could	be	assigned	to	the	incorrect	patient	sample	or	
treatment.	
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4 HuNoV	diversity	in	longitudinal	
samples	over	the	course	of	infection	
4.1 Introduction	
4.1.1 Evolution	of	RNA	viruses	
The	persistence	of	a	virus	in	the	population	is	dictated	by	its	ability	to	infect	a	host	
and	generate	transmissible	progeny;	which	can	induce	further	infections	by	intra-	
or	inter-host	transmission.	Therefore,	experimentally,	the	infectious	progeny	titre	
of	an	RNA	virus	is	measured	as	a	proxy	for	viral	fitness	(Domingo	et	al.	1997).	An	
RNA	virus	replicating	in	a	host	exists	as	a	population	of	randomly	mutating	swarms,	
or	quasispecies,	and	if	a	selective	pressure	is	present	swarms	with	higher	fitness	will	
become	more	prevalent	and	lead	to	evolution	of	the	population.	However,	more	
recently,	investigations	have	implied	that	quasispecies	dynamics	are	more	complex,	
and	that	interactions	between	viruses	in	the	population	have	a	role	in	the	
maintenance	of	high	or	low	fitness	variants,	by	complementation	or	interference	
(Andino	and	Domingo	2015).		
Complementation	(positive	interaction)	or	interference	(negative	interaction)	
occurs	when	a	subpopulation	of	the	same	quasispecies	interacts	with	another	to	
promote	or	inhibit	replication	(Andino	and	Domingo	2015).	The	existence	of	
complementation	in	virus	populations	has	been	shown	with	a	Poliovirus	mutant	
population	(G64S),	which	replicates	at	high	fidelity	and	therefore	is	limited	in	the	
diversity	it	can	generate	after	replication	when	compared	to	the	wild-type	(Vignuzzi	
et	al.	2006).	Vignuzzi	and	colleagues	proved	that	limited	diversity	in	the	G64S	
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population	precluded	neurotropism	in	mice,	however	the	presence	of	a	diverse	
wild-type	or	G64S	population	recovered	the	neurotropic	phenotype	(Vignuzzi	et	al.	
2006).	On	the	other	hand,	subpopulations	that	interfere	with	replication,	or	
defectors,	have	been	demonstrated	by	electroporation	of	Foot-and-mouth	disease	
virus	(FMDV)	wild-type	RNA	with	capsid	and	polymerase	mutants,	which	
subsequently	led	to	a	relative	decrease	in	the	wild-type	titre	(Perales	et	al.	2007).	
4.1.2 MPS	as	a	tool	to	infer	virus	population	dynamics	in	a	host	
The	availability	of	MPS	platforms	has	facilitated	broad,	in-depth	and	high-
throughput	analysis	of	virus	swarms,	through	the	alignment	of	many	highly	
repeated	and	overlapping	short	sequence	fragments	encompassing	the	whole	viral	
genome.	This	contrasts	with	previous	sequencing	technologies	(e.g	Sanger	
sequencing)	that	relied	on	sequential	generation	of	relatively	short	regions	of	
consensus	sequence,	that	are	limited	in	their	detection	of	minority	variants	(Palmer	
et	al.	2005).	MPS	is	a	highly	sensitive	tool	which	can	be	used	to	infer	relative	viral	
load,	virus	interactions	with	the	host	or	other	pathogens,	genetic	linkage,	virus	
mutation	rate	or	regions	of	the	virus	genome	under	selective	pressure	(Thys	et	al.	
2015;	Töpfer	et	al.	2013;	Zagordi	et	al.	2011).		
4.1.3 The	impact	of	MPS	on	public	health	and	disease	control	
Several	different	types	of	MPS	platform	have	demonstrated	the	diversity	present	in	
RNA	virus	swarms,	and	how	the	frequency	of	minority	variants	can	change	over	
time.	MPS	of	RNA	viruses	has	been	applied	to	study	population	dynamics	to	inform	
on:	adaption	to	cross-species	barrier	transmission,	efficacy	of	antiviral	drug	
regimens	in	clinic,	hypervariable	positions	in	the	virus	genome	and	the	genetic	
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stability	of		live	vaccine	formulations	(Hasing	et	al.	2016;	Jonges	et	al.	2013;	Majid	
et	al.	2015).	
4.1.3.1 Detection	of	a	minority	variant	adaption	to	cross-species	
transmission	
MPS	has	been	used	to	successfully	identify	markers	for	human	host	adaption	
present	in	minority	variants	of	Influenza	A	virus.	Influenza	A	viruses	are	thought	to	
exist	in	wild	aquatic	birds	as	reservoir	hosts,	and	mutations	can	occur	that	allow	
adaption	to	mammalian	host	infection	(Yoon	et	al.	2014).	Avian	influenza	viruses	
that	have	adapted	to	infect	humans	replicate	more	efficiently	in	a	lower	
temperature	environment,	the	upper	respiratory	tract	(~33oC),	when	compared	to	
the	gastrointestinal	tract	of	wild	aquatic	birds	(42oC).	This	has	been	demonstrated	
in	vitro	by	the	transfection	of	plasmids	expressing	Influenza	A	virus	(IAV)	subunits	
into	mammalian	cells	alongside	a	chloramphenicol	acetyl	transferase	(CAT)	
expressing	plasmid	with	a	virus-like	promoter	(Massin	et	al.	2001).	During	avian	
influenza	virus	infection	of	mammalian	cells,	transcription	and	replication	of	CAT	
was	noted	to	be	recovered	at	33oC	by	a	compensatory	amino	acid	(AA)	change	in	
the	PB2	subunit	(E627K)	(Massin	et	al.	2001).	Jonges	and	colleagues,	using	MPS,	
demonstrated	the	presence	of	the	E627K	mutation	as	the	majority	variant	in	a	
mixed	H7N7	virus	population	after	zoonotic	transmission	to	a	human	(Jonges	et	al.	
2014).	The	majority	E627K	variant	was	detected	in	bronchoalveolar	lavage	(75%)	
and	sputum	samples	(93%);	reaching	100%	frequency	after	five	days.	However,	the	
mutant	could	not	be	detected	in	poultry	prior	to	the	transmission	event	(Jonges	et	
al.	2014).	
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4.1.3.2 Identification	of	minority	variants	as	an	indicator	of	poor	antiviral	
drug	efficacy	
MPS	platforms	could	be	an	important	clinical	tool	in	monitoring	how	combination	
therapy	controls	chronic	hepatitis	C	virus	(HCV)	or	human	immunodeficiency	virus	
(HIV)	infection,	and	reducing	the	likelihood	of	antiviral	resistant	minority	variants	
from	emerging.	The	sensitivity	of	MPS	is	advantageous	in	chronic	viral	illness	as	it	is	
possible	to	detect	emergent	resistance	mutations	early,	which	could	be	selected	for	
in	chronic	infection	and	lead	to	treatment	failure.	However,	the	relationship	
between	the	presence	of	minority	variants	with	antiviral	resistance	and	the	patient	
outcome	on	clinical	therapy	is	controversial.	HCV	populations	in	individuals	treated	
with	interferon	and	ribavirin	consisted	of	minority	resistance	mutations	to	direct	
acting	antivirals	(polymerase	&	protease	inhibitors)	without	exposure,	implying	a	
resistant	genotype	occurs	at	random	(Nasu	et	al.	2011).	During	chronic	HIV	
infection,	several	MPS	publications	have	demonstrated	the	therapeutic	success	of	
antivirals	in	the	presence	of	a	minority	variant	known	to	have	resistance;	whilst	
others	have	proposed	that	minority	variants	may	have	to	be	present	at	a	threshold	
to	become	predominant	(Delobel	et	al.	2011;	Nicot	et	al.	2015).	
4.1.3.3 Surveillance	of	vaccine	formulations	for	genetic	instability	or	a	loss	
of	immunogenicity	
MPS	technology	is	a	putative	replacement	for	the	detection	of	minority	adaptive	
mutations	or	reversions	to	virulence	in	live	virus	vaccine	formulations	(Neverov	and	
Chumakov	2010).		Several	live	RNA	virus	vaccines	exist,	which	aim	to	eradicate	
disease	or	control	seasonal	infection	and	transmission.	Two	examples	would	be	the	
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oral	poliovirus	vaccine	(OPV)	and	the	seasonal	Influenza	A	vaccine.	Prior	to	
formulating	a	vaccine,	Influenza	A	virus	is	replicated	in	embryonated	chicken	eggs	
and	Poliovirus	is	replicated	in	mammalian	cell	cultures.	MPS	can	detect	mutations	
at	high	sensitivity	which	have	occurred	during	Influenza	A	virus	replication;	
mutations	in	the	haemagglutinin	protein	can	be	beneficial	to	the	vaccine	
development	process	and	lead	to	an	increase	in	replication	efficiency	during	in	vivo	
growth,	or	detrimental,	leading	to	a	decrease	in	vaccine	antigenicity	or	safety	in	
humans	(Majid	et	al.	2015).	Oral	poliovirus	(OPV)	strains	can	revert	to	virulence,	
known	as	vaccine-derived	poliovirus	(VDPV),	during	in	vitro	replication	(Sarcey	et	al.	
2017).	Reversion	of	a	poliovirus	vaccine	strain	is	traditionally	detected	by	Mutant	
Analysis	by	PCR	and	Restriction	Enzyme	Cleavage	(MAPREC),	however	MPS	can	be	
equally	effective	and	is	not	limited	by	the	analysis	of	known	sites	of	virulence	only	
(Sarcey	et	al.	2017).		
4.1.3.1 Surveillance	of	viruses	in	vaccinated	populations	
MPS	can	provide	a	powerful	tool	to	monitor	virus	change	in	a	population	under	
vaccine	pressure;	high	throughput	and	sequence	depth	are	combined	to	monitor	
how	a	virus	is	changing	in	the	population	or	elucidate	conserved	and	variable	
epitopes	to	better	inform	on	vaccine	impact	and	potentially,	vaccine	efficacy	and	
design.	
Chong	and	colleagues	recently	applied	MPS	to	Influenza	A	virus	(IAV)	isolates	from	
individuals	who	had	or	had	not	received	the	vaccine,	and	observed	an	increase	in	
the	number	of	epitope	AA	changes,	or	positive	selection,	among	viruses	recovered	
from	vaccinated	individuals	(Chong	and	Ikematsu	2017).	Furthermore,	MPS	has	
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been	used	to	identify	VDPV	minority	variants	in	stool	samples	after	administration	
of	the	OPV;	unlike	other	studies,	the	surveillance	of	VDPVs	was	achieved	without	
the	potential	bias	of	a	tissue	culture	system	(Chi	et	al.	2009;	Sahoo	et	al.	2017;	van	
der	Sanden	et	al.	2009).	The	investigators	noted	MPS	could	detect	VDPV	reversion	
to	neurovirulence	at	high	sensitivity	(<	1%	frequency),	which	can	occur	if	it	is	
transmitted	amongst	a	community	or	through	chronic	infection	in		
immunocompromised	individuals	(Sahoo	et	al.	2017).	
MPS	is	also	an	integral	part	of	a	recently	published	technology	which	demonstrated	
an	ability	to	isolate	single	HIV	particles	with	a	broadly	neutralizing	antibody,	and	
subsequently	generate	envelope	sequence	data	to	aid	in	the	identification	of	
vaccine	candidates	(Chaipan	et	al.	2017).		
4.1.4 True	variant	calling	vs	error	rate	
Four	out	of	the	six	MPS	platforms	currently	available	(Bridge	amplification,	
Pyrosequencing,	Semiconductor	sequencing	and	Single	molecule	real-time	
sequencing)	determine	nucleotide	base	calls	by	DNA	polymerase	incorporation	and	
strand	elongation,	and	cannot	sequence	RNA	directly	(Bentley	et	al.	2008;	
Braslavsky	et	al.	2003;	Margulies	et	al.	2005;	Rothberg	et	al.	2011).	Therefore,	an	
RNA	virus	genome	must	be	reverse	transcribed	to	cDNA,	and	can	require	PCR	
amplification	prior	to	MPS	if	the	amount	of	RNA	before,	or	cDNA	after,	RT	is	low.	
From	sample	preparation	to	data	analysis,	cumulative	errors	can	be	induced	by	
enzyme	misincorporations	at	each	step.	
The	threshold	for	distinguishing	true	minority	variants	from	erroneous	base	calls	on	
the	Genome	Analyzer	IIx	platform	(Illumina)	was	found	to	be	≥	2000-fold	coverage	
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at	a	base	position,	for	which	the	true	mutant	base	call	represented	≥	1%	(Thys	et	al.	
2015).	This	threshold	was	determined	by	sequencing	a	HCV	plasmid	mixture	
containing	a	wild	type	and	a	mutant	at	different	ratios	(Thys	et	al.	2015).	However	
inter-run	variability	can	occur	(Verbist	et	al.	2015).	Most	MPS	investigations	which	
aim	to	detect	the	presence	of	minority	variants	will	amplify	and	sequence	a	
plasmid,	containing	the	virus	genome,	to	indicate	how	much	PCR	and	the	MPS	
platform	contribute	to	background	error	(Bartolini	et	al.	2013;	Delobel	et	al.	2011;	
Van	den	Hoecke	et	al.	2015;	Nasu	et	al.	2011;	Nicot	et	al.	2015;	Sarcey	et	al.	2017).	
Furthermore,	if	errors	generated	during	MPS	are	random,	the	reliability	of	observed	
minority	variants	can	be	increased	by	performing	sample	replicates	(Majid	et	al.	
2015).	Otherwise,	true	and	false	positives	can	be	discerned	by	filtering	variants	
based	on	thresholds	set	in	the	literature	or	several	criteria	which,	in	theory,	should	
separate	error	from	true	base	calls	(Batty	et	al.	2013;	Hasing	et	al.	2016).	
4.1.5 Selective	pressure	on	HuNoV	in	an	immunocompetent	or	
immunocompromised	host	
Accurately	identified	HuNoV	minority	variants	in	a	host	can	be	measured	to	indicate	
whether	the	population	is	undergoing	selection.	HuNoV,	in	a	similar	manner	to	
other	RNA	viruses,	will	undergo	positive	selection	to	increase	fitness	of	the	virus	
population,	or	purifying	selection	to	maintain	fitness	(Domingo	et	al.	1997).	The	
selective	pressures	placed	upon	a	HuNoV	population	are	an	avoidance	of	
neutralization	by	the	host	immune	response,	maintenance	of	virus	ability	for	
transmission	between	hosts	and	through	environmental	routes,	and	to	preserve	or	
enhance	host	receptor	binding	affinity.	
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4.1.5.1 Chronic	infection	
In	the	literature,	MPS	studies	of	HuNoV	chronic	infection	have	largely	investigated	
individuals	awaiting	or	following	bone	marrow	transplantation	(BMT)	(Hasing	et	al.	
2016;	Kundu	et	al.	2013;	Vega	et	al.	2014b).	Prior	to	BMT,	an	individual	must	be	
highly	immunosuppressed	to	permit	acceptance	of	the	graft	and	prevent	graft-
versus-host	disease,	and	thereafter	immune	reconstitution	is	stringently	controlled	
(Welniak	et	al.	2007).	
Bull	and	colleagues	were	the	first	to	use	MPS,	the	454	(Roche)	instrument,	to	
characterise	chronic	HuNoV	infection	by	targeting	the	ORF2/3	region	in	an	infant	
with	a	severe	undefined	immunodeficiency	(Bull	et	al.	2012).	Over	the	course	of	
infection	(Day	1,	4	and	288)	a	highly	heterogeneous	population	of	HuNoV	minority	
variants	were	present	at	low	frequencies.	Subsequently,	minority	variants	in	18	
bases	(3/5	non-synonymous	mutations	in	epitopes	of	the	P2	domain)	reached	
fixation	in	the	last	time	point	that	were	not	observed	in	the	early	stages	(Day	1	or	4)	
of	infection	(Bull	et	al.	2012).	A	separate	study	using	similar	MPS	technology	in	
three	chronic	HuNoV	infections	(random	sampling	across	days	5-19,	1-61	and	0-30,	
respectively),	of	patients	which	were	awaiting	or	had	undergone	BMT,	identified	an	
excess	of	synonymous	mutation	fixation	(846/1082),	implying	the	presence	of	
purifying	selection	(Kundu	et	al.	2013).	In	the	ORF2	region,	50%	of	the	non-
synonymous	mutations	were	present	in	the	P2	domain.	However,	within	the	P2	
subdomain	the	number	of	synonymous	mutations	exceeded	the	non-synonymous	
mutations	(67	versus	40),	and	none	of	the	AA	changes	corresponded	to	known	
epitopes	(Kundu	et	al.	2013).	In	contrast,	Vega	and	colleagues	sampled	chronic	
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infection	in	three	BMT	patients	at	single	time	points	and	described	the	presence	of	
positive	selection	in	the	P2	region	by	Sanger	sequencing,	when	VP1	sequences	were	
compared	to	GII.4	HuNoVs	circulating	in	the	population	(Vega	et	al.	2014b).	
Furthermore,	MPS	of	the	whole	virus	genome	in	the	same	samples,	via	the	454	
(Roche)	system,	demonstrated	most	variable	sites	and	positively	selected	sites	were	
in	the	VP1	gene	(Vega	et	al.	2014b).		
4.1.5.2 Acute	infection	
MPS	studies	solely	characterising	minority	variants	in	acute	HuNoV	infection	are	
underrepresented	in	the	literature.	In	an	immunocompetent	host,	HuNoV	minority	
variants	have	been	reported	as	much	more	homogenous.	Over	the	course	of	
infection	(Day	1	and	10),	a	single	minority	variant	was	detected	(~20	%)	in	the	
ORF2/3	region	and	the	maximum	difference	in	variant	frequency	between	both	
time	points	was	2.6%	(Bull	et	al.	2012).	This	finding	agrees	with	the	MiSeq	(Illumina)	
findings	of	Hasing	and	colleagues,	who	were	unable	to	identify	any	minority	
variants	in	four	patients	with	acute	HuNoV	infection	at	single	time	points	(Hasing	et	
al.	2016).	
4.1.6 The	role	of	copro-antibody	in	HuNoV	immunity	
The	correlates	of	HuNoV	protection	reported	so	far	are	host	genetics,	serum	HBGA	
blocking	antibody	(Ab),	serum	haemagglutination	inhibition	Ab,	salivary	
immunoglobulin	A	(IgA),	faecal	IgA,	virus-specific	memory	immunoglobulin	G	(IgG)	
cells,	serum	HBGA	blocking	Ab	and	serum	IgA	(Ramani	et	al.	2016).	Several	of	these	
are	components	of	the	adaptive	immune	system,	and	could	place	selective	pressure	
upon	HuNoV	during	infection.	
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The	site	of	HuNoV	infection	in	the	human	host	is	the	small	intestine	(de	Graaf	et	al.	
2016),	and	therefore	mucosal-antibody	should	have	an	important	role	in	virus	
neutralisation.	The	appearance	of	HuNoV	strain-specific	faecal	IgA	in	an	infant	has	
been	demonstrated	to	coincide	with	a	reduction	in	genome	copy	numbers,	and	
eventual	clearance	(Iritani	et	al.	2007).	However,	in	adult	volunteer	studies,	NV-
specific	faecal	IgA	has	not	been	found	to	neutralise	infection	or	illness,	but	did	
correlate	with	reduced	viral	loads	and	a	decreased	duration	of	virus	shedding	
(Okhuysen	et	al.	1995;	Ramani	et	al.	2015).	In	a	similar	manner	to	that	described	by	
Iritani,	copro-antibodies	are	described	as	having	an	important	role	in	the	protection	
of	infants	from	Rotavirus	(RoV)	infection,	and	were	recently	shown	to	correlate	
with	serum	IgA	responses	pre-	and	post-vaccination	(Lappalainen	et	al.	2017).	
Coulson	and	colleagues	described	the	existence	of	a	RoV	specific	copro-antibody	
plateau	in	a	subset	of	infants,	after	repeated	natural	virus	infection,	which	reduced	
the	number	of	symptoms	or	symptom	severity	upon	infection	(Coulson	et	al.	1992).	
The	presence	of	a	RoV	specific	copro-antibody	plateau	paralleled	virus-neutralising	
Ab	in	faeces	to	several	RoV	serotypes	(RV	3,	RV	4,	Wa,	Ku	and	ST-3)	(Coulson	et	al.	
1992).			
4.2 Materials	and	methods	
4.2.1 Clinical	sample	preparation,	enrichment,	library	preparation	and	
sequencing	
Faecal	suspensions	were	prepared	from	archived,	and	newly	collected,	longitudinal	
samples	from	six	patients	(A-F)	(Table	4.1).	Ethical	approval	for	collection	and	the	
method	of	preparation	was	identical	to	the	protocol	described	in	Chapter	3.	The	
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stool	suspension	supernatant	was	enriched	with	PGM-MBs	(10:1	by	volume),	at	pH	
3.6	and	room	temperature	(RT)	for	15	minutes	as	previously	described.	The	PGM-
MBs	were	used	to	capture	and	pool	each	sample	3	to	10-fold,	depending	on	the	
amount	of	stool	available.	
Material	captured	by	the	bead-protein	complex	was	magnetically	separated	from	
the	supernatant,	and	the	nucleic	acid	extracted	with	a	Gn	silica	nucleic	extraction	
(Boom	et	al.	1990).	Subsequent	post-extraction	methodology	and	library	
preparations	were	identical	to	the	protocols	described	in	Chapter	3.	
MPS	was	performed	in	an	identical	manner	to	Chapter	3,	however,	library	
preparations	from	patients	A,	B	and	C	sequences	were	prepared	in	duplicate	rather	
than	once	(Table	4.1).	In	total	two	sets	of	library	preparations	were	prepared	for	
each	sample.	The	first	set	of	library	preparations	were	sequenced	on	flow	cell	1	
(Table	4.2).	The	sequencing	process	was	then	repeated	for	set	1	in	combination	
with	set	2	on	flow	cell	2	(Table	4.2).	
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Table	4.1	Quantification	of	GII	HuNoV	in	archived	and	collected	clinical	samples	by	
qPCR	(One	case	was	severely	immunocompromised	(B)	whilst	no	known	
immunodeficiencies	or	immunosuppressive	therapy	were	present	in	the	
remaining	five	cases).		
Patient	
ID	
Immunosuppresive	
comorbidity	
Genotype	 Year	of	
detection	
Day	
collected	
post	
recruitment	
GII	HuNoV	
genome	
copies/qPCR	
reaction	
A	 None	 GII.4	 2012	
	
3	 7.59´107	
7	 2.17´107	
15	 1.33´103	
B	 Haemopoetic	stem	
cell	transplantation	
GII.7	 2012	 3	 1.03´109	
9	 1.29´109	
12	 1.54´108	
15	 1.29´109	
C	 None	 GII.4	 2012	 3	 3.23´107	
5	 2.94´107	
6	 1.22´107	
10	 5.91´105	
11	 1.25´104	
D	 None	 GII.4	 2017	 1	 4.36´105	
2	 3.59´105	
E	 None	 GII.16P/GII.4	 2017	 0	 7.11´106	
1	 1.41´107	
1	 9.15´106	
F	 None	 GII.4	 2017	 0	 1.69´105	
1	 2.40´107	
2	 6.89´106	
3	 1.46´106	
	
Table	4.2	The	order	of	MPS	replicates	for	patients	A,	B	and	C.	
Patient	ID	 HiSeq	(Illumina)	flow	cell	number	
1	 2	
A,	B	and	C	 Replicate	1	 Replicate	1	
Replicate	2	
	
4.2.2 Expression	of	HuNoV	GII	Virus-like	particles	(VLPs)	
Two	HuNoV	positive	stool	samples,	containing	GII.4	New	Orleans	and	GII.4	Sydney	
strains,	were	prepared	as	a	10-20%	(v/v)	faecal	suspension	in	Medium	199	(Fisher	
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Scientific,	Leicestershire,	UK),	and	the	nucleic	acid	extracted	by	Gn	silica	method	
(Boom	et	al.	1990).		
Copy	DNA	of	the	ORF1+ORF2	region	was	generated	with	the	SuperScriptTM	III	
Reverse	Transcriptase	System	(Fisher	Scientific,	Leicestershire,	UK).	Firstly,	40	µL	of	
the	nucleic	acid	extract	and	0.9	µM	of	primer	TVN	(Table	4.3)	were	denatured	at	
70°C	for	5	minutes,	and	incubated	on	ice	for	2	minutes.	The	RT	reaction	mixture	(28	
µL)	was	combined	with	the	extract	after	denaturation,	and	thus	the	concentrations	
overall	(68	µL	in	total)	were	1	×	First-Strand	Buffer,	5	mM	MgCl2,	0.5	mM	dNTPs	
(Fisher	Scientific,	Leicestershire,	UK),	200	units	of	SuperScriptTM	III	reverse	
transcriptase/reaction.	The	RT	reaction	was	incubated	at	42°C	for	1	hour	and	then	
on	ice	for	2	minutes.		
The	cDNA	was	amplified	with	the	Expand	High	Fidelity	System	(Roche,	West	Sussex,	
UK)	to	amplify	from	the	ORF1/2	junction	to	the	3’	untranslated	region	(UTR).	The	
PCR	reaction	comprised	1	×	Expand	High	Fidelity	Buffer	with	MgCl2	(Roche,	West	
Sussex,	UK),	0.5	mM	dNTPs	(Fisher	Scientific,	Leicestershire,	UK),	2.5	mM	MgCl2	
(Roche,	West	Sussex,	UK),	0.4	µM	primer	ORF1/2-F1,	0.4	µM	primer	TVN-Linker	and	
3.5	units	of	Expand	High	Fidelity	Enzyme	Mix	(Roche,	West	Sussex,	UK)	in	a	total	
volume	of	50	µL.	The	amplification	mixture	underwent	a	Touch-Down	PCR	thermal	
profile	of	95°C	for	5	minutes	followed	by	three	cycles	of	denaturation	at	95°C	for	1	
minute,	annealing	at	60°C	for	30	seconds	and	extension	at	72°C	for	3	minutes.	After	
cycling	the	annealing	temperature	decreased	incrementally	by	2°	until	50°C,	at	
which	point	25	cycles	would	occur,	prior	to	a	final	extension	step	of	72°	for	5	
minutes.	
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Each	amplicon	of	the	expected	size	was	purified	from	agarose	gels	with	the	
Minelute	Gel	Extraction	kit	(Qiagen,	West	Sussex,	UK),	following	the	manufacturer’s	
instructions.	The	purified	amplicons	were	cloned	into	the	intermediate	vector	
pCR2.1-TOPO®	(Fisher	Scientific,	Leicestershire,	UK),	and	modified	for	directional	
cloning	(Appendices	D	and	E)	into	a	vector	containing	overlapping	regions	with	
Autographa	californica	nuclear	polyhedrosis	virus	(AcMNPV)	for	lipid	mediated	co-
transfection	and	purification	(Appendices	F,	G	and	H),	as	described	previously	(Allen	
et	al.	2009).	The	protein	concentration	of	the	VLP	preparation	was	measured	using	
the	Qubit	Protein	Assay	Kit	(Fisher	Scientific,	Leicestershire,	UK).	
Table	4.3	Primer	oligonucleotides.	
Primer	 Sequence	(5’-3’)	 GCa	
(%)	
Tmb	
(°C)	
Amplicon	
size	(bp)	
Reference	
ORF1/2-F1	 CTG	AG	CAC	GTG	GGA	GGG	CG	 74	 59.7	 ~2500	 (Allen	et	
al.	2008)	
TVN-Linker	 CGA	CCT	AGG	TGA	TAC	ATG	AT	 45	 49.7	 (Allen	et	
al.	2009)	TVN	 NTT	TTT	TTT	TTT	TTT	TTT	TTT	
CGA	CCT	AGG	TGA	TAC	ATG	AT	
22-
24	
57.5-
58.5	
	
New	Orleans	
modification	1	
AGA	TAT	CGA	GCT	CTA	TAA	
ATA	TGA	AGA	TGG	CGT	CGA	
GTG	ACG	
43	 66.5	 2500	 This	study	
New	Orleans	
modification	2	
AGA	TAT	CGC	ATG	CTT	TTT	
AAA	AGA	CAT	CAG	AGA	AAA	
AGA	AAG	ATA	A	
28	 61.9	
Sydney	
modification	1	
AGA	TAT	CGG	ATC	CTA	TAA	
ATA	TGA	AGA	TGG	CGT	CGA	
GTG	ACG	C	
44	 67.4	 2501	
Sydney	
modification	2	
AGA	TAT	CCT	GCA	GTT	TTT	
AAA	AGA	CAC	TAA	AGA	AAA	
AGA	AAG	ATA	A	
26	 61	
a	Guanidine	/	Cytosine	content.	
b	Melting	temperature	(20	µM	-	Basic).	
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4.2.3 Serology	
4.2.3.1 Sandwich	enzyme-linked	immunosorbent	assay	(ELISA)	for	the	
detection	of	total	faecal	IgA	
Flat-bottom	Costar	StripwellTM	96	well	plates	(Sigma,	Dorset,	UK)	were	coated	with	
100	µL	of	polyclonal	rabbit	anti-human	IgA	(Stratech	Limited,	Suffolk,	UK),	diluted,	1	
in	4000	in	carbonate-bicarbonate	buffer,	pH	9.6	(Sigma,	Dorset,	UK).	Each	plate	
containing	coating	buffer	was	incubated	overnight	in	a	moist	environment	at	4°C.	
All	subsequent	incubation	steps	were	performed	at	37°C	in	a	moist	environment.	
After	overnight	incubation,	coated	plates	were	washed	five	times	with	300	µL	of	
wash	buffer,	which	consisted	of	sterile	PBS	and	0.05	%	(v/v)	TWEEN	20	(Sigma,	
Dorset,	UK).	Each	well	was	then	blocked	in	300	µL	sterile	PBS	(Sigma,	Dorset,	UK)	
and	5%	(w/v)	instant	dried	skimmed	milk,	pH	7.4,	for	2	hours.	Faecal	suspensions	
were	clarified	by	centrifugation,	as	described	previously,	and	100	µL	of	each	serial	
dilution	(1:50,	1:500	and	1:1000)	incubated	for	2	hours	on	the	plate.	Prior	to	
detection	each	well	was	washed	with	300	µL	of	wash	buffer	three	times.	The	total	
IgA	bound	was	detected	by	adding	100	µL	polyclonal	goat-anti	human	IgA	
conjugated	to	horse	radish	peroxidase	(BioRad,	Herfordshire,	UK),	diluted	1	in	4000	
in	sterile	PBS	(Sigma,	Dorset,	UK)	and	1%	instant	dried	skimmed	milk,	for	1	hour.	
The	plate	was	then	washed	five	times	with	300	µL	of	wash	buffer,	and	
subsequently,	a	signal	was	developed	by	adding	100	µL	3’,3’,5’,5’-
tetramethylbenzidine	liquid	substrate	(TMB),	supersensitive,	for	ELISA	(Sigma,	
Dorset,	UK)	to	each	well	prior	to	a	10-minute	incubation	in	darkness.	Once	the	
incubation	period	was	finished,	the	reaction	was	stopped	with	50	µL	of	1	M	H2SO4	
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and	the	absorbance	read	at	450	nm	(A450nm)	on	the	Multiskanâ	Spectrum	(Fisher	
Scientific,	Leicestershire,	UK)	microplate	reader.	A	dilution	series	of	a	known	
concentration	of	Purified	Human	Secretory	IgA	(BioRad,	Herfordshire,	UK)	and	three	
negative	controls	(faecal	suspension	replaced	by	sterile	PBS)	were	included	in	each	
assay.	
4.2.3.2 Capture	ELISA	for	the	detection	of	strain	specific	IgA	
Strain	specific	IgA	was	determined	in	an	identical	manner	to	that	described	above	
with	the	following	exceptions.	Firstly,	plates	were	coated	with	7.5	mg/mL	PGM	III	
(Sigma,	Dorset,	UK).	Secondly,	wells	were	blocked	for	1,	rather	than	2	hours,	and	
after	the	blocking	stage	washing	was	repeated	three	times	in	total.	Thirdly,	prior	to	
the	addition	of	serially	diluted	sample,	a	preparation	of	partially	purified	VLP	was	
added	for	1.5	hours,	and	washed	three	times	with	wash	buffer	(Farmington	Hills	=	
20	µg/well,	New	Orleans	or	Sydney	=	2	µg/well).	Lastly,	after	the	addition	of	faecal	
suspension,	the	plate	was	incubated	for	1.5,	rather	than	2	hours.	
4.2.4 Data	analysis	
4.2.4.1 Bioinformatic	analysis	
HiSeq	(Illumina)	sequences	were	analysed	in	an	identical	manner	to	that	described	
in	Chapter	3.	To	identify	a	true	consensus	sequence	change	or	minority	variant	at	
one	time	point,	in	patient	A,	B	or	C,	complete	agreement	between	all	library	
preparation	replicates	was	necessary.	The	frequency	of	true	minority	variants	at	
different	coverage	levels	was	then	deduced,	and	used	as	a	threshold	to	analyse	
each	time	point	in	patients	D,	E	and	F.	
	 166	
Mutations	which	altered	the	molecular	surface	of	the	HuNoV	P	domain	were	
mapped	with	YASARA	(www.yasara.org	-	version	16.11.20)	and	modelled	with	NOC	
(noch.sourceforge.net	-	version	3.01).	The	ORF2	of	selected	consensus	sequences	
were	modelled	against	the	HuNoV	strain	NSW0514,	and	is	available	as	a	PDB	file	
from	www.rcsb.org,	DOI:10.2210/pdb4oos/pdb	(Singh	et	al.	2015).	
4.2.4.2 Phylogenetic	analysis	
Phylogenetic	analysis	was	performed	with	Molecular	Evolutionary	Genetics	Analysis	
(MEGA)	software	(version	7).	Nucleic	acid	sequences	were	aligned	with	Clustalw,	
under	the	default	settings,	and	phylogenetic	relationships	were	inferred	with	the	
Maximum-Likelihood	algorithm	(Kumar	et	al.	2016;	Tamura	and	Nei	1993).	
Phylogenetic	trees	were	subsequently	reformatted	using	the	online	Interactive	Tree	
of	Life	(ITOL)	software	(Letunic	and	Bork	2016).	
4.2.4.3 ELISA	data	analysis	
A	standard	curve	of	a	known	concentration	of	pure	secretory	human	IgA	was	
generated	by	four	parameter	logistic	regression	(“Four	Parameter	Logistic	Curve”	
online	data	analysis	tool,	MyAssays	Ltd.,	6th	September	2017,	
http://www.myassays.com/four_parameter-logistic-curve.assay).	The	total	IgA	and	
VLP	specific	IgA	concentration	was	determined	by	subtracting	sample	A450	from	the	
average	of	the	negative	control	replicates.	A	sample	of	A450	≤	0.3	was	negative,	and	
those	above	were	extrapolated	against	the	standard	curve	to	deduce	VLP	specific	
IgA	as	a	percentage	of	total	IgA.	
4.2.4.4 Statistical	analysis	
Minority	variant	distributions	were	analysed	by	a	Wilcoxon	rank	sum	test.	
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4.3 Results	
	
4.3.1 PGM-MB	enrichment	of	longitudinal	samples	was	reproducible	and	the	
mean	coverage	reflected	the	stage	of	clinical	infection	
HiSeq	(Illumina)	reads	from	patients	A,	B,	C,	D,	E	and	F	were	assembled	into	
contiguous	sequences	de	novo,	and	a	local	nucleotide	alignment	showed	all	but	one	
infections	were	GII.4	HuNoVs,	whilst	the	virus	present	in	patient	B	was	a	GII.7	
HuNoV	(Table	4.1).	A	consensus	was	derived	from	the	highest	quality	replicate	from	
each	patient	for	read	alignment,	or	the	earliest	time	point	if	replicates	were	not	
available,	and	this	meant	read	coverage	and	the	percentage	of	the	HuNoV	genome	
recovered	could	be	determined	(Tables	4.4	-	4.7).	
Table	4.4	Summary	of	GII.4	virus	reads	recovered	from	the	longitudinal	samples	of	
patient	A	(*	=	Failed	library,	**	=	Unusually	high	number	of	total	reads	and	
IQR=Interquartile	range).	
Day	 Replicate	 Coverage	 Percentage	of	
genome	recovered	
(%)	Median	 IQR	
3	 1	 129	 269	 99.6	
2**	 3634	 2553	 100.0	
3	 2	 2	 27.9	
7	 1*	 0	 NA	 0.0	
2	 5	 6	 83.7	
15	 1	 2	 2	 22.3	
2	 2	 1	 26.4	
3	 1	 1	 9.5	
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Table	4.5	Summary	of	GII.7	virus	reads	recovered	from	the	longitudinal	samples	of	
patient	B	(*=	Failed	library	and	IQR=Interquartile	range).	
Day	 Replicate	 Coverage	 Percentage	of	
genome	recovered	
(%)	
Median	 IQR	
3	 1	 14	 13	 97.7	
2	 54	 43	 99.8	
3	 86	 86	 99.8	
9	 1	 45	 35	 99.9	
2	 56	 47	 99.9	
3	 53	 49	 100.0	
12	 1	 189	 136	 99.8	
2	 1	 0	 0.3	
3	 13	 12	 98.9	
15	 1	 40	 28	 99.8	
2	 161	 131	 99.8	
3	 41	 38	 99.8	
	
Table	4.6	Summary	of	GII.4	virus	reads	recovered	from	the	longitudinal	samples	of	
patient	C	(IQR=Interquartile	range).		
Day	 Replicate	 Coverage	 Percentage	of	
genome	recovered	
(%)	Median	 IQR	
3	 1	 136	 88	 99.8	
2	 5	 4	 80.8	
5	 1	 323	 201	 100	
2	 513	 294	 99.9	
3	 8	 9	 94.7	
6	 1	 139	 91	 99.9	
2	 28	 17	 99.2	
3	 892	 551	 99.9	
10	 1	 5	 7	 77.8	
2	 10	 11	 96.8	
11	 1	 1	 1	 13.0	
2	 3	 4	 73.8	
3	 2	 1	 49.1	
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Table	4.7	Summary	of	GII.4	virus	reads	recovered	from	the	longitudinal	samples	of	
patient’s	D,	E	and	F	(IQR=Interquartile	range).		
Patient	
ID	
Day	 Coverage	 Percentage	of	
genome	recovered	
(%)	Median	 IQR	
D	 0	 36	 38	 99.64	
1	 53	 51	 99.3	
E	 0	 78	 63	 99.9	
1	 117	 122	 100.0	
1	 43	 310	 99.8	
F	 0	 201	 166	 100.0	
1	 16	 17	 99.1	
2	 7	 7	 86.8	
3	 5	 7	 88.5	
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Figure	4.1	The	range,	interquartile	range	(IQR)	and	median	of	coverage	for	each	
sample	analysed.	
If	library	preparation	failures	were	excluded,	complete	or	near	complete	genomes	
were	recovered,	except	for	the	third	replicate	collected	on	day	3	from	patient	A	and	
the	latter	time	points	of	patient	A	(Day	15)	and	C	(Day	11).	Patient	A	and	C	were	the	
only	two	immunocompetent	individuals	who	had	samples	collected	for	longer	than	
a	week,	and	at	the	latter	time	points	partial	HuNoV	genomes	were	recovered	at	low	
median	coverage	(Tables	4.4	and	4.6).	The	decrease	in	median	coverage	and	loss	in	
genome	recovery	coincided	with	a	low	virus	titre	on	day	15	and	11	for	patient	A	and	
C,	respectively	(Tables	4.2,	4.4	and	4.6).	This	correlation	however	could	not	be	seen	
	 171	
in	patient	B	or	D,	E	and	F,	and	was	most	likely	due	to	chronic	illness	and	a	shorter	
clinical	sample	collection	period	(Tables	4.5	and	4.7).	In	contrast,	patient	B	had	
consistently	high	virus	titres	(Table	4.2)	and,	despite	variability	in	coverage	between	
replicates,	the	median	coverage	was	at	least	tenfold	across	the	HuNoV	genome	
(Table	4.5).	In	the	thirty-three	clinical	samples	analysed	(Patient’s	B	-	F),	twenty-nine	
had	an	upper	quartile	range	greater	than	the	lower	quartile	range	(Figure	4.1).	
4.3.2 The	GII	HuNoV	consensus	genome	was	highly	stable	in	acute	infection	
In	total,	three	replicate	data	sets	were	available	for	most	of	the	samples	from	
patient	A	and	C,	and	all	the	samples	collected	from	patient	B	(Tables	4.4	-	4.6),	
therefore	consensus	genome	changes	could	be	inferred	reliably.	However,	due	to	
an	insufficient	amount	of	longitudinal	sequence	data	from	patient	A	none	of	the	
replicates	were	analysed,	whilst	one	replicate	from	patient	B	(Day	12)	and	three	
replicates	from	patient	C	(one	each	from	day	3,	10	and	11)	were	excluded	
(Appendix	C).	In	patient’s	B	and	C,	three	synonymous	consensus	genome	changes	
were	detected	in	total	over	the	course	of	both	infections	(Tables	4.8	and	4.9).	
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Table	4.8	Consensus	genome	changes	observed	in	longitudinal	samples	from	
Patient	B.	
Patient	B	
Day	of	sample	
collection	post	
recruitment	
Replicate	 Nucleotide	frequency	at	
position	(%)	
725	
A	 C	 G	 T	
3	 1	 	 25	 	 75	
2	 45	 55	
3	 43.1	 56.9	
9	 1	 60.6	 39.4	
2	 43.5	 56.5	
3	 61.3	 38.7	
12	 1	 64.1	 35.9	
2	 33.3	 66.7	
15	 1	 66.7	 33.3	
2	 55.8	 44.2	
3	 72.7	 27.3	
	
Table	4.9	Consensus	genome	changes	observed	in	longitudinal	samples	from	
Patient	C.	
Patient	C	
Day	of	sample	
collection	post	
recruitment	
Replicate	 Nucleotide	frequency	at	position	(%)	
5323	 5431	
A	 C	 G	 T	 A	 C	 G	 T	
3	 1	 	 	 	 100	 	 	 100	 	
2	 100	 100	
5	 1	 100	 100	
2	 0.2	 0.2	 99.6	 99.8	
3	 	 	 100	 100	
6	 1	 100	 100	
2	 0.2	 99.8	 0.1	 0.1	 99.8	
3	 9.8	 90.2	 3.6	 	 96.4	
10	 1	 70	 30	 21.1	 78.9	
2	 0	 100	 0	 100	
11	 1	 100	 	 100	 	
2	 100	 100	
	
The	synonymous	mutation	in	patient	B	was	in	position	725	of	the	p48	gene	of	ORF1	
(Table	4.8).	The	sequence	data	obtained	over	all	four	time	points	indicated	that	the	
alleles	at	position	725	were	present	as	a	heterogeneous	mixture	of	cytosine	and	
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thymine.	For	patient	B,	on	day	3	most	of	the	alleles	at	position	725	were	thymine,	
and	then	on	day	9	and	12	a	mixture	of	cytosine	and	thymine	existed.	However,	by	
day	15	most	of	the	alleles	in	each	replicate	were	cytosine	(Table	4.8).		
The	two	synonymous	mutations	detected	in	patient	C	were	present	at	positions	
5323	and	5431	of	the	ORF2	S	domain	(Table	4.9).	In	contrast	to	patient	B,	these	
consensus	alleles	were	highly	homogenous.	For	patient	C,	on	day	3,	5	and	6	the	
consensus	allele	was	thymine	and	guanine	at	position	5323	and	5431,	respectively	
(Table	4.9).	Although	minority	alleles	were	detected	on	day	6,	the	allele	switching	
point	for	position	5323	(T	>	C)	and	5341	(G	>	A)	was	between	day	10	and	11	and	
subsequently	became	fixed	on	day	11	(Table	4.9).	
4.3.3 High	quality	base	call	filtering	led	to	a	marginal	loss	of	sequence	data	
	
In	HiSeq	(Illumina)	read	data,	every	base	call	is	assigned	a	Phred	quality	score,	
which	the	instrument	determines	as	the	probability	a	nucleotide	is	incorrect.	The	
Phred	score	can	be	calculated	as	the	-10	log10	of	the	error	probability,	and	therefore	
a	score	of	30	would	mean	the	inferred	base	is	99.9%	likely	to	be	correct	(Ewing	and	
Green	1998).	To	ensure	minority	variants	were	being	called	with	high	quality	data	
sets,	base	calls	with	a	Phred	score	<	30	were	filtered	out.		
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Figure	4.2	The	effects	of	Phred	score	filtering	on	HuNoV	clinical	sample	data	sets.	
	
The	data	sets	were	filtered	at	high	and	low	Phred	score	stringency	to	examine	how	
much	data	would	be	lost.	If	base	calls	below	Q30	or	Q20	were	removed	1.6	%	or	
0.23	%	of	the	total	nucleotides	in	the	sequence	data	were	lost	(Figure	4.2).	
4.3.4 The	distribution	of	minority	variants	across	different	codon	positions	were	
more	evenly	distributed	in	acute	GII.4	infection	
	
To	investigate	whether	any	selective	pressure	existed	upon	the	virus	populations	
present	in	patient	B	and	C,	and	in	which	regions	of	the	HuNoV	genome	this	
occurred,	the	presence	of	minority	variants	was	measured	at	the	1st,	2nd	and	3rd	
codon	positions	of	each	AA	reading	frame.	Most	AA	redundancy	exists	in	the	3rd	
codon	position,	and	therefore	could	be	used	as	a	proxy	to	determine	the	presence	
of	positive	or	purifying	selection.	For	this	analysis,	one	replicate	from	patient	B	was	
excluded	due	to	library	failure	(Day	12	replicate	2),	two	replicates	from	the	early	
time	points	of	patient	C	were	excluded	due	to	library	failure	or	low	coverage	(Day	3	
replicate	2	&	day	5	replicate	3)	and	all	the	latter	time	points	from	patient	C	due	to	
low	coverage	(Day	10	and	11)	(Tables	4.5	and	4.6).	
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In	chronic	GII.7	infection	(patient	B),	a	disproportionately	larger	number	of	minority	
variants	were	present	in	the	1st	codon	position	of	ORF1	over	all	time	points	
(Figure	4.3).	In	relation	to	ORF1,	ORF2	and	ORF3	contained	few	minority	variants	
which	were	at	similar	frequencies	across	the	three	codon	positions,	however,	there	
were	two	exceptions	(Figure	4.3).	The	exceptions	existed	in	ORF3,	where	a	larger	
frequency	of	2nd	and	3rd	codon	mutations	were	detected	on	day	9	(replicate	1)	and	
a	similar	pattern	was	present	on	day	11	(replicate	1)	at	the	1st	codon	position	
(Figure	4.3).	On	the	other	hand,	in	acute	GII.4	infection	(Patient	C)	the	frequency	of	
variants	appeared	to	decrease	proportionally	across	all	ORFs,	the	1st	codon	position	
had	the	most	minority	variants,	followed	by	the	2nd	and	3rd	codon	positions,	
respectively	(Figure	4.3).	Interestingly,	an	increase	in	the	frequency	of	minority	
variants	over	time,	whilst	coverage	remained	consistent,	was	observed	in	patient	C,	
between	day	3	replicate	1	and	day	6	replicate	1	(Figure	4.3).	
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Figure	4.3	Minority	variant	frequencies	in	longitudinal	samples	of	patient	B	and	
patient	C	at	different	codon	positions	(Blue	=	position	1,	Orange	=	position	2,	Grey	
=	position	3,	R	=	replicate).	
	
If	the	minority	variant	frequencies	at	each	codon	position	were	normalised	by	gene	
size	there	were	no	differences	between	the	ORFs	in	patient	C,	except	less	3rd	
position	mutations	were	present	in	ORF3	compared	to	ORF1	(Table	4.10).	In	patient	
B,	however,	the	1st	codon	position	had	more	mutations	in	ORF1	(p	=	<	0.05)	and	3	
(p=	<	0.05)	when	compared	to	ORF2.	In	the	2nd	codon	position	there	were	more	in	
ORF2	and	3	(p=	<	0.05)	than	ORF1	and	in	the	3rd	position	more	were	present	in	
ORF3	than	1	(p=	<	0.05)	or	2	(p=	<	0.05)	(Table	4.10).	
	 177	
Table	4.10	The	mean	minority	variant	frequencies	normalised	by	ORF	size	in	
patient	B	and	C.	
Patient	 Codon	
position	
ORF	
1	 2	 3	
B	 1	 0.029±0.0076	 0.0087±0.0019	 0.040±0.017	
2	 0.0040±0.00070	 0.0073±0.0017	 0.022±0.013	
3	 0.0037±0.0011	 0.0043±0.001	 0.056±0.002	
C	 1	 0.076±0.025	 0.080±0.025	 0.070±0.023	
2	 0.056±0.019	 0.037±0.011	 0.045±0.015	
3	 0.043±0.014	 0.029±0.010	 0.020±0.0075	
	
4.3.5 GII.4	acute	infection	minority	variants	were	present	in	more	genes	across	
the	whole	HuNoV	genome	
Investigations	were	performed	to	identify	the	specific	locations	of	mutations,	and	
whether	minority	variants	persisted	in	chronic	GII.7	(Patient	B)	and	acute	GII.4	
(Patient	C)	infection.	If	a	minority	variant	was	present	in	all	the	replicates	of	a	single	
time	point,	the	genomic	position	was	carried	forward	for	further	analysis,	and	if	this	
variant	crossed	over	into	a	later	time	point,	it	was	considered	persistent.	
The	minority	variants	present	in	the	GII.7	virus	population	existed	in	less	positions	
across	the	whole	genome,	but	of	those	detected	most	were	present	at	all	four	time	
points	from	patient	B	when	compared	to	the	GII.4	infection	in	patient	C	(Figures	4.4	
-	4.8).	However,	this	could	be	due	to	the	analysis	of	more	replicates	and	time	points	
in	patient	B,	which	meant	more	stringent	criteria	for	minority	variant	filtering.	
	
	
	 178	
	
Figure	4.4	Genome	locations	of	minority	variants	from	day	3	to	15	of	chronic	GII.7	
HuNoV	infection	in	patient	B.	
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Figure	4.5	Minority	variants	located	in	the	p48,	NTPase	and	p22	non-structural	
genes	over	the	course	of	acute	GII.4	infection	in	patient	C.	
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Figure	4.6	Minority	variants	located	in	the	Vpg	and	3CL	protease	non-structural	
genes	over	the	course	of	acute	GII.4	infection	in	patient	C.	
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Figure	4.7	Minority	variants	located	in	the	RNA-dependent	RNA	polymerase	non-
structural	gene	over	the	course	of	acute	GII.4	infection	in	patient	C.	
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Figure	4.8	Minority	variants	located	in	the	major	(VP1)	and	minor	(VP2)	structural	
genes	over	the	course	of	acute	GII.4	infection	in	patient	C.	
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Table	4.11	The	number	of	persistent	minority	variants	across	the	collection	time	
points	in	each	gene	over	the	course	of	infection	in	patient	B	and	C.	
Gene	 Frequency	at	gene	
GII.4	 GII.7	
p48	 1	 5	
NTPase	 1	 3	
p22	 2	 4	
Vpg	 1	 2	
3CLpro	 3	 1	
RdRp	 13	 0	
VP1	 S	 2	 0	
P1	 0	
P2	 3	
VP2	 3	 1	
	
In	agreement	with	analysis	performed	to	determine	which	positions	of	the	codon	
were	diverse,	most	of	the	GII.7	minority	variants	were	in	ORF1	and	one	was	found	
in	ORF3,	whilst	most	of	the	GII.4	minority	variants	were	in	ORF1,	followed	by	ORF2	
and	then	ORF3	(Table	4.11).		
If	a	minority	variant	was	found	in	all	replicates	from	patient	B	at	a	single	time	point,	
there	was	a	tendency	for	it	to	be	detected	at	all	time	points,	implying	in	GII.7	or	
chronic	HuNoV	infection	there	are	underlying	sets	of	variants	that	are	maintained	
over	short	time	periods	(Figure	4.4).	However,	there	were	several	exceptions,	at	
positions	725,	2089,	2186	and	3128	where	variant	replacements	have	occurred	
(described	previously)	or	the	mutation	can	no	longer	be	detected	(Figure	4.4).	
Although	more	persistent	minority	variants	existed	in	the	GII.4	population	of	
patient	C,	there	were	also	multiple	examples	of	mutations	present	at	a	single	time	
point	only,	which	shows	there	are	subpopulations	that	exist	over	the	course	of	
infection	and	others	which	move	in	and	out	of	existence.	
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4.3.6 In	chronic	GII.7	illness,	fewer	minority	variants	were	present	as	a	larger	
fraction	of	the	virus	population	in	contrast	to	acute	GII.4	infection	
To	better	understand	how	each	virus	population	was	changing,	the	frequency	of	
mutations	at	loci	identified	to	contain	persistent	minority	variants	were	measured	
as	a	fraction	of	the	total	number	of	base	calls	(Figure	4.9).	Although	there	were	
fewer	subpopulations	in	chronic	GII.7	infection	when	compared	to	the	GII.4	
infection,	those	present	occupied	a	much	larger	fraction	of	the	virus	population	
(Figure	4.9).	
	
Figure	4.9	The	mean	proportion	of	persistent	minority	variants	in	acute	GII.4	(A)	
and	chronic	GII.7	(B)	infection.	
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4.3.7 Identification	of	true	minority	variants	in	replicate	sequencing	
investigations	can	be	used	to	create	an	inference	threshold	
The	nucleic	acid	extracts	obtained	from	the	longitudinal	samples	of	patients	D,	E	
and	F	were	converted	into	library	preparations	once	and,	unlike	patients	A,	B	and	C,	
not	sequenced	in	triplicate.	For	patient’s	B	and	C,	a	true	variant	was	defined	as	a	
mutation	present	in	all	three	data	sets,	and	therefore	true	and	false	variants	could	
be	compared	to	determine	a	base	call	frequency	and	total	coverage	threshold	to	
discern	mutants	from	errors.	
In	the	replicate	libraries	originating	from	patient	B	and	C	it	was	possible	to	call	true	
variants	at	a	lower	fraction	of	the	total	base	calls	if	the	coverage	was	higher	
(Figure	4.10).	Greater	separation	was	observed	in	a	subset	of	variants	present	in	the	
chronic	GII.7	HuNoV	infection	in	contrast	to	GII.4	acute	infection	(Figure	4.10).	
However,	both	data	sets	showed	the	same	pattern	and	were	combined	to	identify	a	
threshold	at	which	only	true	variants	were	called	(Figure	4.11).	In	the	combined	
data	set	there	were	22079	mutations,	of	which	17583	(79.7%)	were	false	positives	
and	4496	(20.3%)	were	true	positives.	Two	separate	criteria	were	applied	to	the	
base	miscalls	(true	variants	and	sequence	errors)	present	in	a	dataset	of	patient	B	
and	C	combined,	which	were:	≥	5	%	of	the	total	base	calls	and	≥	200-fold	coverage	
or	≥	20	%	of	the	total	base	calls	and	≥	50-fold.	Independently,	these	two	criteria	
incorporated	regions	of	moderate	and	high	coverage	to	select	for	93	variable	sites,	
of	which	92	were	classed	as	true	positives	(Figure	4.11).	However,	this	represented	
a	small	fraction	(2%)	of	the	total	true	positives	(Figure	4.11).	
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Figure	4.10	Comparison	of	variant	frequency	and	total	coverage	of	true	and	false	
minority	variants.	
	
Figure	4.11	The	frequency	of	true	versus	false	positive	variants	called	at	different	
coverage	thresholds.	
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4.3.8 Minority	variants	called	in	patient	D,	E	and	F	
In	total,	126	minority	variants	were	found	to	be	present	across	nine	different	time	
points	in	stool	samples	collected	from	patient’s	D,	E	and	F	(Figures	4.12	-	4.14).	
Most	mutations	were	detected	in	patient	E	(76.9	%),	followed	by	patient	D	(20.6%)	
and	F	(2.4%).	Furthermore,	the	minority	variant	subpopulation	was	most	diverse	on	
day	0	in	patient	D,	day	1	(the	last	time	point)	in	patient	E	and	day	0	in	patient	F.	
However,	accurate	base	calling	from	the	latter	samples	of	patient	F	was	likely	
restricted	by	the	amount	of	sequence	data	available	(Table	4.7).	
In	agreement	with	data	from	patient	C,	minority	variants	in	patient	D	and	E	were	
present	in	every	ORF,	whilst	those	found	in	patient	F	were	in	ORF1	and	2	only	
(Table	4.12).	Despite	this	similarity,	the	mutations	detected	in	patient	E	were	
detected	at	a	much	higher	frequency	across	the	genome,	and	further,	those	in	
ORF1	were	clustered	(Table	4.12	and	Figure	4.13).	
In	patient	D,	every	minority	variant	identified	by	the	criteria	described	was	
identified	across	the	time	points,	but	none	replaced	the	wild	type	allele	
(Figure	4.12).	However,	in	patient	F,	2	of	the	3	corresponding	minority	variants	
were	not	detected	on	day	2,	and	none	were	present	on	day	3	which	is	likely	due	to	
the	limited	amount	of	sequence	data	available	(Table	4.7).	In	contrast,	in	patient	E,	
the	sample	collected	at	the	last	time	point	showed	allele	replacement	at	various	
positions,	in	which	the	minority	variants	were	identical	to	the	consensus	in	the	
previous	time	points	(e.g	position	6189	-	Figure	4.13).	In	addition,	various	positions	
had	almost	equivalent	representation	of	two	distinct	variants	(e.g	position	2615	-	
Figure	4.13).	Overall	52	strain	replacements	occurred,	and	just	below	a	fifth	of	
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these	were	in	the	P2	domain,	whilst	the	remainder	were	present	in	ORF1	
(Figure	4.13).	
	
Figure	4.12	Allele	frequencies	at	HuNoV	GII.4	genomic	loci	identified	to	contain	
minority	variants	over	the	course	of	patient	D	infection.	
	
Figure	4.13	Allele	frequencies	at	HuNoV	GII.4	genomic	loci	identified	to	contain	
minority	variants	over	the	course	of	patient	E	infection.	
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Figure	4.14	Allele	frequencies	at	HuNoV	GII.4	genomic	loci	identified	to	contain	
minority	variants	over	the	course	of	patient	F	infection.	
	
Table	4.12	The	number	of	minority	variants	across	the	collection	time	points	in	
each	gene	over	the	course	of	infection	in	patient	D,	E	and	F.	
Gene	 Frequency	at	gene	
Patient	D	 Patient	E	 Patient	F	
p48	 0	 0	 0	
NTPase	 0	 1	 0	
p22	 0	 33	 0	
Vpg	 0	 11	 1	
3CLpro	 0	 26	 0	
RdRp	 1	 11	 1	
VP1	 S	 11	 0	 1	
P1	 0	 0	 0	
P2	 8	 10	 0	
VP2	 5	 1	 0	
	
4.3.9 The	sudden	increase	in	diversity	observed	in	patient	E	may	have	been	
caused	by	superinfection	
The	longitudinal	samples	obtained	from	patient	E	were	aligned	against	the	
consensus	sequence	present	on	day	0.	In	the	subsequent	samples,	genomic	
homogeneity	was	observed	on	day	1	(99.9%	similarity),	but	at	the	last	time	point,	
collected	on	the	same	day,	a	sudden	divergence	in	the	virus	population	occurred	
(91.8%	similarity).	Interestingly,	at	the	last	time	point,	read	coverage	mapping	to	
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the	first	two	time	points	decreased	in	ORF1	but	ORF2	and	3	were	not	affected	
(Appendix	C).	
	
Figure	4.15	The	proportions	of	base	calls	at	genomic	loci	from	patient	E	samples	
after	alignment	to	the	consensus	sequence	of	day	0	(Blue=Adenine,	Red=Thymine,	
Green=Guanine,	Gold=Cytosine).	
	
If	the	non-structural	and	structural	genes	were	aligned	separately,	the	ORF1	(90.1%	
similarity)	was	a	more	significant	contributor	to	the	increase	in	diversity	than	ORF2	
and	3	(95.3%).	To	examine	the	change	in	diversity	further,	the	proportions	of	alleles	
were	measured	across	the	genome	in	different	samples	(Figure	4.15).	On	day	0	and	
1,	predominant	consensus	alleles	and	minority	alleles	at	low	prevalence	could	be	
clearly	discerned	(Figure	4.15).	However,	on	the	latter	time	point	of	day	1	a	mixed	
population	of	alleles	was	present	in	ORF1,	whilst	ORF2	and	3	remained	
homogenous	(Figure	4.15).	
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On	the	last	time	point	of	patient	E	the	consensus	genome	had	changed	markedly	in	
contrast	to	the	earlier	two	samples,	and	diversity	appeared	to	be	greater	in	the	
non-structural	than	structural	genes,	therefore	de	novo	assembled	contiguous	
sequences	(>	500	bases)	from	each	sample	were	mapped	to	each	sample	consensus	
sequence	(Figure	4.16).	On	day	0	and	day	1,	there	were	two	different	populations	a	
GII.16P/GII.4	recombinant	and	a	GII.4.	However,	at	day	1	(+	6	hours)	a	contiguous	
sequence	more	like	a	complete	GII.4	genome	was	detected,	and	recombinant	
sequences	were	still	present	but	mapped	to	a	very	small	proportion	of	the	genome	
(Figure	4.16).	
	
Figure	4.16	Mapping	of	de	novo	assembled	contiguous	sequences	from	patient	E	
to	the	virus	consensus	sequences	and	phylogenetic	analysis	of	the	closest	BLAST	
relative	(The	black	arrows	correspond	to	gaps	in	the	consensus	sequence	equal	to	
or	below	five	after	mapping).	
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4.3.10 Minority	variants	and	consensus	changes	map	to	exposed	sites	in	the	P2	
domain	
Overall,	four	non-synonymous	changes	were	detected	in	the	HuNoV	P2	subdomain.	
Two	of	these	existed	as	minority	variants	in	the	early	stages	of	patient	C	infection,	
whilst	the	remainder	were	actual	consensus	changes	that	occurred	on	the	last	time	
point	of	patient	E	infection.		
Table	4.13	Mapped	epitope	locations	on	the	GII.4	P	domain	in	the	literature.	The	
colours	correspond	to	the	AA	positions	in	the	model	below.	
	
Figure	4.17	Epitope	residue	mapping	of	a	GII.4	P	domain	mapped	to	X-ray	
crystallography	data	from	the	Protein	Data	Bank	(PDB):	4OOS	(Singh	et	al.	2015).	
Sites	mapped	from	monoclonal	antibody	(mAb)	and	phage	mapping	studies	in	the	
literature	(Table	4.13).	The	minority	variant	changes	in	patient	C	and	consensus	
changes	in	patient	E	are	labelled	(cyan).	
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In	patient	C,	two	different	non-synonymous	mutations	existed	at	each	site	over	the	
course	of	infection,	I389N	or	I389S	and	S409T	or	S409P.	Position	389	is	known	to	
influence	HBGA	binding	affinity	(Tan	and	Jiang	2008),	and	is	in	a	pocket	which	is	
adjacent	to	AAs	that	contribute	to	conformational	epitope	D	and	HBGA	binding	
(Figure	4.17).	Position	409	is	also	present	in	a	pocket,	but	is	closer	to	residues	which	
form	epitope	E	(Figure	4.17).	The	two	consensus	changes	in	patient	E	demonstrated	
a	similar	pattern,	as	residue	309	is	next	to	a	component	of	epitope	N	and	351	is	in	a	
pocket	just	below	AAs	which	form	epitope	A	(Figure	4.17).		
	
Figure	4.18	Protein	modelling	of	the	non-synonymous	mutation	at	position	6001	
(309)	in	patient	E	(Day	1	+	6	hours).	Sequence	mapped	to	X-ray	crystallography	
data	from	the	Protein	Data	Bank	(PDB):	4OOS	(Singh	et	al.	2015).		
	
By	modelling	the	non-synonymous	mutations	to	an	analogous	GII.4	P	domain	
structure	it	was	possible	to	identify	changes	to	the	molecular	surface	(Figure	4.17	
and	4.18).	In	patient	E,	L351V	was	buried	within	the	antiparallel	b-barrel	of	the	P2	
subdomain	and	did	not	appear	to	alter	the	surface	structure	(data	not	shown).	On	
the	other	hand,	N309S	was	present	on	an	exposed	loop	and	did	change	the	
molecular	structure,	but	not	the	electrostatic	surface	charge	(Figure	4.18).	In	
patient	C,	none	of	the	mutations	altered	the	electrostatic	surface	charge,	but	
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S409P,	I389S	and	I389N	did	change	the	predicted	shape	of	their	respective	cavities	
(Figure	4.19).	
	
Figure	4.19	Protein	modelling	of	the	non-synonymous	mutation	at	position	6243	
(389)	&	6302	(409)	in	patient	C	(Day	3,5	&	6).	Sequence	mapped	to	X-ray	
crystallography	data	from	the	Protein	Data	Bank	(PDB):	4OOS	(Singh	et	al.	2015).		
	
4.3.11 Secretory	Ab	responses	to	a	panel	of	time-ordered	VLPs	were	highly	
variable	between	patients	
To	understand	whether	a	relationship	existed	between	the	diversity	of	a	HuNoV	
population	and	the	host	immune	response	at	different	stages	of	infection,	a	capture	
ELISA	was	developed	to	measure	VLP	specific	copro-antibody	responses	in	stool.	To	
normalise	the	observations	at	different	time	points	the	specific	HuNoV	response	
was	measured	as	a	percentage	of	the	total	IgA.	The	average	total	IgA	concentration	
in	individuals	with	acute	infection	(1930±2338	µg/mL)	was	greater	than	in	chronic	
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infection	was	(190±208	µg/mL).	The	proportion	of	HuNoV	specific	IgA/total	IgA	
ranged	from	0	to	7%.	
	
	
Figure	4.20	HuNoV	GII.4	variant	VLP	specific	copro-antibody	responses	over	the	
course	of	infection.	
	
The	time	ordered	panel	of	GII.4	HuNoV	VLPs	consisted	of	Farmington	Hills-2002	
(FH),	New	Orleans-2009	(NO)	and	Sydney-2012	(SY).	Stool	samples	from	patient’s	A	
and	C	were	analysed	for	reactivity	to	the	whole	panel,	but	samples	from	B,	D,	E	and	
F	were	exposed	to	the	Sydney	and	New	Orleans	strain	only	(Figure	4.20).	An	
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insufficient	amount	of	Farmington	Hills	VLP	was	available	to	assay	all	the	patient	
samples,	whilst	a	limited	amount	of	stool	sample	from	patient	F	on	day	1	meant	
reactivity	could	not	be	tested	against	the	panel.		
GII.4	HuNoV-specific	secretory	IgA	was	not	detected	in	patient’s	A	or	B	at	any	time	
point	(Figure	4.20).	In	patient’s	D	and	F,	no	response	was	detected	to	either	the	NO	
or	SY	VLPs	on	day	0,	and	in	patient	E	no	response	was	detectable	to	NO	on	day	0	or	
the	first	sample	from	day	1,	but	a	response	to	NO	was	seen	in	the	second	sample	
from	the	same	day	(Figure	4.20).	In	patient	C,	no	responses	were	detected	until	day	
5	post	infection,	and	from	that	point	onwards	an	increase	in	the	HuNoV	specific	
response	was	observed	at	each	time	point	with	the	response	being	predominant	
against	FH,	but	also	detectable	and	increasing	against	the	NO	and	SY	VLPs	
(Figure	4.20).	
4.3.12 Correlation	between	GII.4	HuNoV-specifc	copro-antibody	and	non-
synonymous	mutations	during	infection	varied	between	patients	
To	further	characterise	interactions	between	the	host	immune	response	and	
infecting	virus	population,	it	was	necessary	to	identify	which	GII.4	strain	was	the	
closest	relative	to	the	HuNoV	shed	by	the	patient,	and	any	capsid	antigenic	
similarities	between	the	population	and	the	VLP.		
The	GII.7	virus	population	shed	by	patient	B	had	identical	capsid	sequences	over	the	
course	of	infection	(Figure	4.21).	In	contrast	the	capsid	sequences	recovered	from	
patients	A,	C,	D,	E	and	F	clustered	closest	to	the	Sydney-2012	strain	(Figure	4.21).		
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Figure	4.21	A	rooted	Maximum-Likelihood	Tree	of	the	capsid	nucleic	acid	
sequence	for	each	patient	sequence	and	GII.4	reference	strains	(boot	strap	values	
of	nodes	over	0.8	of	1000	bootstrap	replicates	are	shown	as	red	squares).	
	
In	agreement	with	the	phylogenetic	analysis,	every	virus	population	recovered	was	
more	closely	related	to	the	SY-VLP	in	the	P2	domain	than	to	NO	or	FH	(Tables	4.14	
and	4.15).	In	the	infection	of	patient	C,	the	P2	domain	of	the	virus	population	was	
near	identical	to	the	SY-VLP	in	the	P2	domain,	with	a	single	mismatch	at	AA	position	
329	(Table	4.14).	However,	if	non-synonymous	changes	during	infection	were	
excluded,	the	virus	populations	present	in	patient	D,	E	and	F	differed	from	patient	C	
in	the	P2	domain	at	sites	323,	329	and	340,	and	likely	reflects	strain	divergence	over	
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time	since	the	emergence	and	spread	of	the	GII.4	Sydney	strains	(Tables	4.14	and	
4.15).	
Despite	the	virus	identified	at	all-time	points	in	patient	C	having	the	highest	
homology	with	the	SY-VLP,	the	earliest	and	highest	magnitude	Ab	response	was	
directed	towards	FH,	which	was	the	most	divergent.	This	was	followed	by	the	
response	to	the	homologous	VLP,	whilst	the	latest	and	lowest	in	magnitude	was	to	
the	NO-VLP.	In	contrast,	patient’s	D	and	F	had	detectable	NoV-specific	IgA	to	the	
homologous	SY	variant	at	days	1	or	2	post-date	of	onset,	and	patient	E	on	the	day	
of	diarrhoea	onset.	The	strains	identified	in	these	patients	had	a	few	mutations	in	
the	P2	domain,	including	a	consistent	A323T	and	a	A340T,	which	has	been	
identified	in	the	literature	as	a	putative	epitope.	In	addition,	further	mutations	
along	the	P2	domain	were	mapped	to	putative	epitopes	in	those	patients	where	
non-synonymous	mutations	were	detected	during	infection:	Patient	E,	3/8	were	
present	in	sites	known	to	be	epitopes,	and	in	patient	F	or	D	there	were	2/5	and	1/2,	
respectively	(Tables	4.14	and	4.15).	
In	patient	D,	the	appearance	of	HuNoV-specific	copro-antibody	to	NO	or	SY	
coincided	with	all	the	non-synonymous	mutations	observed	during	infection	
(Table	4.15).	On	the	other	hand,	AA	changes	in	patient	E	occurred	on	the	last	time	
point,	despite	the	presence	of	SY-specific	secretory	IgA	in	all	the	stool	samples	
collected	(Table	4.15).	Of	the	5	non-synonymous	mutations	which	were	found	in	
the	virus	population	of	patient	F,	a	single	epitope	and	non-epitope	change	was	
detected	on	day	3	when	an	increase	in	SY-specific	copro-antibody	was	observed	
(Table	4.15).	
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Table	4.14	Conserved	and	variable	AAs	in	the	virus	population	of	patient	C	sites	
identified	by	comparison	with	the	VLP	panel	(Red=Epitope	A,	Blue=Epitope	B,	
Green=Epitope	C,	Orange=Epitope	D,	Grey=Epitope	E,	Yellow=HBGA	binding	and	
CAb	=	Coproantibody).	
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Table	4.15	Conserved	and	variable	AAs	in	the	virus	population	of	patient	D,	E	and	
F	sites	identified	by	comparison	with	the	VLP	panel	(Red=Epitope	A,	Blue=Epitope	
B,	Green=Epitope	C,	Orange=Epitope	D,	Grey=Epitope	E,	Yellow=HBGA	binding,	
CAb	=	Coproantibody	and	NT=Not	tested).	
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4.4 Discussion	
	
4.4.1 HuNoV	load	in	stool	samples	is	critical	for	high	genome	coverage	using	
MPS	
In	molecular	biology,	MPS	technology	provides	a	powerful	tool	to	recover	complete	
data	from	a	nucleic	acid	extract,	and	then	infer	what	is	present,	and	whether	it	has	
undergone	or	is	undergoing	selective	change.	In	this	investigation,	a	total	of	21	
longitudinal	samples	from	different	patients	underwent	sequencing,	and	five	GII.4	
HuNoVs	were	identified	in	patient’s	A,	C,	D,	E	and	F	with	acute	illness,	whilst	the	
virus	responsible	for	chronic	infection	in	patient	B	was	a	GII.7.		
Overall,	library	preparations	were	reproducible	and	PGM-MB	capture	meant	near	
complete	HuNoV	genomes	were	recovered	at	the	earlier	stages	of	acute	infection	
and	throughout	chronic	infection.	However,	two	library	failures	did	occur,	which	did	
not	provide	any	HuNoV	reads	or	close	to	zero	reads	(Patient	B	Day	12	&	Patient	A	
Day	7).	Prior	to	sample	submission	and	pooling,	each	library	was	quality	controlled	
by	measuring	the	DNA	concentration	and	targeting	the	GII	HuNoV	ORF1/2	region	by	
qPCR	(Kageyama	et	al.	2003).	Therefore,	failures	could	occur	if	the	sample	
degrades,	the	ORF1/2	junction	is	overrepresented	relative	to	the	whole	genome	or	
the	DNA	concentration	is	not	accurate	and	inadequate	pooling	occurs.	Inter-
replicate	variability	was	present	in	those	library	preparations	which	were	not	
considered	to	be	failures,	and	could	be	attributed	to	PCR	drift	and	the	variability	
that	exists	between	different	sequencing	runs	(Verbist	et	al.	2015;	Wagner	et	al.	
1994).	Although	this	variability	existed,	in	individuals	with	acute	infection	there	was	
a	general	trend	of	the	HuNoV	genome	becoming	more	fragmented	and	decreasing	
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in	mean	genome	coverage	as	shedding	progressed	over	a	week,	which	was	not	
observed	in	chronic	infection.	This	pattern	correlated	with	reducing	virus	titres,	and	
presumably	progression	of	the	infection	into	the	convalescent	stages,	leading	to	
higher	coverage	levels	being	inherently	more	difficult	to	attain.	On	the	other	hand,	
mean	coverage	in	patient	B	likely	remained	consistent	due	to	prolonged	shedding	
of	high	viral	loads	which	is	well	established	in	chronic	HuNoV	infection	(Bok	and	
Green	2012).	An	inability	to	recover	whole	genomes	from	non-longitudinal	samples	
collected	during	acute	infection	has	been	described	previously	(Hasing	et	al.	2016).	
4.4.2 In	an	acute	GII.4	infection	allele	frequencies	are	stable	and	unlike	those	
found	in	GII.7	chronic	infection	
To	reliably	identify	genomic	mutations	in	acute	and	chronic	HuNoV	infection,	
replicate	library	preparations	from	longitudinal	patient	stool	samples	underwent	
MPS.	In	a	viral	infection	at	a	single	time	point,	the	virus	with	the	greatest	fitness	will	
exist	as	the	dominant	allele,	and	therefore	allele	frequencies	can	be	measured	to	
detect	strain	replacement.	
In	agreement	with	a	previous	study,	different	allele	frequencies	in	acute	infection	
were	stable	in	comparison	to	chronic	infection	(Bull	et	al.	2012).	Overall,	two	
synonymous	mutations	occurred	in	the	ORF2	of	the	GII.4	over	11	days	and	a	single	
synonymous	mutation	was	present	in	the	ORF1	of	the	GII.7	over	15	days.	Hoffman	
and	colleagues	determined	a	nucleic	acid	substitution	rate	of	8.76	per	100	days	by	
Sanger	sequencing	clonal	isolates,	which	is	in	close	agreement	with	that	obtained	
(6.66	vs	8.76)	(Hoffmann	et	al.	2012b).	Moreover,	Hoffman	proposed	the	presence	
of	positive	selection	by	comparing	sequences	with	published	genomic	data	to	
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represent	virus	transmission	in	the	population,	however,	this	would	be	difficult	to	
infer	given	the	short	time	period	over	which	samples	were	collected.	
4.4.3 GII.7	in	chronic	infection	and	GII.4	in	acute	infection	appear	to	be	under	
selective	pressure	
HuNoV	genomic	loci	that	comprised	heterogeneous	base	calls	from	the	consensus	
sequence,	and	were	present	in	all	the	replicates	at	a	given	time	point,	were	
separated	by	codon	position	to	identify	whether	the	virus	populations	in	patient’s	A	
and	C	were	changing	under	selective	pressure.	In	patient	C,	an	increase	in	the	
number	of	minority	variants	was	observed	from	day	1	to	6	(replicate	1),	
respectively,	whilst	coverage	remained	similar,	which	could	imply	the	mutant	
repertoire	is	expanding	over	time.	Most	of	the	minority	variant	diversity	in	patient	
C’s	GII.4	virus	population	led	to	non-synonymous	mutations	in	ORF1,	and	a	similar	
trend	was	observed	in	the	GII.7	virus	population	of	patient	B.	However,	if	the	
frequency	of	mutations	at	each	codon	position	were	normalized	by	gene	size	the	
difference	between	ORFs	in	patient	C	were	not	significantly	different,	which	implies	
the	selective	pressure	is	equal	across	the	non-structural	and	structural	genes.	But	in	
patient	B,	the	greatest	frequency	of	mutations	in	the	1st	codon	position	was	in	the	
ORF1,	and	when	normalized	by	gene	size	the	rate	of	mutation	was	significantly	
different	to	ORF2,	but	not	ORF3.	
In	contrast	to	these	data,	a	separate	study	identified	purifying	selection	(846	
dS/236	dN)	in	a	cohort	of	immunocompromised	individuals	with	chronic	HuNoV	
infection	(Kundu	et	al.	2013).	However,	the	AA	fixation	rate	has	been	shown	to	
depend	upon	the	extent	of	immunosuppression,	and	in	immunocompetent	
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individuals	the	fixation	rate	is	highest	(0.13	AA/day)	(Siebenga	et	al.	2008).	This	
study	agreed	with	Siebenga	and	colleagues,	as	patient	C	had	more	mutations	per	
sample	at	all	codon	positions	when	compared	to	patient	B	(1236	vs	310).	The	low	
frequency	of	mutations	in	the	major	capsid	protein	of	the	GII.7	virus	population	
would	suggest	that	the	immune	system	of	patient	B	is	not	placing	any	selective	
pressure	upon	their	virus.	Interestingly,	in	vitro	experiments	performed	by	Bull	and	
colleagues	determined	GII.7	viruses	to	have	a	faster	RdRp	incorporation	rate	than	
GII.4,	but	a	lower	mutation	rate	(Bull	et	al.	2010).	Moreover,	this	study	proposed	
the	mutation	and	replication	rate	in	GII.4	HuNoVs	is	optimal	for	adaption	leading	to	
global	predominance,	and	hence	why	GII.7	tends	to	be	detected	in	naïve	paediatric	
populations	(Bruggink	et	al.	2012;	Bull	et	al.	2010;	Puustinen	et	al.	2012;	Qiao	et	al.	
2017;	Supadej	et	al.	2017).	Despite	these	observations	there	are	three	limitations	in	
making	direct	comparisons	between	patient	B	and	C,	and	comparisons	with	other	
studies.	Firstly,	two	different	HuNoV	genotypes	are	in	separate	environments	and	
therefore	it	is	difficult	to	elucidate	whether	virus	population	changes	are	induced	
by	the	host	or	an	inherent	property	of	the	virus.	Secondly,	more	replicates	of	
adequate	quality	were	available	for	patient	B,	which	meant	variant	filtering	will	
have	been	more	stringent	in	relation	to	patient	C.	Thirdly,	our	samples	were	
collected	over	a	much	shorter	period	when	compared	to	other	MPS	studies	of	
HuNoV	in	immunocompromised	individuals	(Bull	et	al.	2012;	Kundu	et	al.	2013).	
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4.4.4 Minority	variants	in	the	GII.4	HuNoV	population	were	spread	over	more	
genes	at	a	lower	frequency	in	contrast	to	GII.7	
In	patient	B,	minority	variants	were	detected	in	ORF1	and	3,	but	none	were	present	
in	the	RdRp	gene.	However,	in	patient	C	minority	variants	were	detected	in	all	
regions	across	the	genome,	but	not	in	the	P1	subdomain	of	ORF2.	Although	more	
minority	variants	were	present	across	a	broader	selection	of	genes	in	GII.4	acute	
infection	(patient	C),	those	that	were	detected	in	GII.7	(patient	B)	chronic	infection	
existed,	on	average,	as	a	larger	proportion	of	the	virus	population	(0.05	vs	0.19).		
In	acute	HuNoV	infection,	emergent	minority	variants	were	reported	to	largely	exist	
at	below	2.5%	of	the	virus	population,	and	over	10	days	to	change	by	0.07%	on	
average	with	a	maximum	variation	of	2.6%	(Bull	et	al.	2012).	In	this	study,	11/29	of	
the	minority	variants	were	within	this	range,	and	the	average	was	more	than	10-
fold	higher	(0.07	vs	5%).	Over	a	much	longer	period	of	chronic	infection	(288	vs	15	
days),	Bull	and	colleagues	demonstrated	allele	frequencies	were	much	more	
variable	(2.1	–	59.5%),	which	are	similar	proportions	to	those	detected	in	patient	B	
(1.8	–	37.1	%)	(Bull	et	al.	2012).	Furthermore,	the	454	(Roche)	instrument	
highlighted	that	the	high	allele	frequencies	comprised	multiple	separate	haplotypes	
with	common	single	nucleotide	polymorphisms	(Bull	et	al.	2012),	however,	this	
analysis	was	not	possible	as	the	HiSeq	(Illumina)	read	lengths	are	much	shorter	and	
therefore	difficult	to	reconstruct.	But	it	was	noted	that	in	the	acute	infection	of	
patient	C	there	was	a	tendency	for	mutations	to	be	present	in	all	replicates,	but	not	
all	time	points	when	contrasted	to	the	chronic	infection	of	patient	B.	
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4.4.5 An	arbitrary	cut-off	for	calling	true	minority	variants	can	lead	to	data	loss	
	
The	availability	of	replicate	HuNoV	MPS	data	sets,	meant	criteria	could	be	designed	
to	call	minority	variants	in	samples	where	replicates	were	not	available.	The	criteria	
could	identify	true	variants	with	98.9%	accuracy,	but	would	also	ignore	98%	of	the	
total	true	variants	present	if	identified	by	using	replicates	instead.	The	criteria	were	
applied	to	the	longitudinal	sequence	data	from	patient	E,	D	and	F	to	identify	121	
minority	variants.	In	total	86	(71%)	of	the	minority	variants	were	present	in	at	least	
one	other	sample	from	the	same	patient.	
In	comparison	to	patient	C,	patient	D	had	a	similar	number	of	mutations	(29	vs	25),	
and	most	were	present	in	VP1.	On	the	other	hand,	in	patient	F	fewer	minority	
variants	were	called,	likely	due	to	inadequate	coverage	(29	vs	3).	In	contrast,	a	
sudden	increase	in	consensus	sequence	diversity	occurred	in	patient	E	on	the	last	
time	point	which	coincided	with	an	unusually	high	number	of	variants.	
Several	bioinformatics	pipelines	such	as	The	Quality	Assessment	of	Short	Read	
Pipeline	(QUASR)	(Watson	et	al.	2013),	Segminator	II	(Archer	et	al.	2012)	and	
VirVarSeq	(Verbist	et	al.	2015)	have	been	developed	and	validated	to	call	minority	
variants	in	virus	populations,	which	can	be	difficult	to	distinguish	from	instrumental	
error.	To	validate	the	pipelines	described,	clinical	samples	or	known	standards	have	
been	analysed	by	one	or	two	different	sequencing	chemistries,	to	measure	the	
instrumental	error	rates.	The	instrumental	mismatch	error	rates	are	in	the	range	of	
0.1-0.3	%	for	Roche	454	sequencing	chemistry,	0.08-0.47	%	for	Illumina	instruments	
and	0.12	%	for	the	Ion	Torrent	PGM	instrument	(Archer	et	al.	2012;	Gall	et	al.	2012;	
Van	den	Hoecke	et	al.	2015;	Thys	et	al.	2015;	Watson	et	al.	2013).	Therefore,	after	
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stringent	filtering	of	the	raw	data,	investigators	have	been	able	to	apply	these	tools	
to	their	data	and	set	thresholds	above	this	range	to	accurately	identify	minority	
variants	(Gall	et	al.	2013;	Henn	et	al.	2012;	Van	den	Hoecke	et	al.	2015).		
It	is	important	to	note	that	prior	to	HiSeq	(Illumina)	MPS	“spreading-of-signals”	or	
“adapter	leakage”	can	occur	in	the	pool,	where	between	5-10%	of	reads	are	
assigned	to	the	incorrect	sample	index;	this	is	due	to	low	levels	of	free	index	
primers,	which	are	carried	forward	by	AMPure	XP	beads	(Beckman	Coulter),	and	
can	be	extended	by	DNA	polymerase	at	the	3’	end	of	a	library	even	though	index	
mismatches	are	present	(Sinha	et	al.	2017).	In	this	study,	clinical	samples	were	
sequenced	on	the	HiSeq	platform,	and	therefore	this	is	a	potential	limitation	of	
calling	minority	variants.	However,	this	would	have	been	required	to	occur	in	an	
identical	manner	across	several	different	time	point	samples,	and	in	patient’s	B	and	
C	across	two	separate	HiSeq	(Illumina)	MPS	reactions.		
4.4.6 A	genotype	mixture	was	present	in	early	HuNoV	infection	of	patient	E	
In	the	transition	from	the	first	two	time	points	of	Patient	E’s	acute	HuNoV	infection	
to	the	last	time	point,	the	ORF1	consensus	sequence	changed	from	99.9%	similarity	
to	91.8%,	which	corresponded	to	a	decrease	in	coverage	and	a	mixed	population	of	
alleles	in	ORF1.	Analysis	of	the	de	novo	assembled	contiguous	sequences	identified	
a	mixed	population	of	GII.4	HuNoV	and	a	GII.P16/GII.4	recombinant.	The	GII.4	virus	
contiguous	sequences	mapped	to	the	consensus	genome	at	68%,	32%	and	100%	
coverage	on	day	0,	1	and	1	(+	6	hours),	whilst	the	recombinant	covered	84%,	65%	
and	17%.	
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At	the	first-time	point,	a	near	complete	GII.P16/GII.4	recombinant	was	assembled,	
alongside	the	ORF1	of	a	GII.4.	Subsequently,	on	the	last	time	point	a	near	complete	
GII.4	HuNoV	was	assembled.	In	the	literature,	the	ORF1/2	junction	is	well-
established	as	a	recombination	hotspot	(Bull	et	al.	2005;	Bull	et	al.	2007).	Further	
investigations	with	longer	sequencing	reads	would	be	required	to	accurately	
reconstruct	virus	populations	and	discern	whether	a	recombination	event	occurred,	
or	whether	competition	existed	between	two	separate	HuNoV	populations.	It	is	
possible	the	stool	sample	from	patient	E’s	last	time	point	was	mislabelled	during	
collection,	and	was	in	fact	from	a	separate	patient,	leading	to	the	sudden	increase	
in	diversity	observed.	However,	the	presence	of	a	near	complete	GII.4	ORF1	on	day	
0	in	patient	E	is	circumstantial	evidence	to	suggest	otherwise.	Another	possibility	
would	be	cross	contamination	during	the	library	preparation	process,	which	is	
difficult	to	exclude	completely.	Although	a	negative	control	was	included	in	the	GII	
ORF	1/2	junction	qPCR,	this	was	not	subsequently	included	in	the	sequencing.	MPS	
investigations	comparing	the	concordance	of	HIV-1	sequences	in	plasma	and	
peripheral	blood	mononuclear	cells	(PBMCs)	have	been	able	to	exclude	this	
possibility	by	phylogenetic	branch	separation	between	patient	samples,	but	this	
would	only	be	possible	for	patient	B	(Figure	4.21)	(Lee	et	al.	2012).	
Recombinants	of	GII.P16	have	been	detected	in	outbreaks	and	sporadic	cases	
across	Germany,	Japan,	South	Korea,	the	United	Kingdom	and	the	United	States	
(Cannon	et	al.	2017;	Choi	et	al.	2017;	Matsushima	et	al.	2016;	Niendorf	et	al.	2017;	
Ruis	et	al.	2017).	Furthermore,	the	GII.P16/GII.4	virus	is	considered	a	replacement	
of	the	predominant	GII.17	in	Asia	(de	Graaf	et	al.	2016).	The	HuNoV	RdRp	is	a	
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determinant	of	virus	transmissibility	(Arias	et	al.	2016;	Bull	et	al.	2010),	moreover,	
four	non-synonymous	mutations	in	the	GII.16P/GII.4	RdRp	have	been	proposed	to	
increase	recombinant	fitness	leading	to	strain	predominance	(Ruis	et	al.	2017).	This	
suggestion	agrees	with	the	early	stages	of	patient	E	infection,	where	the	
GII.16P/GII.4	HuNoV	appears	to	have	outcompeted	the	GII.4,	hence	why	the	
consensus	on	day	0	and	1	is	recombinant-like,	but	on	the	last	time	point	the	GII.4	
predominated	and	could	coincide	with	differences	in	antigenicity.	This	finding	
highlights	a	major	advantage	of	MPS	over	traditional	sequencing,	as	the	whole	
genome	can	be	examined	across	a	recombination	hotspot	and	changes	in	allele	
frequency	detected	at	high	sensitivity.	
4.4.7 Non-synonymous	mutations	in	P2	subdomain	of	patient	E	coincided	with	
increases	in	GII.4-specific	secretory	Ab		
In	total,	15	non-synonymous	consensus	changes	occurred	in	the	P2	domain	of	
patient	D,	E	and	F’s	virus	populations	over	the	course	of	infection.	Interestingly,	
S393G	was	found	in	all	three	patients,	H414P	was	detected	in	patient	D	and	E	and	
mutations	L351D,	D372N,	T377A	were	in	common	between	patient	E	and	F.	Only	a	
fraction	(4/15)	of	these	changes	occurred	upon	the	appearance	of	GII.4-HuNoV	
specific	secretory	antibody,	whilst	a	further	eight	could	have	been	induced	after	
sustained	selective	pressure	from	the	immune	system.	Overall,	three	of	the	AA	
changes	(297,	372,	393)	which	could	have	coincided	with	the	appearance	of	GII.4-
specific	secretory	Ab,	or	from	a	sustained	immune	response,	were	present	in	
previously	described	putative	epitopes	(sites	A	and	D)	(Allen	et	al.	2008;	Debbink	et	
al.	2012;	Lindesmith	et	al.	2012a).	The	remaining	sites	which	are	not	currently	
	 210	
described	in	the	literature	(293,	309,	351,	377,	414)	could	exist	as	uncharacterized	
epitopes	with	a	role	in	HuNoV	escape	from	herd	immunity.	However,	the	sites	
described	should	be	interpreted	with	caution	as,	at	low	levels	of	coverage	which	
were	observed,	toward	the	convalescent	stages	of	acute	HuNoV	infection	
erroneous	base	calls	can	be	determined	as	the	virus	consensus	sequence.	
Two	of	the	consensus	changes	described	in	patient	E	were	present	at	an	earlier	
stage	of	infection	as	minority	variants	(309	and	351).	Whilst	in	patient	C,	two	
minority	variants	were	found	(389	and	409)	that	had	the	potential	to	change	the	P2	
subdomain	surface	structure,	but	were	not	detected	on	day	10	and	11	and	could	be	
a	result	of	under	sampling.	The	mutations	present	at	positions	309,	389	and	409	
were	predicted	to	alter	the	P2	subdomain	surface	structure	after	protein	mapping.	
Moreover,	the	AAs	present	at	309,	389	and	409	were	near	epitopes	N,	D	and	E	
respectively,	and	thus	provided	further	evidence	for	these	regions	to	have	a	role	in	
GII.4	HuNoV	escape	from	herd	immunity	(Allen	et	al.	2008;	Debbink	et	al.	2012;	
Lindesmith	et	al.	2014;	Lindesmith	et	al.	2012a).	
4.4.8 A	dominant	copro-antibody	was	induced	to	an	earlier	GII.4	strain	after	
exposure	to	a	contemporary	GII.4	strain	
In	patient	C,	the	virus	population	was	near	identical	to	the	SY	VLP	in	the	P2	domain	
with	one	AA	difference	at	position	329.	However,	a	stronger	GII.4	secretory-Ab	was	
induced	toward	the	FH	VLP	on	day	6	and	11,	which	was	highly	dissimilar	(11/20	
differences	at	known	epitopes).	
Two	concepts	exist	that	could	explain	the	secretory	Ab	measurements	observed	in	
patient	C,	which	are	known	as	original	antigenic	sin	(OAS)	(Francis	1960)	and	
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Antigenic	Seniority	(Lessler	et	al.	2012).	OAS	is	the	theory	that	the	naïve	host	
immune	system	is	imprinted	by	the	first	antigen	it	encounters,	and	thereafter	the	
highest	Ab	affinity	responses	will	be	induced	to	the	first	antigen	when	similar	
antigens	are	encountered	(Francis	1960).	On	the	other	hand,	Antigenic	Seniority	
proposes	that	every	similar	antigen	encountered	form	a	hierarchy	over	time,	and	
the	Ab	affinity	for	each	is	boosted	by	encountering	similar	antigens	(Lessler	et	al.	
2012).	Antigenic	Seniority	was	proposed	to	have	occurred	after	the	administration	
an	intramuscular	HuNoV	VLP	vaccine	(consensus	VLP	of	contemporary	strains),	
where	cohorts	over	18	years	old	mounted	a	persistent	response	to	GII.4-1997	
(Lindesmith	et	al.	2015).	However,	Tamminen	and	colleagues	demonstrated	that	
exposure	to	GII.4,	followed	by	GII.12	(after	14	weeks),	did	not	affect	GII.12	IgG	titres	
or	avidity	in	mice	(Tamminen	et	al.	2013).	Contrasted	to	this	study,	GII.4	and	GII.12	
are	more	distantly	related	than	GII.4	FH	and	GII.4	SY,	and	therefore	it	is	possible	
that	the	GII.12	was	dissimilar	enough	to	evoke	a	separate	immune	response.	In	the	
surrogate	neutralisation	assays,	ten	times	more	FH	VLP	was	applied	to	the	PGM	
receptor,	which	cannot	be	excluded	as	an	explanation.	But	both	concentrations	(2	
and	20	µg)	would	have	been	expected	to	saturate	the	PGM	receptors	and	the	
excess	would	be	washed	away.	
It	must	be	noted	that	differences	in	phylogenetic	clustering	(Figure	4.21)	of	capsid	
sequences	from	the	same	patient	at	different	time	points	could	be	due	to	a	
superinfection,	an	allele	replacement	within	the	virus	population	or	a	low-quality	
library	preparation	(decrease	in	read	coverage).	
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4.4.9 Despite	the	presence	of	Sydney	strain	specific	coproantibody	patients	D,	E	
and	F	were	infected	by	a	novel	HuNoV	strain	
Patients	D,	E	and	F	were	infected	by	a	HuNoV	strain	which	was	phylogenetically	
closely	related	to	the	Sydney	2012	strain	(Figure	4.21),	even	though	SY-VLP	specific	
coproantibody	was	present	and	most	likely	originated	from	a	previous	infection.	
Therefore,	the	three	separate	virus	populations	in	these	individuals	were	
sufficiently	different	in	the	P2	domain	to	escape	immunological	memory	and	induce	
GE.	In	the	P2	domain	of	each	virus	population,	two	conserved	non-synonymous	
mutations	existed	as	dominant	alleles	over	the	course	of	infection,	A323T	and	
A340T.	The	latter	has	been	described	as	a	component	of	a	putative	epitope	on	the	
virus	surface,	whilst	AA	position	323	has	not	been	reported	and	therefore	could	
potentially	be	a	site	of	antigenic	importance	(Lindesmith	et	al.	2012a).	
Understanding	how	the	diversity	of	a	HuNoV	population	changes	in	an	
immunosuppressed/immunodeficient	host	in	comparison	to	an	immunocompetent	
host	can	lead	to	the	identification	of	regions	or	putative	epitopes	that	may	be	
under	direct	immune	pressure.	In	the	absence	of	a	suitable	and	readily	available	cell	
culture	or	animal	model,	this	approach	may	provide	a	way	forward	for	identifying	
epitopes,	and	changes	to	the	virus	capsid	that	drive	HuNoV	persistence.	
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5 Whole	genome	sequencing	as	a	tool	
for	tracking	transmission	during	
outbreaks	
	
5.1 Introduction	
5.1.1 The	importance	of	tracking	pathogen	transmission	in	public	health	
In	public	health,	it	is	important	to	identify	pathogens	present	in	the	population	and	
their	transmission	routes,	which	can	lead	onto	effective	intervention	strategies	and	
disease	control.	Epidemiological	investigations	can	infer	the	source	of	infection.	
However,	high	resolution	pathogen	genomic	characterisation	coupled	with	
epidemiological	data	can	increase	the	accuracy	of	the	investigations	and	distinguish	
transmission	events	from	multiple	seeding	events	to	improve	intervention	
strategies.	
5.1.2 Sanger	sequencing	as	a	tool	for	tracking	virus	outbreak	transmission	
The	earliest	developed	tool	for	characterizing	the	genomes	of	viruses	in	point	
source	and	propagated	outbreaks	is	Sanger	sequencing,	which	is	still	commonly	
used	to	sequence	short	variable	regions	with	high	phylogenetic	resolving	power	
(Sanger	et	al.	1977).	Sanger	sequencing	technology	can	be	applied	directly	to	
amplicons	or	indirectly	by	cloning	extracted	DNA	sequences	into	a	plasmid	vector.	
This	technique	can	determine	the	complete	genome	sequence	of	the	predominant	
virus	in	a	population,	but	requires	bridging	of	multiple	amplicons.		
Partial	sequencing	of	an	off-season	Dengue	outbreak	in	Kerala	was	performed	by	
Anoop	and	colleagues,	which	led	to	the	conclusion	that	the	virus	was	
phylogenetically	very	like	another	Dengue	virus	previously	detected	in	a	separate	
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part	of	India	(Anoop	et	al.	2012).	More	recently,	partial	and	complete	genome	
sequencing	aided	transmission	mapping	of	an	Ebola	outbreak	in	Guinea	(Baize	et	al.	
2014).	In	a	similar	manner,	Sanger	sequencing	of	complete	Measles	virus	(MV)	
genomes	was	used	retrospectively	to	characterize	an	outbreak	of	MV	at	the	2010	
Olympic	Winter	Games	(Gardy	et	al.	2015).	MV	was	found	to	undergo	strong	
purifying	selection,	and	often	the	virus	transmitted	from	person-to-person	was	
100%	identical,	but	enough	diversity	was	present	over	a	short	time	period	to	
ascertain	spatiotemporal	clusters	(Gardy	et	al.	2015).	
5.1.3 MPS	as	a	tool	for	tracking	outbreak	virus	transmission	
In	contrast	to	Sanger	sequencing	technology,	MPS	is	not	primer	mediated	and	can	
provide	complete	genomes	at	much	greater	coverage	depth.	The	depth	of	
sequence	data	obtained	can	further	inform	on	short	regions	of	high	variability	
(Penedos	et	al.	2015),	and	detect	minority	variant	transmission	from	donor	to	
recipient	to	improve	the	resolution	of	phylogenetic	relationships	(genetic	
bottleneck)	(Montoya	et	al.	2016;	Redd	et	al.	2012).	Furthermore,	the	MinIon	
(Oxford	Nanopore	Technologies)	platform	was	used	in	the	recent	Ebola	virus	
outbreak	to	recover	complete	genome	sequence	data	and	inform	on	the	
geographical	spread	of	variants	within	and	between	African	countries	(Quick	et	al.	
2016).	In	a	similar	manner,	two	other	MPS	platforms,	the	454	(Roche)	and	the	Ion	
torrent	(Fisher	Scientific)	instruments,	have	been	applied	to	Zika	virus	to	define	the	
introduction	of	different	strains	across	South	America	(Faria	et	al.	2016).	
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5.1.4 Sanger	sequencing	and	MPS	in	HuNoV	outbreaks	
In	the	literature,	partial	Sanger	sequencing	of	the	HuNoV	genome	is	an	established	
epidemiological	tool	to	assign	genotypes	to	sporadic	cases	of	illness	within	the	
population	or	causative	agents	in	outbreaks,	and	further	transmission.	The	earliest	
investigation	to	characterize	transmission	in	separate	local	HuNoV	outbreaks	
amplified	and	sequenced	3,225	nucleotides	from	the	3’	terminal,	and	proposed	
person-to-person	transmission	to	coincide	with	an	accumulation	of	mutations	as	
opposed	to	infection	from	a	common	source	(Dingle	and	Norovirus	Infection	
Control	in	Oxfordshire	Communities	2004).	On	the	other	hand,	Xerry	and	colleagues	
partially	sequenced	a	shorter	region	which	could	be	equally	informative,	the	HuNoV	
P2	domain	or	hypervariable	region	(600	bases),	in	several	studies	(Xerry	et	al.	2010;	
Xerry	et	al.	2009;	Xerry	et	al.	2008).	These	investigations	led	to	the	definition	of	a	
common	source	outbreak	as	100%	identical	between	susceptible	individuals.	
However,	in	a	small	proportion	of	individuals	(10%)	1-2	nucleotide	changes	can	
occur	3	weeks	after	the	onset	of	shedding,	which	would	reduce	sensitivity	if	the	
mutated	virus	was	transmitted	further	(Sukhrie	et	al.	2013).	
Despite	the	establishment	of	MPS	platforms	in	molecular	biology,	only	a	handful	of	
studies	have	applied	this	technology	to	HuNoV	transmission.	Bull	and	colleagues	
partially	sequenced	the	structural	genes	of	a	HuNoV	recombinant	transmission	
event	between	three	immunocompetent	individuals,	with	the	454	(Roche)	
instrument	(Bull	et	al.	2012).	The	major	alleles	present	in	both	recipients,	were	
found	as	minor	variants	in	the	donor	(<	0.01%)	(Bull	et	al.	2012).	A	separate	study,	
using	the	same	instrument,	also	characterized	a	genetic	bottleneck	transmission	
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event	between	two	immunocompromised	patients	by	complete	genome	
sequencing	of	HuNoV	(Kundu	et	al.	2013).	More	recently,	the	complete	HuNoV	
genome	of	a	recombinant	was	characterized,	with	the	Ion	Torrent	instrument	
(FisherScientific),	in	a	subset	of	individuals	infected	in	a	presumed	point	source	
outbreak	which	occurred	in	the	1970s	(Johnson	et	al.	2017).	
5.1.4.1 Point	source	versus	secondary	transmission	
A	point	source	outbreak	occurs	when	individuals	encounter	HuNoV	indirectly	
through	a	contaminated	fomite	(i.e	foodborne,	waterborne	or	food	handler	
transmission).	Further,	if	a	point	source	outbreak	is	induced	by	sewage	
contamination	the	genotypes	detected	will	tend	to	be	more	heterogeneous,	in	
contrast	to	food	handler	transmission	(Le	Guyader	et	al.	2006).	Le	Guyader	and	
colleagues	elegantly	traced	an	international,	mixed	genotype,	HuNoV	outbreak	to	
an	oyster	farm,	contaminated	by	sewage,	through	epidemiological	analysis	and	
partial	sequencing	of	region	C	and	the	P2	domain	(Le	Guyader	et	al.	2006).	
Moreover,	partial	sequencing	of	region	A	and	C	linked	frozen	strawberries	to	a	
multistate	HuNoV	outbreak	in	Germany,	likely	to	have	been	caused	by	sewage	
contamination	(Hohne	et	al.	2015).	Partial	sequencing	of	region	C	and	the	P2	
domain	recently	indicated	a	high	prevalence	of	asymptomatic	healthcare	workers	
or	food	handlers	existed	in	point	source	outbreaks	(Sabria	et	al.	2016).	
Most	HuNoV	infections	are	transmitted	through	person-to-person	transmission	(i.e	
nosocomial	transmission).	Transmission	of	HuNoV	between	patients	has	been	
reported	rarely,	and	is	more	difficult	to	characterize	than	common	source	
outbreaks.	A	mutation	which	has	occurred	in	one	individual	must	be	conserved	in	a	
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latter	infection	for	circumstantial	evidence	of	person-to-person	transmission	
(Kundu	et	al.	2013;	Sukhrie	et	al.	2010).	
5.2 Materials	and	methods	
5.2.1 Clinical	sample	preparation,	enrichment,	library	preparation	and	
sequencing	
Faecal	suspensions	were	prepared	from	38	archived	samples	from	various	
outbreaks	gifted	from	Public	Health	England	(PHE),	for	which	epidemiological	data	
had	been	obtained	retrospectively.	The	stool	suspension	supernatant	enrichment	
methodology,	RNA	extraction	protocol	and	post-extraction	processes	(including	
library	preparation)	were	identical	to	that	described	in	Chapter	4,	whilst	MPS	was	
performed	in	an	identical	manner	to	Chapter	3.	In	total	38	samples	were	prepared,	
however,	sufficient	MPS	data	to	infer	the	P2	domain	consensus	sequence	was	only	
obtained	in	25/38	library	preparations	(Tables	5.1	-	5.6).	
	
Table	5.1	Stool	sample	details	from	outbreak	A	(*	=	RNA	extract	not	positive	for	
GII	but	was	present	after	repeated	library	preparation).	
Outbreak	 Environment	 Sample	 Genotype	 GII	HuNoV	Ct	value	
A	 Restaurant	 1	 GII.20	 23.16	
2	 24.86	
3	 27.88	
4	 NA*	
5	 25.33	
6	 24.95	
	
Table	5.2	Stool	sample	details	from	outbreak	B.	
Outbreak	 Environment	 Sample	 Genotype	 GII	HuNoV	Ct	value	
B	 Hospital	 1	 GII.4	 18.75	
2	 21.99	
3	 24.86	
4	 24.38	
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Table	5.3	Stool	sample	details	from	outbreak	C.	
Outbreak	 Environment	 Sample	 Genotype	 GII	HuNoV	Ct	value	
C	 Pub	 1	 GII.Pe/GII.4	 21.74	
2	 26.88	
3	 GII.4	 32.41	
4	 22.54	
	
Table	5.4	Stool	samples	details	from	outbreak	D.	
Outbreak	 Environment	 Sample	 Genotype	 GII	HuNoV	
titre/qPCR	reaction	
D	
	
Hospital	 1	 GII.4	 29.00	
2	 31.27	
3	 30.24	
4	 28.37	
	
Table	5.5	Stool	sample	details	from	outbreak	E.	
Outbreak	 Environment	 Sample	 Genotype	 GII	HuNoV	
titre/qPCR	reaction	
E	 Hospital	 1	 GII.4	 37.11	
2	 14.09	
3	 24.89	
	
Table	5.6	Stool	sample	details	from	outbreak	F.	
Outbreak	 Environment	 Sample	 Genotype	 GII	HuNoV	
titre/qPCR	reaction	
F	 Hospital	 1	 GII.Pe/GII.4	 20.64	
2	 33.95	
3	 21.15	
4	 26.53	
	
5.2.2 Data	analysis	
5.2.2.1 Bioinformatic	analysis	
The	HiSeq	(Illumina)	data	was	analysed	using	the	pipeline	described	in	Chapter	3,	
whilst	the	identification	of	true	minority	variants	was	achieved	by	applying	the	
criteria	mentioned	in	Chapter	4.	Multiple	alignment	analysis	was	performed	in	
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Geneious	8.0.5	(Kearse	et	al.	2012)	–	www.geneious.com,	with	the	MUSCLE	
algorithm	(Edgar	2004)	under	default	settings.	
5.2.2.2 Phylogenetic	analysis	
Phylogenetic	relationships	were	inferred	as	described	in	Chapter	4.	
5.3 Results	
	
5.3.1 A	higher	HuNoV	virus	titre	correlated	with	a	greater	depth	of	read	
coverage	
HiSeq	(Illumina)	reads	from	outbreaks	A,	B,	C,	D,	E	and	F	were	assembled	into	
contiguous	sequences	de	novo,	and	a	local	nucleotide	alignment	showed	the	
aetiological	agents	were	all	genogroup	II	HuNoVs,	in	agreement	with	the	partial	
sequence	data	obtained	upon	sample	collection	(data	not	shown).	In	half	of	the	
outbreaks,	which	were	all	health	care	environments,	a	non-recombinant	GII.4	
HuNoV	was	present	in	all	the	stool	samples	collected	(Tables	5.2,	5.4	and	5.5).	In	
the	remaining	environments,	the	GII.Pe/GII.4	recombinant	was	detected	alongside	
a	GII.4	in	a	pub	(Table	5.3),	whilst	the	same	recombinant	was	detected	solely	in	a	
hospital	(Table	5.6),	and	a	GII.20	was	assembled	from	the	stool	samples	collected	in	
a	restaurant	(Table	5.1).	Consensus	sequences	were	derived	individually	after	
mapping	each	set	of	reads	to	their	respective	reference	sequence.	
Complete	or	near	complete	HuNoV	genomes	were	recovered	from	most	stool	
samples	(22/25)	via	PGM-MB	enrichment,	and	none	were	classed	as	library	
preparation	failures.	Two	of	the	three	samples	for	which	a	fragmented	GII	HuNoV	
genome	was	recovered	belonged	to	the	same	outbreak	(Outbreak	E),	but	did	not	
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appear	to	be	associated	with	the	genotype	present	(Table	5.11).	In	total,	six	
samples	across	all	outbreaks	had	a	median	coverage	below	ten,	and	half	of	these	
were	from	the	outbreak	E	(Tables	5.7	–	5.12).	Over	half	of	the	samples	(56%)	had	a	
median	coverage	above	100	(Tables	5.7	–	5.12),	and	in	two	of	the	samples	the	
lower	quartile	range	was	greater	than	the	upper	quartile	range	(Figure	5.1).	
Table	5.7	Summary	of	GII.20	reads	recovered	from	stool	samples	obtained	in	
outbreak	A	(IQR=Interquartile	range).	
Outbreak	 Sample	 Coverage	 Percentage	of	the	
genome	covered	
(%)		
Median	 IQR	
A	 1	 520	 617	 99.67	
2	 8	 11	 95.33	
3	 331	 479	 99.57	
4	 218	 252	 99.83	
5	 172	 219	 99.73	
6	 49	 54	 98.54	
	
Table	5.8	Summary	of	GII.4	reads	recovered	from	stool	samples	obtained	in	
outbreak	B	(IQR=Interquartile	range).	
Outbreak	 Sample	 Coverage	 Percentage	of	the	
genome	covered	
(%)	
Median	 IQR	
B	 1	 74	 69	 99.44	
2	 1600	 760	 99.88	
3	 203	 146	 99.74	
4	 201	 108	 99.56	
	
Table	5.9	Summary	of	GII.Pe/GII.4	and	GII.4	reads	recovered	from	stool	samples	
obtained	in	outbreak	C	(IQR=Interquartile	range).	
Outbreak	 Sample	 Coverage	 Percentage	of	the	
genome	covered	
(%)	
Median	 IQR	
C	 1	 12	 13	 95.75	
2	 103	 79	 99.54	
3	 7	 7	 94.12	
4	 1128	 744	 100.0	
	
	 221	
Table	5.10	Summary	of	GII.4	reads	recovered	from	stool	samples	obtained	in	
outbreak	D	(IQR=Interquartile	range).	
Outbreak	 Sample	 Coverage	 Percentage	of	the	
genome	covered	
(%)	
Median	 IQR	
D	
	
1	 4	 5	 85.06	
2	 16	 14	 98.19	
3	 179	 191	 99.91	
4	 349	 225	 100.0	
	
Table	5.11	Summary	of	GII.Pe/GII.4	reads	recovered	from	stool	samples	obtained	
in	outbreak	E	(IQR=Interquartile	range).	
Outbreak	 Sample	 Coverage	 Percentage	of	the	
genome	covered	
(%)	
Median	 IQR	
E	 1	 3	 3	 83.85	
2	 2	 2	 54.25	
3	 4	 5	 90.24	
	
Table	5.12	Summary	of	GII.4	reads	recovered	from	stool	samples	obtained	in	
outbreak	F	(IQR=Interquartile	range).	
Outbreak	 Sample	 Coverage	 Percentage	of	the	
genome	covered	
(%)	
Median	 IQR	
F	 1	 3008	 1693	 99.99	
2	 13	 16	 95.70	
3	 3251	 1908	 100.0	
4	 260	 219	 99.77	
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Figure	5.1	The	range,	interquartile	range	(IQR)	and	median	of	coverage	for	each	
sample	analysed.	
	
To	assess	whether	differences	in	coverage	between	each	sample	were	related	to	
the	HuNoV	virus	titre	a	linear	regression	analysis	of	mean	coverage	against	the	
relative	Ct	value	was	performed	(Figure	5.2).	In	this	investigation,	a	negative	trend	
was	observed	between	the	mean	coverage	and	Ct	value	(Figure	5.2).	
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Figure	5.2	Linear	regression	analysis	of	mean	sample	coverage	against	the	GII	
HuNoV	Ct	value	of	the	RNA	extract.	
	
5.3.2 Partial	Sanger	sequencing	of	the	HuNoV	P2	domain	was	in	closer	
agreement	with	its	own	consensus	than	MPS	
Over	half	(58%)	of	the	amplicons	used	in	P2	domain	Sanger	sequencing	were	
identical	to	their	respective	outbreak	consensus	sequence	(Tables	5.13	-	5.18).	If	
MPS	was	applied	to	the	complete	genome	instead,	the	number	of	complete	P2	
domain	matches	decreased	to	48%	(Tables	5.13	-	5.18).	Overall,	the	P2	domain	of	
samples	sequenced	by	Sanger	method	differed	from	the	outbreak	consensus	
sequence	by	0-0.11%,	in	contrast	if	the	P2	domain	sequence	was	obtained	via	MPS	
this	ranged	from	0-3.94%	(Tables	5.13	-	5.18).	In	the	MPS	data	set	if	samples	with	a	
mean	coverage	below	21	were	excluded	the	range	was	reduced	to	0-0.58%	(Tables	
5.13	-	5.18).	Complete	genome	mapping	to	the	consensus	sequence	was	not	
attained	in	any	of	the	outbreaks	(Tables	5.13	-	5.18).	
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Table	5.13	Outbreak	A	consensus	identity	measurements	within	partial	Sanger	
sequencing	and	MPS.	
Outbreak	 Sample	 Sanger	sequence	
P2	identity	(%)	
MPS	P2	
identity	(%)	
MPS	Overall	
identity	(%)	
A	 1	 100	 100	 99.34	
2	 99.69	 99.46	 95.75	
3	 100	 100	 99.16	
4	 100	 100	 99.07	
5	 100	 100	 99.02	
6	 100	 100	 98.43	
	
Table	5.14	Outbreak	B	consensus	identity	measurements	within	partial	Sanger	
sequencing	and	MPS.	
Outbreak	 Sample	 Sanger	sequence	
P2	identity	(%)	
MPS	P2	
identity	(%)	
MPS	Overall	
identity	(%)	
B	 1	 99.75	 100	 99.54	
2	 100	 100	 99.90	
3	 100	 100	 99.81	
4	 100	 100	 99.64	
	
Table	5.15	Outbreak	C	consensus	identity	measurements	within	partial	Sanger	
sequencing	and	MPS.	
Outbreak	 Sample	 Sanger	sequence	
P2	identity	(%)	
MPS	P2	
identity	(%)	
MPS	Overall	
identity	(%)	
C	 1	 	 99.08	 96.04	
2	 	 99.42	 99.42	
3	 100	 97.93	 93.97	
4	 100	 99.42	 99.77	
	
Table	5.16	Outbreak	D	consensus	identity	measurements	within	partial	Sanger	
sequencing	and	MPS.	
Outbreak	 Sample	 Sanger	sequence	
P2	identity	(%)	
MPS	P2	
identity	(%)	
MPS	Overall	
identity	(%)	
D	 1	 99.88	 99.79	 88.01	
2	 99.58	 98.09	 96.57	
3	 98.92	 99.79	 99.70	
4	 99.78	 99.79	 99.77	
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Table	5.17	Outbreak	E	consensus	identity	measurements	within	partial	Sanger	
sequencing	and	MPS.	
Outbreak	 Sample	 Sanger	sequence	
P2	identity	(%)	
MPS	P2	
identity	(%)	
MPS	Overall	
identity	(%)	
E	 1	 100	 99.90	 99.64	
2	 99.89	 95.95	 65.14	
3	 99.90	 98.44	 91.03	
	
Table	5.18	Outbreak	F	consensus	identity	measurements	within	partial	Sanger	
sequencing	and	MPS.	
Outbreak	 Sample	 Sanger	sequence	
P2	identity	(%)	
MPS	P2	
identity	(%)	
MPS	Overall	
identity	(%)	
F	 1	 	 100	 99.94	
2	 	 99.68	 96.01	
3	 	 100	 99.79	
4	 	 100	 99.94	
	
5.3.3 MPS	data	agreed	closely	with	partial	Sanger	sequences	at	sufficient	mean	
coverage	
In	a	pairwise	comparison	of	all	outbreaks,	there	was	>	98%	agreement	between	the	
P2	domain	obtained	by	MPS	and	the	partial	Sanger	sequencing	with	four	exceptions	
(Tables	5.19	–	5.23).	The	four	exceptions	were	outbreak	C	sample	3	(97.22%),	
outbreak	D	sample	2	(97.88%),	outbreak	E	sample	2	(88.91%)	and	outbreak	E	
sample	3	(97.92%)	for	which	the	mean	coverage	ranged	from	2.96-20.72	(Tables	
5.21	and	5.23).	Interestingly,	there	were	samples	with	similar	levels	of	coverage	
where	heterogeneity	between	the	two	techniques	at	the	P2	domain	was	not	
observed.	In	outbreak	A	and	B,	conserved	mismatches	were	observed	between	
MPS	and	Sanger	method	that	were	near	the	5’	and	3’	end	of	the	amplicon	(data	not	
shown).	
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Table	5.19	Outbreak	A	mismatch	identity	of	the	P2	domain	between	Sanger	
method	and	MPS.	The	fraction	represents	the	number	of	matching	base	calls	in	
the	MPS	data	out	of	the	total	number	of	base	calls	in	the	Sanger	sequence	data.	
Outbreak	 Sample	 Sanger	sequence	versus	MPS	
identity	at	P2		
A	 1	 319/321	(99.4%)	
2	 315/320	(98.4%)	
3	 318/320	(99.4%)	
4	 319/322	(99.1%)	
5	 319/322	(99.1%)	
6	 317/319	(99.4%)	
	
Table	5.20	Outbreak	B	mismatch	identity	of	the	P2	domain	between	Sanger	
method	and	MPS	(Grey	shading	=	identical).	The	fraction	represents	the	number	
of	matching	base	calls	in	the	MPS	data	out	of	the	total	number	of	base	calls	in	the	
Sanger	sequence	data.	
Outbreak	 Sample	 Sanger	sequence	versus	MPS	
identity	at	P2		
B	 1	 399/399	(100%)	
2	 577/578	(99.8%)	
3	 578/580	(99.7%)	
4	 577/578	(99.8%)	
	
Table	5.21	Outbreak	C	mismatch	identity	of	the	P2	domain	between	Sanger	
method	and	MPS	(Cross	hatching	=	Sanger	sequence	data	not	available).	The	
fraction	represents	the	number	of	matching	base	calls	in	the	MPS	data	out	of	the	
total	number	of	base	calls	in	the	Sanger	sequence	data.	
Outbreak	 Sample	 Sanger	sequence	versus	MPS	
identity	at	P2		
C	 1	 	
2	 	
3	 489/503	(97.2%)	
4	 516/518	(99.6%)	
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Table	5.22	Outbreak	D	mismatch	identity	of	the	P2	domain	between	Sanger	
method	and	MPS	(Grey	shading	=	identical).	The	fraction	represents	the	number	
of	matching	base	calls	in	the	MPS	data	out	of	the	total	number	of	base	calls	in	the	
Sanger	sequence	data.	
Outbreak	 Sample	 Sanger	sequence	versus	MPS	
identity	at	P2		
D	 1	 407/408	(99.8%)	
2	 462/472	(97.9%)	
3	 413/417	(99.0%)	
4	 459/459	(100%)	
	
Table	5.23	Outbreak	E	mismatch	identity	of	the	P2	domain	between	Sanger	
method	and	MPS	(Grey	shading	=	identical).	The	fraction	represents	the	number	
of	matching	base	calls	in	the	MPS	data	out	of	the	total	number	of	base	calls	in	the	
Sanger	sequence	data.	
Outbreak	 Sample	 Sanger	sequence	versus	MPS	
identity	at	P2		
E	 1	 453/453	(100%)	
2	 393/442	(88.9%)	
3	 471/481	(97.9%)	
	
5.3.4 Outbreaks	clustered	in	an	identical	manner	across	techniques	if	MPS	
coverage	was	sufficient	
To	examine	whether	the	sequencing	technique	used,	or	the	completeness	of	the	
HuNoV	genome,	affected	the	phylogenetic	relationship	inferred	within	outbreaks	
the	Maximum-Likelihood	algorithm	was	applied	to	each	genotype	after	alignment	
(Figures	5.3	–	5.7).	The	samples	from	Outbreak	A,	B,	C	and	F	clustered	together	
regardless	of	whether	the	Sanger	method	or	MPS	was	used	to	discern	the	complete	
or	partial	genomic	sequence	(Figures	5.3	–	5.7).	However,	if	the	complete	genome	
sequence	was	available	via	MPS,	phylogenetic	relationships	between	samples	in	an	
outbreak	could	be	inferred	at	greater	sensitivity	(Figures	5.3	–	5.7).	HuNoVs	from	
outbreaks	C,	D	and	E	had	sufficient	similarity	to	cluster	as	a	group	near	to	the	GII.4	
Sydney	2012	strain	in	each	phylogenetic	tree	(Figures	5.4).	However,	in	agreement	
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with	the	mismatch	analysis	between	Sanger	method	and	MPS,	those	samples	with	
low	coverage	and	<	98	%	similarity	did	not	remain	in	the	clusters	assigned	by	partial	
amplicon	sequencing	of	the	P2	domain	(Figures	5.4	–	5.6).	
	
	
Figure	5.3	Outbreak	A	Maximum-Likelihood	phylogenetic	trees	(A=Sanger	method	
of	the	P2	domain,	B=MPS	of	the	P2	domain,	C=MPS	of	the	complete	genome,	boot	
strap	values	of	nodes	over	0.8	of	1000	bootstrap	replicates	are	shown	as	red	
squares).	
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Figure	5.4	Outbreak	B,	C,	D	and	E	Maximum-Likelihood	phylogenetic	tree	of	P2	
domain	Sanger	method	(boot	strap	values	of	nodes	over	0.8	of	1000	bootstrap	
replicates	are	shown	as	red	squares).	
	
Figure	5.5	Outbreak	B,	C,	D	and	E	Maximum-Likelihood	phylogenetic	tree	of	P2	
domain	MPS	(boot	strap	values	of	nodes	over	0.8	of	1000	bootstrap	replicates	are	
shown	as	red	squares).	
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Figure	5.6	Outbreak	B,	C,	D	and	E	Maximum-Likelihood	phylogenetic	tree	of	
complete	genome	MPS	(boot	strap	values	of	nodes	over	0.8	of	1000	bootstrap	
replicates	are	shown	as	red	squares).	
	
Figure	5.7	Outbreak	C	and	F	Maximum-Likelihood	phylogenetic	trees	(A=Sanger	
method	of	region	C,	B=MPS	of	region	C,	C=MPS	of	the	complete	genome,	boot	
strap	values	of	nodes	over	0.8	of	1000	bootstrap	replicates	are	shown	as	red	
squares).	
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5.3.5 MPS	offers	a	tool	to	detect	differential	selection	in	hosts	
Minority	variants	were	identified	by	applying	the	criteria	described	in	Chapter	4.	In	
total	45	minor	mutations	were	present	in	the	HuNoV	populations	of	outbreaks	A-F	
(Table	5.24).	It	was	not	possible	to	detect	minority	variants	in	outbreak	E,	due	to	
the	low	coverage	(Table	5.11).	Interestingly,	outbreak	B	did	have	sufficient	
coverage,	but	far	fewer	minority	variants	were	called	in	contrast	to	the	other	
outbreaks	(Table	5.24).	
Table	5.24	The	frequency	of	minority	variants	identified	in	each	ORF	from	
outbreaks	A-F.	
ORF	 Outbreak	
A	 B	 C	 D	 E	 F	
1	 10	 0	 7	 8	 0	 2	
2	 6	 0	 2	 7	 0	 2	
3	 0	 1	 0	 0	 0	 0	
Total	 16	 1	 9	 15	 0	 4	
	
Most	of	the	minority	variants,	across	all	outbreaks,	did	not	correspond	to	an	
identical	change	in	the	consensus	sequence	of	a	separate	individual	(42/45)	(Figures	
5.8	–	5.11).	However,	there	were	three	exceptions,	in	outbreak	A,	position	2011	
and	5137	(Figure	5.8),	and	in	outbreak	F,	position	4072	(Figure	5.11).	If	outbreak	A	
was	compared	to	the	other	outbreaks	there	were	2	positions	(position	4941	and	
5137)	that	demonstrated	a	similar	heterogeneous	population	of	minority	variants	
across	different	individuals	(Figure	5.8).		
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Figure	5.8	The	frequency	of	minority	variants	identified	in	stool	samples	from	
outbreak	A	compared	to	each	consensus	sequence	(Blue	=	Adenine,	Red	=	
Cytosine,	Green	=	Guanine,	Yellow	=	Thymine).	
	 233	
	
Figure	5.9	The	frequency	of	minority	variants	identified	in	stool	samples	from	
outbreak	C	compared	to	each	consensus	sequence	(Blue	=	Adenine,	Red	=	
Cytosine,	Green	=	Guanine,	Yellow	=	Thymine).	
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Figure	5.10	The	frequency	of	minority	variants	identified	in	stool	samples	from	
outbreak	D	compared	to	each	consensus	sequence	(Blue	=	Adenine,	Red	=	
Cytosine,	Green	=	Guanine,	Yellow	=	Thymine).	
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Figure	5.11	The	frequency	of	minority	variants	identified	in	stool	samples	from	
outbreak	F	compared	to	each	consensus	sequence	(Blue	=	Adenine,	Red	=	
Cytosine,	Green	=	Guanine,	Yellow	=	Thymine).	
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5.4 Discussion	
	
5.4.1 Clinical	samples	with	higher	HuNoV	viral	loads	tend	to	generate	a	higher	
mean	coverage		
This	investigation	has	demonstrated	that	stool	samples	with	lower	HuNoV	Ct	values	
(higher	viral	loads)	tend	to	generate	a	higher	mean	coverage	of	the	virus	genome,	
and	has	implications	for	data	analysis	and	the	ability	to	discriminate	minority	
variants	from	error.	Although	this	observation	was	not	significant,	it	agrees	with	the	
findings	of	other	research	groups	that	have	applied	MPS	to	HuNoV	clinical	samples	
(Fonager	et	al.	2017;	Nasheri	et	al.	2017),	and	it	remains	a	major	limitation.	Fonager	
and	colleagues	demonstrated	a	strong	negative	correlation	between	the	HuNoV	Ct	
value	after	poly-(A)	capture	and	the	number	of	HuNoV	reads	present	prior	to	
sequencing	(Fonager	et	al.	2017).	Similarly,	a	strong	positive	correlation	was	shown	
to	exist	between	the	virus	titre	and	number	of	reads	mapped	to	the	HuNoV	genome	
without	a	capture	method	(Nasheri	et	al.	2017).	There	are	three	potential	reasons	
why	the	correlation	observed	in	this	investigation	was	weak	in	comparison.	Fonager	
and	colleagues	captured	HuNoV	reads	after	extraction,	when	the	sample	would	be	
less	complex,	and	pooled	their	nucleic	acid	material	directly	after	capture	which	
would	exclude	any	PCR	selection	bias	(Fonager	et	al.	2017).	In	this	study,	PGM-MBs	
were	used	to	capture	HuNoV	in	the	clinical	sample,	but	Nasheri	and	colleagues	did	
not	use	a	capture	method	which	meant	HuNoV	saturation	could	not	occur	if	the	
virus	titre	is	too	high	(Nasheri	et	al.	2017).	
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5.4.2 Partial	Sanger	sequencing	of	the	P2	domain	is	a	valid	tool	to	discern	
separate	HuNoV	outbreaks	
A	pairwise	comparison	between	partial	sequencing	of	the	P2	domain	and	MPS	has	
proved	that	Sanger	method	is	an	equally	valid	tool,	if	not	more	accurate,	to	
distinguish	separate	HuNoV	outbreaks.		
The	efficacy	of	partial	P2	domain	sequencing	in	HuNoV	outbreaks	has	been	
established	across	multiple	environments	in	the	literature.	If	the	definition,	
proposed	by	Xerry	and	colleagues,	of	a	common	source	outbreak	being	100%	
identical	in	the	P2	domain	is	applied	then	58%	of	samples,	by	Sanger	sequencing,	
rather	than	48%,	by	MPS	were	attributed	to	a	common	source	(Xerry	et	al.	2008).	
Other	outbreak	studies	have	proposed	this	criterion	is	too	stringent,	and	could	
misinterpret	prolonged	outbreaks	or	asymptomatic	transmission	(Morillo	et	al.	
2017;	Sukhrie	et	al.	2013).	If	Sanger	or	MPS	was	applied,	samples	from	each	
outbreak	clustered	together	spatio-temporally,	but	limited	depth	in	MPS	data	or	
mismatches	outside	of	the	P2	domain	led	to	phylogenetic	rearrangements	within	
clusters.	It	is	also	possible	the	phylogenetic	rearrangements	observed	during	the	
analysis	of	sequence	data	outside	of	the	P2	domain	(i.e	Outbreak	C	–	Sample	3	and	
4)	could	have	been	caused	by	recombination,	the	presence	of	two	different	HuNoVs	
or	cross-contamination	during	the	library	preparation	stage	(Figures	5.4	–	5.6).	
Barrabeig	and	colleagues	previously	targeted	a	highly-conserved	site	of	a	GII.2	
HuNoV	genome	(region	C)	to	implicate	an	asymptomatic	food	handler	in	a	point	
source	outbreak	(Barrabeig	et	al.	2010).	However,	genomic	regions	that	are	more	
variable	will	provide	greater	sensitivity	in	detecting	genetic	linkage	of	transmission	
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between	individual	hosts.	The	difference	in	sensitivity	between	the	P2	subdomain	
of	HuNoV	and	region	C	was	proved	when	partial	sequences	of	each	site	from	stool	
samples	in	two	immunocompromised	individuals	were	compared	to	environmental	
swabs	(Xerry	et	al.	2010).	Although,	discernment	of	nosocomial	transmission	from	
novel	HuNoV	virus	introductions	has	been	achieved	by	targeting	region	C	in	a	
hospital	outbreak	previously	(Rahamat-Langendoen	et	al.	2013).	
5.4.3 MPS	can	provide	evidence	of	differential	selection	in	the	host	and	increase	
the	resolution	of	transmission	within	an	outbreak	
This	study	has	however	highlighted	the	advantages	of	deep	sequencing,	over	
Sanger	sequencing,	by	providing	complete	resolution	of	the	HuNoV	genome	in	each	
stool	sample,	and	detecting	minority	variants	which	can	further	characterize	
differences	in	virus	populations	of	individual	hosts.	The	advantage	of	MPS	in	HuNoV	
outbreak	control	has	been	described	previously,	where	the	454	(Roche)	instrument	
was	used	to	show	nosocomial	transmission	of	minority	alleles	from	one	
immunosuppressed	patient	to	another,	which	then	became	predominant	in	the	
latter	(Kundu	et	al.	2013).	In	a	similar	manner,	outbreak	F	occurred	in	a	hospital,	
and	a	minor	allele	(At	position	4072)	observed	in	an	individual	was	observed	to	be	
the	dominant	allele	in	a	separate	individual.	However,	without	further	
epidemiological	data	it	can	only	be	speculated	whether	this	was	due	to	a	bottleneck	
transmission	event	or	exposure	to	a	common	source	of	infection	and	differential	
selection	in	each	host.	The	minor	allele	present	in	individual	F3,	provided	further	
support	to	the	MPS	P2	subdomain	sequence	data	that	F1,	F3	and	F4	were	from	the	
same	HuNoV	introduction,	even	though	Sanger	sequencing	had	failed.	It	should	be	
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noted	that	it	is	possible	to	detect	minority	variants	in	chromatograms	generated	by	
Sanger	sequencing	technology,	however,	the	minor	allele	must	be	present	above	a	
greater	threshold	in	contrast	to	deep	sequencing	(Larder	et	al.	1993;	Palmer	et	al.	
2005).	
Outbreak	A	occurred	in	a	restaurant,	and	in	this	suspected	outbreak	by	applying	the	
100%	criteria	on	P2	subdomain	identity	to	the	MPS	or	Sanger	sequence	consensus	
data,	this	would	have	been	considered	as	more	than	one	virus	introduction,	with	
five	identical	strains	constituting	one	outbreak	and	another	discrete	event	with	a	
single	case.	However,	the	ability	to	obtain	greater	coverage	and	the	identification	of	
minority	variants	highlighted	the	presence	of	one	variant	(position	5137)	in	more	
than	one	sample	and	another	variant	present	in	one	other	sample	(position	2011),	
supporting	the	notion	that	all	six	strains	were	linked	and	constituted	the	same	
outbreak.	The	observed	change,	in	individual	A2,	for	which	minority	variants	could	
not	be	detected	due	to	insufficient	coverage	could	be	further	evidence	of	
differential	selection.		
A	retrospective	MPS	investigation	of	a	presumed	GII.Pg/GII.3	recombinant	point	
source	outbreak	in	1972	was	recently	performed	with	the	Ion	torrent	instrument	
(Johnson	et	al.	2017).	Johnson	and	colleagues	described	the	presence	of	significant	
subpopulation	heterogeneity	in	the	GIIPg/GII.3	recombinant	population	across	
several	individuals	at	amino	acid	positions	315	and	1293,	which	was	proposed	to	be	
a	consequence	of	the	same	virus	population	infecting	separate	hosts	(Johnson	et	al.	
2017).	In	this	investigation,	a	heterogeneous	subpopulation	was	present	in	
outbreak	A	across	4/6	individuals	at	position	5137,	which	could	be	due	to	exposure	
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to	a	common	infection	source.	To	a	lesser	extent	there	was	a	heterogeneous	
subpopulation	at	position	4941	in	2/6	individuals.	The	capability	of	HuNoV	P2	
domain	Sanger	sequencing	to	track	virus	transmission	between	individuals	was	
evident	when	a	predominant	mutation,	that	appeared	in	a	chronically	infected	
individual,	was	detected	6-month-old	child	(Sukhrie	et	al.	2010).	However,	P2	
domain	sequencing	would	be	less	sensitive	to	mutations	that	occur	outside	of	the	
hypervariable	region,	which	could	be	more	likely	if	the	virus	is	not	under	selective	
pressure.		
MPS	and	partial	Sanger	sequencing	of	the	P2	domain	offer	two	separate	
methodologies	to	discern	separate	HuNoV	introduction	events	and	different	
outbreaks.	If	sufficient	depth	of	MPS	sequence	data	was	available,	then	agreement	
existed	between	both	techniques	phylogenetically.	However,	from	a	public	health	
perspective,	Sanger	sequencing	would	have	a	higher	rate	of	agreement	toward	the	
respective	outbreak	consensus	sequence	(58%)	at	a	shorter	turnaround	time	and	
reduced	cost,	which	is	often	necessary	to	implement	interventions	and	control	the	
spread	of	illness.	If	MPS	is	applied,	a	narrow	window	of	time	will	exist	at	which	
individuals	have	not	reached	the	convalescent	stages	of	illness	and	the	viral	load	in	
clinical	samples	is	high.	Those	stool	samples	with	the	highest	viral	loads	can	provide	
the	complete	HuNoV	sequence	at	high	accuracy,	and	minority	variants	can	be	
reliably	called,	to	further	strengthen	confidence	in	individual	transmission	events	if	
they	correspond	to	minority	or	dominant	alleles	in	other	infected	individuals.	This	
advantage	has	already	been	demonstrated	in	HCV	infection,	as	Montoya	and	
colleagues	shown	linkages	could	be	made	between	minority	variants	of	NS5	gene	
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that	were	not	detectable	by	Sanger	sequencing	(Montoya	et	al.	2016).	In	this	study,	
four	minority	variants	were	detected	in	four	individual	hosts	that	supported	the	
formation	of	two	additional	clusters	in	comparison	to	Sanger	sequencing	(Montoya	
et	al.	2016).	
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6 Final	discussion	and	conclusions	
	
	
A	highly	reproducible	quantitative	assay	for	human	norovirus	(HuNoV)	in	stool	
samples	has	been	optimized.	The	approach	developed	and	optimized	in	this	thesis	
has	several	clinical	applications:	in	monitoring	progress	of	disease,	establishment	of	
standardized	cut	off	values	from	discrimination	between	symptomatic	and	
asymptomatic	infection,	based	on	viral	RNA	copies	rather	than	assay	Ct	values	
which	is	subject	to	significant	lab	to	lab	variability.	This	work	confirmed	the	
unreliability	of	the	use	of	a	house	keeping	gene	in	sample	standardization	and	
relative	quantification,	but	demonstrated	that	the	expression	of	copy	numbers	in	
relation	to	stool	weight	yielded	highly	reproducible	results	in	repeated	
experiments,	dispelling	concerns	around	the	lack	of	homogenous	distribution	of	the	
virus	in	a	stool	sample.	Furthermore,	the	development	of	an	RNA	standard	
demonstrated	that	currently	widely	used	cDNA	standards	(ISO	Method	for	
norovirus	detection	in	food	and	the	environment)	significantly	and	systematically	
underestimated	the	amount	of	virus	present	in	a	sample.	This	is	an	important	
consideration,	when	viral	load	may	be	used	as	a	proxy	for	determining	the	risk	a	
contaminated	food	item	may	pose	to	consumers,	and	suggests	recalibration	of	such	
standards	and	assumptions	on	viral	load	and	contamination	may	be	necessary.	
Further	work	should	examine	how	effective	this	methodology	is	in	the	
quantification	of	other	genotypes,	for	instance	whether	under	this	methodology	
the	GII	specific	qPCR	is	equally	efficient	and	sensitive	in	amplifying	other	genotypes	
from	the	same	group.	Similarly,	it	may	also	be	interesting	and	useful	to	validate	
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these	findings	by	designing	and	producing	a	genogroup	I	specific	standard	that	can	
be	used	to	quantify	GI	HuNoVs,	which	are	frequently	associated	with	food	borne	
infections.	
This	optimized	HuNoV	quantification	protocol	was	subsequently	applied	for	the	
optimization	of	the	capture/enrichment	and	MPS	sequencing	methods	developed	
and	described	in	this	thesis.	Furthermore,	the	protocol	is	also	being	successfully	
applied	for	monitoring	viral	load	in	a	chronically	infected	patient	undergoing	
experimental	treatment	with	Ribavirin	(this	ongoing	work	is	not	part	of	this	thesis).	
Porcine	gastric	mucin-Magnetic	beads	(PGM-MBs)	were	used	for	the	first	time	to	
capture	HuNoV	from	clinical	samples	prior	to	Massively	Parallel	Sequencing	(MPS)	
as	a	method	for	HuNoV	sequence	enrichment.	Although	the	PGM-MB	capture	
methods	showed	inter-stool	suspension	variability	that	did	not	always	correlate	
with	viral	load,	it	allowed	the	recovery	of	near	complete	genomes	in	most	samples	
even	from	those	collected	post-acute	phase	of	disease,	where	viral	loads	were	low.	
A	tendency	for	mean	coverage	to	decrease	in	the	samples	collected	in	the	
convalescent	phase	was	found,	coupled	with	an	inability	to	use	the	capture	method	
to	efficiently	serve	as	a	virus	concentration	method.	It	is	possible	that	in	these	
samples,	virus	capture	with	PGM	may	be	limited	by	the	presence	of	copro-
antibodies	bound	to	the	virus,	as	subsequently	seen	by	performing	HuNoV	VLP-
specific	EIA.	Therefore,	to	further	improve	the	capture	method	to	allow	virus	
concentration	in	low	viral	load	samples,	further	investigations	should	examine	the	
potential	for	use	of	detergents,	acid	solutions	or	light	sonication	to	dissociate	virus-
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antibody	complexes	prior	to	PGM-MB	capture,	which	would	increase	accessibility	to	
aggregated	or	antibody	(Ab)	neutralized	virus.	
The	developed	capture	method	provided	an	opportunity	to	apply	MPS	to	HuNoV	
virus	populations	of	acute	infections	in	immunocompetent	individuals	across	more	
time	points,	and	over	a	longer	period	than	any	previous	studies	have	described.	A	
pipeline	was	developed	to	call	minority	variants	and	two	separate	methods	were	
applied	to	discriminate	true	positives	from	sequencing	error,	which	led	to	further	
proof	of	the	existence	of	quasispecies	in	acute	infection.	This	is	the	first	study	to	
link	the	presence	of	coproantibodies	to	the	presence	of	minority	variants	or	
dominant	nonsynonymous	mutations	in	the	HuNoV	major	capsid	protein,	and	
further,	map	these	changes	to	the	virus	surface.	Comparisons	made	between	a	
small	subset	of	epochal	VLPs	demonstrated	a	potential	role	for	Original	Antigenic	
Sin	(OAS)	or	Antigenic	Seniority	in	coproantibody	responses	to	HuNoV,	and	the	
presence	of	a	virus,	closely	related	to	the	Sydney	strain,	for	which	the	Ab	response	
present	in	the	acute	phase	appeared	to	be	ineffective.	However,	it	was	noted	that	
an	arbitrary	cut-off	for	minority	variants	is	accurate	but	insensitive,	and	instead	
further	experiments	should	determine	true	minority	variants	through	repeat	
experiments	or	an	RNA	sequencing	internal	control.	Moreover,	if	a	minority	variant	
exists	it	should	exist	at	a	similar	frequency	among	the	replicates,	and	therefore	
further	investigations	should	assess	whether	this	is	true.	Those	mapped	amino	acids	
(AAs)	considered	to	be	of	antigenic	importance	in	this	study	should	be	further	
characterized	by	site	directed	mutagenesis	of	VLPs	to	further	strengthen	these	
observations.	
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This	study	is	the	first	direct	comparison	between	MPS	and	Sanger	sequencing,	and	
how	each	technique	can	influence	how	a	HuNoV	outbreak/transmission	event	is	
interpreted,	with	potential	impact	on	infection	control	and	public	health	actions.	
The	presence	of	minority	variants	strengthened	phylogenetic	relationships	in	
common	source	outbreaks,	when	the	consensus	sequence	would	suggest	
otherwise.	But	given	the	variability	in	MPS	coverage	that	can	occur	and	the	slow	
turn	over	time	in	contrast	to	Sanger	sequencing,	the	latter	can	still	be	considered	a	
more	suitable	or	pragmatic	public	health	tool.	Further	investigations	should	
examine	whether	3rd	generation	sequencing	technologies	(i.e	MinION)	are	more	
reasonable	tools	for	HuNoV	outbreaks,	as	these	also	have	added	benefits	such	as	
lower	cost	and	near-real	time	processing.	
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8.2 Appendix	B	–	Transmission	samples	coverage	graphs	
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8.3 Appendix	C	–	Longitudinal	patient	sample	coverage	graphs	
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8.4 Appendix	D	–	Sydney	VLP	plasmid	
	
	
8.5 Appendix	E	–	New	Orleans	VLP	plasmid	
	
	
8.6 Appendix	F	–	Farmington	Hills	post	purification	protein	gel	(A=	cell	
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8.7 Appendix	G	–	New	Orleans	recombinant	baculovirus	time	course	in	
hours	(Black	rectangle:	The	HuNoV	major	capsid	protein)	
	
	
8.8 Appendix	H	–	Sydney	recombinant	baculovirus	time	course	in	hours	
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8.9 Appendix	I	Sydney	–	EM	picture	of	Sydney	strain	VLPs	
	
8.10 Appendix	J	–	EM	picture	of	New	Orleans	VLPs	
	
